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ABSTRACT 
The aim of this thesis was to develop an Experimental Medicine Model for the assessment of 
the potential efficacy and psychiatric safety of novel anti-obesity drugs. Chapter 1 provides a 
general introduction to the research area. Chapter 2 presents evidence that the satiety 
enhancing effects of an appetite suppressant drug (meta-chlorophenylpiperazine – mCPP) can 
be detected after acute administration to healthy women participants using a Universal Eating 
Monitor (UEM) that provides measures of eating microstructure such as eating rate. 
Assessment of emotional responses using the P1vital® Oxford Emotional Test Battery (ETB) 
suggested an absence of psychiatric side-effects induced by mCPP at the doses tested. 
Chapter 3 reports that eating responses measured by the UEM are similar whether or not the 
participants are aware that their eating behaviour is being assessed, indicating that the 
practical limitations associated with assessing meal microstructure covertly can be avoided.  
Chapter 4 presents two studies which provide evidence that 1) repeated use of the ETB is 
feasible, thereby enabling it to be used in cross-over experimental designs and 2) 
performance on the ETB is not affected by satiety. In Chapter 5, functional magnetic 
resonance imaging (fMRI) was used to identify a profile of natural satiety against which the 
effect of drugs that enhance satiety can be compared. Chapter 6 reports the results of a study 
that combined the use of the UEM with fMRI to examine the effects of mCPP on behavioural 
and neural markers, in a cross-over design. mCPP significantly reduced blood oxygen level 
dependent (BOLD) activations to the sight of high calorie food images in key appetitive and 
reward areas and reduced consumption of a palatable cookie snack but did not decrease the 
intake of a pasta meal. Analysis of individual differences in responses to mCPP revealed that 
BOLD activity in reward-related brain areas predicted an anorectic response to drug 
administration.  Chapter 7 provides a reflection on the experimental work and it is concluded 
that the proposed Experimental Medicine Model may be valuable for the development of 
efficacious and safe appetite suppressant drugs by providing additional data to inform go/no 
go decisions on drugs in early phase clinical trials.   
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CHAPTER 1: GENERAL INTRODUCTION 
1.1. Obesity  
1.1.1. Introduction 
Obesity is a worldwide health priority because it is associated with an increased risk of 
coronary heart disease, hypertension, type II diabetes, and cancer (Finucane et al. 2011). It is 
also associated with a wide spectrum of co-morbidities, both physiological and psychological 
(e.g. depression), and is linked to early mortality (Brown et al. 2009). Therefore, obesity and 
its consequences present a massive public health challenge. Obesity is associated with 
excessive fat accumulation and is defined currently as body mass index (BMI - kg/m2) > 30. 
However, there is evidence that waist circumference might be a more reliable indicator of 
health risk than BMI (Janssen et al. 2004) and that waist-to-height ratio might be an even 
more effective measure (Ashwell et al. 2013).  
 
Data from the World Health Organization (WHO) showed that in 2008, more than 10% of the 
world’s adult population were obese (WHO, 2012). In the UK in 2008, almost 25% of adults 
in England were obese, with close to 30% of boys and girls aged 2-15 classed as overweight-
obese (Health and Social Care Information Centre, 2009). More recent data suggest that the 
increase in obesity rate may be slowing in children; possibly due to successful prevention 
campaigns (Health and Social Care Information Centre, 2014). Nevertheless, overall rates of 
obesity are projected to rise over the next decade, and by 2020 it is predicted that 70% of 
British people will be overweight or obese (Sassi, 2010). This is against a backdrop of no 
national success stories in tackling obesity in the past 33 years (Ng et al. 2014). 
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There is a significant financial burden associated with obesity because the treatment of 
obesity and its co-morbidities incurs both direct costs in terms of healthcare and indirect costs 
associated with premature mortality and loss of earnings due to ill health. In 1998, the direct 
and indirect costs of obesity in England were estimated to be £497 million and £2.6 billion 
respectively (National Audit Office, 2001). By 2007, these costs had increased to £4.2 billion 
and £15.8 billion respectively and the financial burden of obesity is projected to increase 
further over the next decade (Butland et al. 2007).  
 
1.1.2. Causes of Obesity 
Obesity was classified recently as a pathophysiological disease by the American Medical 
Association (AMA 2013). It is widely accepted that that obesity is caused by an energy 
imbalance whereby there is greater energy intake than energy expenditure (WHO, 1998). 
This could be due to an increase in energy intake, a decrease in energy expenditure, or both. 
However, the causes of this imbalance are complex. Some evidence suggests that overall 
energy expenditure has not declined in recent decades in Europe and the United States 
(Westerterp and Speakman, 2008). However, other data suggests that energy expenditure at 
work has decreased in the United States over the last 50 years (Church et al. 2011). It should 
be noted though that these data do not cover non-occupational energy expenditure, such as 
exercise or recreational physical activities. Thus, on balance, it seems more likely that an 
increase in energy intake may underlie the increase in obesity. Indeed, Swinburn and 
colleagues (2009) reported that the increase in energy intake over the last few decades, best 
explains the obesity epidemic in the United States.  
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One theory that addresses how energy intake has increased asserts that the environment of the 
developed world provides ready access to energy dense foods, that promotes over indulgence; 
the so called ‘obesogenic environment’ (Swinburn et al. 1999). In addition to the ready 
availability of energy dense food, it has been reported that meal portion sizes have increased 
in parallel to increasing body weight in the US, suggesting that this phenomenon might also 
be responsible for the increased energy intake (Young and Nestle, 2002). More recent work 
has also suggested that eating occasions have increased, so that individuals are now eating 
more meals and snacks which may be contributing to overall increases in energy intake 
(Duffey and Popkin, 2011). Hence, readily available food, increased portion size, and 
frequency of consumption are all important factors related to increased energy intake. 
However, not all individuals exposed to an obesogenic environment become obese, therefore 
there must be other factors involved.  
 
Genetics are one such factor. It has been reported that identical twins reared apart show 
similar body weights (Stunkard et al. 1990), and that when identical twins are overfed over a 
long period, they show similar weight gain (Bouchard et al. 1990). Genetic factors explain up 
to 70% of BMI variance in the general population (Comuzzie and Allison, 1998), and this 
increases to a maximum of 90% in twins reared apart (Maes et al. 1997). While this strongly 
suggests that genetics are involved in weight (and weight-gain) the question arises; how do 
genetics contribute to obesity? 
 
It is possible that the genes involved mediate reward responses to food stimuli. Obese 
individuals show enhanced reward responses to food (Carnell, 2012), which are predictive of 
future weight gain (Yokum et al. 2011; Demos et al. 2012). The hormones leptin and ghrelin 
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regulate food reward (Farooqi et al. 2007; Malik et al. 2008), and are associated with the fat 
mass and obesity-associated gene (FTO) (Wang et al. 2011; Karra et al. 2013). In addition, 
genetic polymorphisms of dopamine receptors, have been associated with differential brain 
responses to palatable foods, which are predictive of increases in body mass (Stice et al. 
2010). Hence, there is compelling evidence linking genetics to food reward and weight gain.  
 
One issue to be resolved is why we would possess a genetic susceptibility for weight gain, 
and why this might be more an issue now than previously. The leading theory which 
addresses this point is known as the “drifty gene” hypothesis (Speakman, 2008). It proposes 
that genes which control the upper limit on body weight have randomly drifted, resulting in a 
larger number of individuals predisposed to gain weight. Hence, it seems possible that some 
of the genes that have ‘drifted’ might be those that underlie reward responsiveness to food, 
thereby promoting the overconsumption of energy dense palatable foods, resulting in obesity 
(Speakman et al. 2011). 
 
The involvement of both environmental and genetic factors suggests the two may interact 
whereby a genetic susceptibility to obesity is more likely to be expressed in an obesogenic 
environment. Previous models relying exclusively on genetic and biological explanations or 
social and environmental explanations of obesity have been criticised for ignoring gene-
environmental interactions, leading to newer models that account for these, that better fit the 
available evidence (Speakman et al. 2011). 
 
In terms of targeting genes and environment, genetic treatments for obesity are unlikely to 
appear in the near future and it is unknown whether such treatments will be effective or free 
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from side effects. In addition, redesigning the global food environment is neither a simple or 
swift task. However, as neurotransmitter and neurohormonal systems underpin these genetic-
environmental interactions, the most sensible immediate strategy for treatment would be to 
focus on the neurocircuitry that underlies responses to food via centrally acting anti-obesity 
drugs. 
 
1.1.3. Summary 
Obesity is a global problem and it’s worldwide prevalence is associated with severe health 
and economic consequences. Increased energy intake due to easily accessible food, larger 
portion sizes and increased eating frequency appear to be key contributors to weight gain. 
However, genetic influences are likely to interact with the environment, such that individuals 
are more likely to over-consume in the current food environment due to genetic 
predisposition. Treatments are urgently needed for obesity and to curb enhanced energy 
intake. 
 
1.2. Appetite and Food Intake 
1.2.1. Introduction 
As the over-consumption of food is a major factor in obesity, a clear understanding of human 
appetite and eating behaviour is necessary if new approaches to obesity treatment are to be 
developed. Ingestion of food provides a flow of nutrients to meet immediate energy needs. 
Energy can also be stored within the body to be used when circulating energy levels drop. 
Such stores exist within the liver and within fat cells, and accumulation of the latter is 
particularly problematic in obesity (Hill et al. 2012). 
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Although the initiation and termination of food intake is primarily influenced by metabolic 
state (i.e. eating is initiated by food deprivation and terminated by eating) there are additional 
influential factors. For instance, enhancing palatability can increase food consumption in the 
absence of physiological hunger (Fisher and Birch, 2002). More food may be also consumed 
at breakfast than usual if an individual is likely to miss lunch. Conversely, an individual 
might stop eating when hungry if they have a dietary goal and are actively restricting the 
amount they consume (Herman and Polivy, 1984; Boon et al. 1998; Johnson et al. 2012). 
Social circumstances can also influence eating and affect food intake such that people eat 
more if other diners are eating more and eat less if others eat a small amount (Herman et al. 
2003). Hence, the consumption of food is influenced by a range of factors in addition to 
metabolic state, as indicated in Figure 1.1 (below). 
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Figure 1.1. The control of appetite (replicated directly from Berthoud, 2011) 
“Schematic diagram showing potential interactions between the so called “homeostatic” energy balance 
regulatory system (blue) and neural systems involved in external sensory information processing (yellowish-
brown), reward processing (purple), and cognition and executive functions (red), collectively referred to as 
“hedonic systems”. Blue arrows indicate bottom-up modulation of hedonic systems by homeostatic signals. 
Broken blue lines represent circulating hormones, metabolites, and other factors; solid blue lines represent 
neural pathways. Red arrows indicate top-down modulation of homeostatic processes by hedonic drives.” 
 
Eating behaviour is orchestrated by a manifold system of neural circuitry, comprised of 
several distinct but interacting components (Figure 1.1). This includes circuitry governing: 
the sensory processing of appetitive stimuli, energy balance, food reward and cognitive 
mechanisms involved in appetite. Each of these systems will now be reviewed in turn. 
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1.2.2. Gustatory and Sensory Processing of Appetitive Stimuli  
The consumption of food involves the stimulation of a variety of sensory pathways. These 
include: gustatory, oral, visual and olfactory pathways. Visceral axons from the gut and 
orosensory neurones from the mouth both project to the medulla oblongata at the nucleus of 
the solitary tract (NTS) (Altschuler et al.1989; Travers and Norgren, 1995). Hence, the NTS 
is considered one of the first major ‘stations’ in the neuraxis for the convergence and 
processing of visceral and oral sensory input (Grill and Hayes, 2009). The NTS projects to 
the insula which is also known as the primary taste cortex (Saper et al. 1980).  
 
Early work by Penfield and Faulk (1955) noted that electrical stimulation of the insula in 
humans produced visceral sensory phenomena such as nausea and gurgling, oral phenomena 
such as chewing and swallowing, and sensations of taste or smell. More recent work with 
primates has confirmed that the insula is involved in encoding taste and other oral 
somatosensory stimuli allowing ‘higher’ cognitive prefrontal structures to utilise this 
information in the execution of decisions which lead to behaviour (Rolls, 2006; Yaxley et al. 
1990; Verhagen et al. 2004). Hence, sensory encoding of food stimuli in the insula is 
conveyed to the adjacent orbitofrontal cortex (OFC) (Shi and Cassell, 1998; Vertes, 2004). 
 
Visual and olfactory information about food is also relayed to the OFC. The initial processing 
of visual information occurs in parts of the cortex specialised for visual stimuli (visual areas 
1, 2 and 4; V1, V2, and V4), before being processing by the inferior temporal visual cortex 
and being relayed to the amygdala and the OFC (Rolls, 2007). In addition, stimulation of the 
olfaction sensory system by the smell of food via chemoreceptors in the nose involves 
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activating the olfactory bulb. This then projects this sensory information to the olfactory 
pyriform cortex, and then as for visual stimuli, to the amygdala and OFC (Rolls, 2007).  
 
Hence, the majority of sensory pathways responsible for processing food stimuli converge at 
the OFC. The presence of multimodal neurones capable of coding two sensory stimuli 
simultaneously (e.g. taste and olfaction) in the OFC has led to the theory that it is the first 
area of cortex where modalities converge and are represented as a combined whole (Rolls and 
Bayliss, 1994). Evidence suggests that the resulting multi-modal sensory representation is 
projected to the hypothalamus, where it is integrated with metabolic signals to influence the 
consumption of food (Rolls, 2000).  
 
1.2.3. Energy Balance Circuitry 
Appetite is strongly influenced by an individual’s energy balance state, such that the 
ingestion of food is more likely when an individual requires energy and is ‘hungry’ than 
when they do not require energy, such as when they are ‘full’ after eating food ( Zheng et al. 
2009). The neural circuitry that monitors this state of energy balance has been intensively 
researched, and includes brainstem structures such as the NTS along with the core 
‘homeostatic’ area, the hypothalamus (Berthoud, 2002).  
 
As noted earlier the NTS receives direct gustatory input, making it the earliest structure to 
receive information that might signal a change in energy state (i.e. incoming energy). The 
NTS contains fenestrated capillaries that allow peripheral blood-based factors such as 
hormones to modulate neural activity at this site (Cunningham, 1994). This is an important 
element of energy balance, as there are a number of hormones that interact with neural 
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circuitry to communicate energy state. For instance, ghrelin is produced in the gastrointestinal 
tract and is secreted when the stomach is empty, while leptin is produced by fat cells as an 
indicator of fat stores (Klok et al. 2007). Hence, ghrelin serves as a more immediate indicator 
of energy needs while leptin acts as a longer term regulator of energy stores (Klok et al. 
2007). 
 
Recent evidence shows that infusion of leptin into the medial NTS reduces food intake in rats 
(Kanoski et al. 2014), while an anti-ghrelin antibody-induced reduction in NTS ghrelin 
achieves the same effect (Solomon et al. 2006). Hence, leptin and ghrelin are referred to as 
satiety and hunger hormones, respectively. Cholecystokinin (CCK) and Glucagon-like 
peptide-1 (GLP-1) are also produced and released in the gastrointestinal (GI) tract upon 
detection of relevant incoming nutrients, and act at receptors on neurones in the NTS to 
signal nutritive content (Glatzle et al. 2001; Punjabi et al. 2011). Consequently, the NTS 
receives multiple neuro-hormonal signals indicating current and long term energy balance, 
which the NTS projects onwards to the hypothalamus (Beckstead et al. 1980). 
 
The hypothalamus includes the dorsomedial hypothalamus (DMH), ventromedial 
hypothalamus (VMH), lateral hypothalamus (LH), arcuate nucleus (ARC) and the 
paraventricular nucleus (PVN). Through the use of electrolytic and neurotoxin lesion and 
drug infusion studies in rodents, the roles of these hypothalamic sub-structures in appetite and 
food intake have been elucidated. For instance, lesions of the VMH and PVN lead to 
hyperphagia (Hetherington and Ranson, 1942; Anand and Brobeck, 1951; Shor-Posner et al., 
1986). Conversely, early LH lesion studies induced hypophagia (Anand and Brobeck, 1951; 
Teitelbaum and Epstein, 1962). However, the selectivity of early LH lesions has been 
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questioned. For instance, Ungerstedt (1971) performed chemical lesions of the LH using 6-
hydroxydopamine (6-OH-DA), which successfully induced hypophagia, but also destroyed 
axons contained in the medial forebrain bundle (MFB), which provide most of the 
monoaminergic innervation of the forebrain. Thus, the lesions caused severe deficits in 
locomotion and the rats were unable to move and so unable to eat and drink unless tube fed. 
However, subsequent work with LH lesions produced with kainic acid which were more 
selective and spared MFB fibres, induced hypophagia in the absence of sensory-motor 
deficits (Grossman et al. 1978). 
 
One of the most important nuclei in the hypothalamus is the ARC nucleus. The ARC 
integrates signals from the NTS (Heijboer et al. 2006). It is also accessible to large peptide 
molecules due to its proximity to a section of the blood-brain barrier that is semi-permeable 
(Cone et al. 2001). ARC neurones are referred to as ‘first-order’ neurones due to their direct 
contact with peripheral peptide hormones, whereas neurones in the PVN, LH, VMH, and 
DMH are referred to as ‘second-order’ neurones (Heijboer et al. 2006). Peptides within the 
ARC nucleus are crucial in the regulation of energy balance and control of food intake. 
Activation of first order neurones that coexpress agouti-related peptide (AgRP) and 
neuropeptide Y (NPY) stimulates food intake in rats, whereas activation of neurones 
expressing pro-opiomelanocortin (POMC) inhibits food intake in rats (Hahn et al, 1998; Elias 
et al. 1999; Cowley et al. 2001). 
 
POMC neurones in the ARC nucleus might be particularly crucial to energy balance and 
could represent a potential target for anti-obesity drugs. Serotonin (5-hydroxytryptamine) is a 
key neurotransmitter involved in the control of appetite (Blundell, 1977; Burton et al. 1981; 
Clifton et al. 1989; Blundell, 1986). Serotonin is implicated in the hypothalamic control of 
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food intake. For example, serotonergic agonists binding at receptors in the hypothalamus 
reduce food consumption in rats (Shor-Posner et al. 1986; Dourish and Hutson, 1989; 
Leibowitz and Alexander, 1998; Smith et al. 1999). Recent evidence indicates that 
enhancement of serotonergic function in the ARC suppresses appetite via effects on POMC 
neurones, suggesting that POMC receptors could be crucial downstream targets for future 
weight-loss drugs (Sohn et al. 2011; Heisler et al. 2002).  
 
Dopamine and noradrenaline acting in the hypothalamus also affect food intake. Infusion of 
either dopamine, the dopamine precursor L-Dopa, or the dopamine agonist d-amphetamine 
into the LH decreases food intake in rats (Leibowitz and Rossakis, 1979). In addition, 
infusion of the selective D2 dopamine receptor antagonist sulpiride into the LH increases food 
intake in rats (Sato et al. 2001).  In contrast, infusion of noradrenaline into the LH and the 
PVN increases food intake in rats and pigeons (Leibowitz, 1978; Hagemann et al. 1998). It is 
probable that many anti-obesity drugs achieve their weight-loss effects, at least in part, by 
acting in the hypothalamus to alter energy balance signals. However, targeting this system 
may be less successful in reducing eating that is motivated by the hedonic appeal of foods.  
 
1.2.4. Food Reward  
While energy state clearly plays a role in eating behaviour, the consumption of food is not 
singularly under the control of energy balance circuitry. It is well documented that highly 
palatable foods are eaten in greater amounts than foods that are less palatable (Yeomans, 
1996). In addition, evidence shows that as foods are eaten their rated pleasantness declines 
when compared to a food that has not been eaten, bringing about meal termination (Rolls et 
al. 1981). This process is referred to as sensory specific satiety (SSS; Rolls et al. 1981). 
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Hence, the pleasure, or ‘hedonic’ aspects of eating food also influence appetite and food 
intake. 
 
It has been suggested that dopamine mediates the subjective pleasure associated with eating 
food (Wise, 1978; Wise, 2008). However, in recent years this idea has been challenged by 
evidence that reward consists of both ‘liking’ (hedonic pleasure) and ‘wanting’ (motivation to 
acquire a stimulus) and that dopamine is more closely associated with incentive salience (the 
‘wanting’ of stimuli), rather than ‘liking (Berridge, 2007). The distinction between wanting 
and liking is crucial to understand conventional reward, which involves both of these 
processes. For instance, liking a stimulus leads to a positive affective state, but without 
wanting, does not lead to acquisition of the rewarding stimulus (i.e. there is no motivation to 
acquire the stimulus). Conversely, wanting without liking will lead to the acquisition of a 
stimulus, but in the absence of pleasure (no hedonic value). Hence, both wanting and liking 
are needed for reward. 
 
The distinction between liking and wanting can be observed on both a neural and behavioural 
level. There is evidence that a limited number of anatomically small brain regions are 
involved in liking, whereas a larger network of regions is involved in wanting (see Berridge 
et al. 2010). Behaviourally, the pleasure (liking) elicited by a stimulus can be measured in 
rodents by examining orofacial responses and body movements. Typically, sweet pleasurable 
tastes elicit positive orofacial responses (tongue protrusions, etc.), and can be observed in the 
absence of dopamine-mediated wanting (Berridge et al. 1998). ‘Wanting’ is measured as a 
function of motivation to acquire a stimulus. It can be measured in various ways, such as via 
the latency to obtain food and can be dissociated from ‘liking’ (Peciña et al. 2003). Hence, 
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food reward in the contemporary sense can be conceptualised as the combination of food 
“wanting” and “liking”. The pharmacological mechanisms of liking and wanting are 
complex, and extend beyond dopamine mechanisms. For instance, opiodergic mechanisms 
have been reported to mediate liking in humans (Yeomans and Gray, 1996) and also food 
“wanting” (for review see Berridge, 2009).  Further exploration of wanting and liking will be 
discussed below. 
 
1.2.4.1. ‘Wanting’ 
The neural substrate of wanting, or incentive salience, comprises a number of brain regions. 
The ventral tegmental area (VTA) is one of the first brain areas in the motivational neuraxis, 
wherein a crude representation of stimulus motivational relevance is formed. It is then 
projected onwards to the ventral pallidum, the nucleus accumbens (NAcc), amygdala, 
hippocampus and prefrontal cortex (Fields et al. 2007). Many of these areas form the basis of 
the mesolimbic and mesocortical dopamine pathways, which in turn, relay the motivational 
relevance of food stimuli to additional brain areas involved in the wider appetite circuitry.  
 
A key brain area in both of these pathways is NAcc, which comprises two regions: the core 
and the shell (Kelley et al, 2005). Experimental evidence from rodents suggests that the core 
and shell are innervated by the dopaminergic nigrostriatal and mesolimbic pathways, 
respectively (Deutch and Cameron, 1992). These are involved in the control of motivation 
and motor actions (Drui et al. 2014; Kim et al. 2003), and the reinforcing effects of stimuli 
such as drugs and food (Martel and Fantino. 1996; Pierce and Kumaresan, 2006). Hence, 
there is strong evidence that both the core and shell of the NAcc are involved in wanting 
behaviours.  
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Other striatal structures are also involved in food motivation, such as the caudate and 
putamen, collectively referred to as the dorsal striatum. Injection of a dopamine antagonist 
into the dorsal striatum decreases lever pressing for food in rats (Beninger et al. 1993). In 
addition, DiFeliceantonio and colleagues (2012) found that injection of a µ-opioid receptor 
agonist into the rat dorsal striatum dramatically increased intake of a palatable sweet food by 
250%, without changing the hedonic impact of sweet tastes, as measured by a taste reactivity 
test. Hence, wanting can be dissociated from liking in rats (DiFeliceantonio et al. 2012).  
 
The amygdala is also involved in motivation and can be divided into several nuclei, including 
the central nucleus, medial nucleus, cortical nucleus, and basolateral group (Solano-Castiella  
2010). Recent work suggests that the amygdala stores associations between conditioned 
stimuli and motivational and affective values (Fernando et al. 2013. It has also been 
suggested that the central nucleus encodes motivational value, while the basolateral amygdala 
encodes emotional events with reference to sensory-specific aspects (Balleine and Killcross 
et al. 2006). Lesions of the basolateral amygdala interfere with the representation of sensory 
aspects of motivational events but not neutral events (Dwyer and Killcross, 2006), suggesting 
that the amygdala provides an input for sensory information into the motivational pathway. 
The amygdala also relays motivational information to the OFC where it is used in the 
selection and execution of subsequent eating behaviour (Schoenbaum et al. 1999).  
 
1.2.4.2. ‘Liking’  
Liking is associated with a number of brain regions including sites in the brainstem through 
to the prefrontal cortex. It is thought that the ‘liking response’ to food is mediated at least in 
part by “hedonic hotspots” in the brain. These are cubic-millimetre regions of neurones which 
enable opioid and endocannabinoid amplification of sensory pleasure (e.g. liking of food) 
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(Berridge, 2009). Such hotspots have been identified in rodents in the NAcc and ventral 
pallidum, are indicated to exist in the brainstem (parabrachial nucleus) and may also exist in 
the amygdala and OFC (Berridge, 2009; Castro and Berridge, 2014a). Hedonic hotspots are 
part of a distributed network across the brain, forming an integrated liking system. 
 
Initial liking reactions to food stimuli are generated in the brainstem. Decerebrate rats that 
have the brainstem isolated from the forebrain are capable of generating orofacial liking 
reactions to sweet tastes (Grill and Norgren, 1978). Opioid mechanisms are thought to 
mediate these liking reactions. Thus, opioid receptor agonists and antagonists infused into the 
NTS increase and decrease respectively food intake in rats (Kotz et al. 1997; Kotz et al. 2000) 
and modulate feeding by acting on the rat parabrachial nucleus (Carr et al. 1991). Multiple 
opioid receptor subtypes are implicated in liking and food intake, although µ-opioid receptors 
are thought to play the most important role (Gosnell et al, 1986). In addition to opioids, 
injection of gamma-aminobutyric acid (GABA) into the rostral-medial accumbens enhances 
eating behaviour and liking reactions in rodents (Reynolds and Berridge, 2002). Also, 
benzodiazepine injection into the parabrachial nucleus enhances food intake (Higgs and 
Cooper, 1996) while injection into the brainstem of decerebrate rats enhances liking reactions 
(Berridge, 1988). Hence, multiple neurotransmitters mediate liking responses.  
 
The NTS projects onwards to the NAcc (Brog et al. 1993) which contains a hedonic hotspot, 
a small region in the NAcc medial shell (Peciña and Berridge, 2000). In a study with rats, 
orofacial liking reactions to sucrose were enhanced by opioid stimulation of the rostromedial 
shell of the NAcc (Peciña and Berridge, 2005). In addition, it has been reported that infusion 
of the endocannabinoid anandamide into the medial shell hotspot induced enhancement of 
liking reactions to sucrose in rats (Mahler et al. 2007), suggesting involvement of 
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endocannabinoid mechanisms. The involvement of cannabinoid and opioid mechanisms is 
also supported by reports that delta(9)-tetrahydrocannabinol and anandamide enhance sucrose 
palatability in rats (Higgs et al, 2003) and that opioids are strongly associated with the 
hedonic perception of food stimuli (Berridge, 1996; Barbano et al. 2007). There is also recent 
evidence for a negative hedonic coldspot in the caudal half of the medial shell, where opioid 
stimulation suppresses liking reactions (Castro and Berridge, 2014b).  
 
The NAcc projects onwards to the prefrontal cortex (PFC) (Berendse et al. 1992), which has 
also been implicated in liking responses. Two subdivisions that have been the focus of 
research include the OFC and the ventromedial PFC (vmPFC). In humans, BOLD activity in 
the OFC correlates with the rated pleasantness of appetitive stimuli, leading to the conclusion 
that brain activity in this area represents the pleasure or ‘liking’ associated with food 
(Kringelbach et al, 2003). The adjacent vmPFC has also been implicated in liking, and in an 
fMRI study with healthy volunteers across a wide age range, increased BOLD activity in the 
vmPFC was associated with more positive valence ratings (Winecoff et al. 2013). In addition, 
greater BOLD responses were detected in the vmPFC to sucrose when it was rated as 
pleasant by participants (Rudenga and Small, 2013).  
 
While there appears to be a functional overlap between the OFC and vmPFC, a recent study 
with monkeys (Bouret et al. 2010) provided evidence that while both areas are responsive to 
liking stimuli, OFC neurones are more sensitive to external/environmental stimuli such as 
visual cues, while vmPFC neurones are more sensitive to internal/subject specific stimuli 
such as satiety. This is supported by evidence showing strong connections between sensory 
cortical areas and the OFC (Ongur and Price, 2000), and the observation that vmPFC activity 
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strongly correlates with internal goal values in humans (Hare et al. 2009). Together, these 
prefrontal liking evaluations guide food reward, learning, and decision making (Rushworth et 
al. 2011). 
 
There is an extensive body of research using measures of liking and wanting in humans. 
However, it is unclear whether these studies have measured the same constructs that have 
been investigated in rats. For instance, Volkow and colleagues (2002) have reported that in 
humans, increases of extracellular dopamine in dorsal striatum are associated with increased 
ratings of desire to eat food. However, Small and colleagues (2003) found that dopamine 
levels in the dorsal striatum correlated with meal pleasantness, but not desire to eat, or satiety 
(Small et al. 2003) suggesting that dopaminergic effects are associated with pleasure, but not 
motivation in humans. More recently, there has been a debate over whether wanting and 
liking can be properly measured and dissociated in humans at all (see the following for the 
most recent discussion: Havermans, 2011; Finlayson and Dalton, 2012; Havermans, 2012). 
Although this is an ongoing debate, it seems unlikely that present methods successfully 
measure in humans the type of wanting and liking observed in rats, for instance, free from 
social cognitions, etc. (Havermans, 2012).  
 
1.2.5. Interactions between Energy Balance and Reward Circuitry 
Energy balance and reward have been discussed separately, but these neural circuits do not 
function independently. Indeed, the hypothalamus is reciprocally connected to and 
influences, or is influenced by, multiple reward regions (Kelley et al. 2005). For instance, the 
NAcc shell projects to several hypothalamic sites, including the ARC and LH (Baldo et al. 
2004) to influence feeding in rats (Kelley et al. 2005). However, the LH also projects back to 
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the NAcc shell to modulate reward, and consequently, food intake (Sears et al. 2010). In 
addition, leptin modulates the activity of dopamine neurones in the ventral tegmental area, 
which project to the nucleus accumbens; enabling metabolic signals to modulate reward 
(Fulton et al. 2006). Hence, energy balance can influence reward processing, and vice versa, 
such that both the hypothalamus and NAcc jointly co-ordinate reward-satiety processes.  
 
Other limbic regions involved in reward, are also connected to the hypothalamus. There are 
neuronal pathways between the amygdala and the VMH, damage to which causes 
hyperphagia and obesity in rats (King, 2006). Serotonin mediates some of these amygdala-
hypothalamic effects. Administration of the selective serotonin reuptake inhibitor zimelidine 
into the medial nucleus of the rat amygdala produces a hypophagic effect, which is blocked 
by the selective 5-HT2C receptor antagonist SB-242084 (Scopinho et al. 2012). It is possible 
that this serotonin mechanism could be upstream of melanocortin expressing neurones in the 
amygdala that also affect appetite for dietary fat (Boghossian et al. 2010). Moving along the 
neuraxis, the PFC is also connected to the hypothalamus (Rempel-Clower and Barbas, 1998). 
It has been suggested that the OFC is sensitive to energy balance information (Rolls et al. 
1989) because activity in the OFC decreases as participants become satiated (Kringelbach et 
al, 2003). Hence, both energy balance and reward circuitry across the neuraxis interacts in an 
adaptive manner to co-ordinate eating behaviour. 
 
1.2.6. Cognitive Mechanisms Involved in Appetite 
Cognitive mechanisms also play an important role in mediating human eating behaviour. At 
the most basic level, attentional mechanisms are needed to orientate individuals towards food 
stimuli. Executive resources are required to make decisions, such as whether to approach, or 
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inhibit the approach towards food. Memory is also required to store associations and 
outcomes with food and for learning to take place. 
 
A key brain region implicated in cognitive control is the cingulate cortex, which can be split 
into anterior (ACC) and posterior (PCC) divisions. It is thought that the PCC is involved in 
sensory events and plays a role in spatial orientation and memory, while the ACC is involved 
in executive tasks, which involve emotional control of visceral related functions (Vogt et al. 
1992). More recent evidence suggests that there may be a further subdivision of function 
within the ACC, whereby the dorsal region is involved in cognitive control and the rostral 
ACC is more engaged with emotion regulation in humans (Mohanty et al, 2007). Weissman 
and colleagues (2004) have reported that the dorsal ACC focuses attention on behaviourally 
relevant stimuli and Holroyd and Yeung (2012) have suggested that the ACC selects and 
maintains behaviour directed towards salient goals. Thus, lesions of the ACC in rats produces 
a marked decrease in foraging for food, but not in other behaviours (Li et al, 2012) and 
Rhesus monkeys with ACC lesions show impairments in using rewarded trials to sustain 
selection of an appropriate object during a learning task (Chudasama et al. 2012).  
 
Furthermore, antagonism of D1 dopamine receptors in the ACC reduces preference for a 
high-cost high-reward response option in rats, suggesting that D1 dopamine receptors are 
involved in ACC regulation of motivation-based decisions (Schweimer and Hauber, 2006). In 
addition, ACC opioid blockade reduces ethanol seeking behaviour in mice suggesting that 
opioidergic neurotransmission is involved in maintaining a cue conditioned reward signal 
(Gremel et al. 2011). Hence, the ACC is probably an important area for maintaining goal-
directed behaviours. 
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Cognitive processes may inhibit as well as enhance approach to food. For instance, increased 
tonic activity in the dorsolateral prefrontal cortex (dlPFC) has also been associated with 
greater behavioural inhibition (Shackman et al. 2009) and a recent meta-analysis reported 
reduced dlPFC activation to food images in obese versus lean participants (Brooks et al. 
2013a) suggesting a role for inhibiting appetitive behaviours. The vmPFC is functionally 
connected to the dlPFC, and the dlPFC shows increased activity when individuals exercise 
self-control (Hare et al. 2009). Further, dlPFC activity modulated vmPFC signal in response 
to food, suggesting that inhibitory control can modulate reward signalling in humans (Hare et 
al. 2009). It is likely that inhibitory control is achieved via the input of other cognitive 
functions, as the dlPFC is involved in preparing for action, based on information stored in 
short-term memory (Pochon et al. 2001). 
 
The hippocampus is crucial for the control of learning and memory (Scovile and Milner, 
1957; Eichenbaum and Cohen, 1993) and projects to areas including the hypothalamus, 
NAcc, amygdala and PFC (Van Groen and Wyss, 1990; Barbas and Blatt, 1995). Studies in 
rats, monkeys and humans, using neurophysiological, neuropsychological and neuroimaging 
techniques, suggests that the hippocampus plays a pivotal role in memory recall (Eichenbaum 
et al. 2007). Recent evidence suggests that the hippocampus is involved in the control of food 
intake (Davidson et al, 2007) as hippocampal lesions in rats increase energy intake and 
weight gain (Davidson et al. 2009). In humans, similar effects have been found with amnesic 
patients with hippocampal damage, who consume multiple meals (consuming more food than 
controls), in the absence of changes in rated appetite (Higgs et al. 2008). Further studies with 
healthy volunteers have reported that disrupting the formation of episodic memories of meal 
consumption, subsequently leads to increased food intake (Higgs and Donohoe, 2011). 
Hence, memories of food, and of food consumption, represent an important cognitive 
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mechanism of eating behaviour and a potential target to exploit in future weight-loss 
treatments. 
 
1.2.7. Summary  
The regulation of appetite and food intake is complex. Sensory engagement with food stimuli 
engages multiple neural sites, from the brainstem where initial processing of gustatory stimuli 
begins, to the prefrontal cortex, where multimodal representations of sensory input are 
formed. At the same time, circuits involving the brainstem and hypothalamus co-ordinate 
energy sensing and responses to peripheral hormonal indicators of short and long-term energy 
balance. Interacting with these systems, reward circuitry induces motivation for relevant 
appetitive stimuli (wanting), and generates pleasure (liking) reactions to food. Finally, 
cognitive mechanisms including attention, executive control and memory are important for 
control of eating behaviour. Together, the interaction of these neural circuits creates a 
complex, dynamic and adaptive eating behaviour control system. Given that this circuitry is 
dependent on neurotransmitter function, a tempting prospect for treating obesity is to target 
these systems with anti-obesity drugs. For instance, drugs might be designed to: (a) influence 
motivational centres, to reduce the ‘wanting’ of food; (b) influence pleasure related areas to 
reduce the impact of highly palatable foods; (c) influence energy sensing circuitry to reduce 
hunger or enhance satiety; (d) influence cognitive functions such as memory, to enhance 
memories of food consumption and reduce subsequent food intake. These are only a few 
examples, but they illustrate how the control of appetite can be modulated in multiple ways, 
at multiple sites, via multiple neurotransmitter systems. 
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1. 3. Treatment of Obesity 
1.3.1. Introduction  
The primary aim of obesity treatment is weight-loss. Even a modest 5-10% weight-loss, 
which is approximately 5kg-10kg in patients with a healthy BMI, is associated with 
improvements in health (Goldstein, 1992; Blackburn, 1995). Weight-loss in excess of 10%, 
which is > 10kg weight-loss in those with healthy BMIs, is classed as moderate and shows 
superior improvements in health, such as decreased blood pressure and cholesterol and 
improved glycemic control (Pasanisi et al. 2001; Wing et al. 2011). Current methods of 
treating obesity include lifestyle interventions, psychological therapies, bariatric surgery and 
anti-obesity drugs.  
 
1.3.2. Lifestyle Interventions  
One of the most popular lifestyle interventions is the use of diets, of which there are a 
staggering variety. For instance, there is a subset of diets that focus on varying the intake of 
certain types of foods. Low fat diets advocate reducing the amount of fat consumed and show 
a mean weight-loss of 3.2kg after at least 2 months of intervention (Astrup et al. 2000), while 
low carbohydrate diets decrease weight by 7.0kg after 3 months intervention (Santos et al. 
2012). Conjunction diets, such as low carbohydrate – high protein can also reduce weight to a 
greater extent that singular diets (e.g. high protein only) (Hession et al. 2008). While some 
individuals follow these diets alone, many join dieting groups. For instance, commercial 
weight-loss programs such as Weight Watchers provide dietary advice and social support and 
produce modest weight-loss of approximately 4.4 - 5.1kg after 12 months (Jolly et al. 2011; 
Jebb et al. 2011). 
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In addition to diets, physical activity is often prescribed as a weight-loss adjunct, although 
there has been considerable debate regarding whether exercise may enhance energy intake 
and thus have a counterproductive effect. For example, there is evidence that exercise is 
associated with increased energy intake (Sonneville and Gortmaker, 2008) and that 
individuals compensate for up to 30% of an exercise-induced energy deficit by enhancing 
their energy intake (Stubbs et al. 2004; Whybrow et al. 2008). In contrast, increased exercise 
does not increase hunger, or energy intake (King et al. 1997) and a recent systematic review 
of 103 research studies found no evidence of increased energy intake following increased 
exercise (Donnelly et al. 2014). Since obese individuals do not tend to show these 
compensatory effects (Donnelly et al. 2000) but lean individuals do (Woo and Pi-Sunyer, 
1985), it has been proposed that the compensatory effects are specific to lean individuals, as a 
mechanism to defend their fat reserves (King et al. 2012). 
 
In a weight-loss intervention study in the obese, promoting higher levels of physical activity 
led to greater weight-loss after 12 and 18 months, compared to controls given standard 
behaviour therapy (Jeffrey et al. 2003). Similarly, exercise has been proposed to be at least as 
effective as dietary interventions, with evidence that modest weight-loss of 7.6kg can be 
achieved after 3 months of either a low calorie diet, or increased exercise in obese men (Ross 
et al. 2000). However, not all studies report such large effects and a meta-analysis by Miller 
and colleagues (1997) showed that 4 months of exercise only resulted in a 2.9kg weight-loss.  
 
While the degree of weight-loss varies, the majority of research concurs that the combination 
of diet and exercise intervention provides greater weight-loss in the long term, than either 
intervention used in isolation. For instance, in the same meta-analysis by Miller and 
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colleagues (1997), diet produced a moderate 10.7kg decrease in weight, while diet and 
exercise decreased weight by 11.0kg. However, after a 1 year follow-up, maintenance of 
weight-loss effects was 6.6kg for the diet and 8.6kg for the diet and exercise group, 
suggesting improved maintenance effects of combining exercise with diet (Miller et al. 1997). 
A more recent systematic review has also reported that exercise in conjunction with diet, 
results in greater weight-loss than diet alone (Curioni and Lourenço, 2005) and that these 
benefits can persist for over 2 years (Wu et al. 2009).  
 
A limitation of the diet and exercise approach is that maintenance of weight-loss effects is 
often poor. In many cases almost half of initial weight-loss is regained 12 months after either 
diet, or diet and exercise interventions (Curioni and Lourenço, 2005). According to a 
systematic review of the literature, while diet and exercise may produce a moderate weight-
loss of 11.1kg after four months, weight-loss maintenance drops to 5.8kg after 1 year 
(Kouvelioti et al. 2014). One explanation of weight regain is that there are biological 
compensatory mechanisms which alter behaviour to ‘correct for’ weight-loss (Leibel et al. 
1995; see Blomain et al. 2013 for review). However, this is a generic hypothesis that applies 
equally to all mechanisms of weight-loss. Specifically in relation to dieting, food liking is 
enhanced after calorie restriction interventions, suggesting that in the long term, dieting might 
increase the reward value of food, leading to over-consumption that promotes weight re-gain 
(Cameron et al. 2008). With regard to exercise, obesity is associated with reduced pleasure 
taking exercise, particularly due to social anxiety, which might explain poor long-term 
compliance and subsequent weight regain (Ekkekakis et al. 2010). 
Weight cycling is the cyclical losing and gaining of weight between diets (Blackburn et al. 
1989). In a population study of almost 7000 people approximately 7% of men and 10% of 
women were severe weight cyclers, with weight loss more than or equal to 5kg on three 
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occasions accompanied by weight regain (Lahti-Koski et al. 2005). There is evidence that it is 
associated with increases in binge eating (Foster et al. 1997) and is a predictor of large weight 
gain (Kroke et al. 2002). Hence, gaining and losing weight via successive weight-loss 
interventions such as dietary and exercise interventions might have a net negative effect on 
weight and health. However, it should be noted that not all studies have found such effects 
(Stevens et al. 2012).  
 
Both diet and exercise are capable of producing modest to moderate weight-loss. A 
combination of diet and exercise seems to be the most efficacious approach, but maintenance 
of weight-loss is an ongoing problem. Recurrent weight cycling due to repeated dieting 
attempts is also common and has negative consequences. Thus, neither dietary nor exercise 
interventions are effective for sustaining moderate (i.e. 10% or more) decreases in body 
weight. 
 
1.3.3. Psychological Therapy  
There are a variety of psychological therapies aimed at supporting lifestyle changes. 
Cognitive behavioural therapy (CBT) is one of the leading therapies. Cooper and Fairburn 
(2001) proposed the idea of adapting CBT to the treatment of obesity, based on the premise 
that changing thinking related to eating behaviour and weight would result in a positive effect 
over time. The aim of CBT for obesity is to adjust an individual’s thinking about their weight 
and weight-loss attempt(s) to help them achieve their goals.  
It has been reported that eight sessions of CBT compared to being on a waiting list, resulted 
in a small but statistically significant reduction in weight in adult women, which was 
sustained at a 4 month follow-up (Pimenta et al. 2012). In adolescents, 20 weeks of CBT 
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compared to a no treatment control group resulted in reductions in body weight (-1.9kg) and 
body fat (-1.5kg) and reduced the intake of sugary drinks which was directly related to the 
reductions in weight (Tsiros et al. 2007). In another study comparing CBT programmes 
ranging from 14-20 weeks in length, approximately 6% of body weight was lost during the 
interventions. However, compliance and follow-up attendance were poor (Melchionda et al. 
2003).  
 
Typically, CBT is not administered alone, but as an adjunct therapy.  A combination of CBT, 
diet and exercise was found to produce greater reductions in weight than diet and exercise 
alone (Shaw et al. 2005). However, for both CBT delivered alone and CBT administered in 
combination with other interventions, the evidence suggests that while it is possible to induce 
weight-loss, the effect is unlikely to be maintained. In a five year follow-up study, morbidly 
obese patients were given a comprehensive intervention, comprising CBT, diet and exercise, 
during a 6 week stay in hospital (Golay et al. 2004). Although modest weight-loss of 7.6kg 
was achieved, after 5 years more than half of patients had regained this weight (mean weight 
regain = 10.4kg). In another study, obese patients were given CBT compared to guided self-
help (minimal intervention). Both interventions resulted in approximately 10% weight-loss, 
however, after 3 years follow-up, both groups regained almost all the weight they had lost 
(Cooper et al. 2010). Hence, while CBT might represent a non-invasive way to induce 
weight-loss, it lacks the ability to produce sustained weight-loss. 
 
Mindfulness training is a type of psychological therapy that has been trialled to assist with 
weight-loss and weight-loss maintenance. Mindfulness raises awareness of an individual’s 
awareness of thoughts and feelings in the present. In a study with obese patients, 6 weeks of a 
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mindfulness-based eating intervention significantly decreased body weight compared to 
baseline, producing a mean weight-loss of 4kg at a 12 week follow-up (Dalen et al. 2010). 
Even very brief interventions might be beneficial to protect and maintain weight-loss. For 
example, patients completing a 6 month weight-loss program were either assigned to a one 
day mindfulness workshop, or placed on a waiting list (control group). At 3 months follow-
up, a higher percentage of patients in the workshop group had lost weight, and fewer showed 
weight gain, compared to controls (Lillis et al. 2009). Hence, mindfulness might have some 
use in maintaining weight-loss, however, further longer-term follow-ups are needed to 
investigate this treatment. 
 
1.3.4. Bariatric Surgery 
Bariatric surgery, which includes gastric bypass, gastric banding and sleeve gastrectomy, is a 
particularly efficacious treatment for obesity, producing significant and reasonably fast 
reductions in BMI between 12 to 17kg/m2 post-surgery (Chang et al, 2013). Gastric bypass 
involves compartmentalising the stomach into two pouches and rerouting a portion of the 
small intestine to the upper section of the stomach; Roux-en-Y Proximal is the most common 
gastric bypass procedure performed. The surgery results in enhanced feelings of fullness and 
satiety and is associated with reduced food intake (Elder and Wolfe, 2007).  
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Figure 1.2 Roux-en-Y Gastric Bypass. The stomach is partitioned into two pouches; a small 
upper pouch and a lower larger pouch. A portion of the small intestine is then rerouted to the 
smaller upper pouch (image is from the American Society for Bariatric Surgery; 
www.asbs.org). 
 
Gastric banding involves restricting the size of the stomach using a silicone band, thereby 
limiting the volume of food that can be ingested (Elder and Wolfe, 2007). Sleeve gastrectomy 
involves removal of the majority of the stomach, to permanently decrease stomach size, 
thereby restricting food intake (Elder and Wolfe, 2007).  
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While gastric restriction is a physical mechanism by which food intake and weight might be 
reduced, bariatric surgery has additional consequences. For instance, high serum leptin levels 
in obese patients are sharply reduced back to the normal range after biliopancreatic diversion 
(Adami et al. 1998), with similar results for gastric bypass surgery (Geloneze et al. 2003). In 
addition, ghrelin is also reduced by gastric bypass surgery, which has led to the hypothesis 
that ghrelin reductions might partly underlie decreases in food intake and body weight 
(Cummings et al. 2002; Geloneze et al. 2003). Hence, there are a range of hormonal effects 
that appear to contribute to the success of these methods. 
 
A comparison of the effectiveness of surgical techniques showed that at 3 month follow-up, 
weight-loss was 35% for Roux-en-Y gastric bypass and 19% for gastric banding (Jan et al. 
2005). However, at 36 months, weight-loss was 60% for Roux-en-Y gastric bypass, and 57% 
for gastric banding (Jan et al. 2005). In a comparison of sleeve gastrectomy versus Roux-en-
Y, the latter showed a greater weight-loss after one year, however, after 2 years there was no 
significant difference between groups (Li et al. 2014). According to a meta-analysis, after 36 
months treatment all bariatric surgeries produced at least 30kg weight-loss (Maggard et al. 
2005). In a long-term follow-up of patients who had undergone gastric banding and gastric 
bypass surgery, mean weight-losses of 47-54% were maintained at 10-15 years (O’Brien et 
al. 2013).  Compared to non-surgical treatments for obesity, a recent systematic review and 
meta-analysis of randomised controlled trials found that participants lost substantially more 
weight with bariatric surgery (mean difference = -26kg), and had higher remission rates of 
type 2 diabetes (Gloy et al. 2013). Hence, all forms of bariatric surgery provide similarly 
substantial levels of weight-loss but the effects are achieved more rapidly with gastric bypass. 
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Clearly, bariatric surgery can be extremely effective, however, it is not without issues. For 
certain populations, bariatric surgery is not effective in addressing the risk of mortality. 
Compared to patients who did not receive surgery, bariatric surgery did not decrease 
mortality in older severely obese individuals (Maciejewski et al. 2011). In addition, a recent 
systematic review and meta-analysis showed that 17% of patients experienced surgical 
complications and the mortality rate 30 days after bariatric surgery was 0.31% (Chang et al. 
2014). Further, surgery does not directly address obesogenic eating behaviours such as the 
consumption of low-nutrient high-calorie foods. Therefore these maladaptive behaviours can 
persist post-surgery leading to nutritional deficiencies. (Xanthakos, 2009; Malinowski, 2006).  
 
At present, bariatric surgery in the UK can either be accessed via the private health care 
system or is available without cost through the UK National Health Service (NHS) for 
patients meeting certain criteria. In the latter case, surgery is indicated when non-surgical 
interventions have proven ineffective with patients who have a BMI of 35-40 with 
comorbidities, or a BMI > 40 without comorbidities; it is also recommended as the first-line 
option for adults with a BMI > 50 (National Institute for Health and Care Excellence - NICE, 
2006). Thus, individuals who do not meet these criteria but are obese have few options. 
Therefore, while bariatric surgery is effective at inducing weight-loss, the post-operative 
issues, and restrictions on eligibility, suggest that other forms of weight-loss interventions are 
required. 
 
1.3.5. Pharmacotherapy 
Weight-loss drugs have been used for decades, however, the vast majority of anti-obesity 
drugs have been withdrawn since they were launched. To understand the contribution of these 
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drugs to the treatment of obesity and the continued potential for anti-obesity drugs, the 
history and future of obesity pharmacotherapy will be reviewed. 
 
1.3.5.1. History of Obesity Pharmacotherapy  
Some of the earliest central nervous system (CNS) appetite suppressants were stimulants such 
as amphetamine, d-amphetamine and methamphetamine, which were used particularly in the 
1950s and 1960s in the USA (Rasmussen, 2008). These drugs act via presynaptic release of 
dopamine and noradrenaline, producing sympathomimetic effects, appetite suppression and a 
decrease in food intake, cumulating in weight-loss (Foltin et al. 1990; Bray et al, 1992). The 
anorectic effect of amphetamine appears to be mediated by dopamine D1 and D2 receptors 
(Chen et al, 2001). Amphetamine produces 2.7kg weight-loss after 4 months treatment in 
obese patients (Haddock et al. 2002). However, due to their addictive properties and potential 
for abuse, the use of amphetamines is now controlled and restricted (Bray, 2001) and in the 
UK amphetamine is scheduled as a Class B illegal drug 
 
Phentermine releases noradrenaline and dopamine, and was approved by the Food and Drug 
Administration (FDA) in 1959. Fenfluramine releases and inhibits the reuptake of serotonin, 
and was approved by the FDA in 1973. Dexfenfluramine (Redux) was approved by the FDA 
in 1996. Phen-fen, the combination of phentermine and fenfluramine, was not a marketed 
compound but the two drugs were often prescribed as a combination by physicians in the US. 
Fenfluramine and dexfenfluramine exert their anorectic effects through serotonergic 
mechanisms, particularly by an agonist action at the 5-HT2C receptor (Vickers et al.1999; 
Vickers et al. 2001), which produces satiety enhancing effects, leading to reduced food intake 
in rats (for reviews see Dourish, 1995; Bickerdike et al. 1999). Phentermine stimulates 
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noradrenaline release, and to a lesser degree, dopamine release which is similar to the profile 
of amphetamine (Rothman et al. 2001). Phentermine has a particularly strong 
sympathomimetic effect, with significantly increased locomotor activity observed in rats 
(Rowley et al, 2000). The drug also has an effect on appetite, reducing hunger in healthy 
volunteers (Silverstone, 1972). Both fenfluramine and dexfenfluramine showed similar levels 
of weight-loss efficacy, in the region of 3.8kg after 8 months treatment (Haddock et al. 2002). 
Phentermine also showed comparable efficacy, producing a 3.6kg weight-loss at 6 months (Li 
et al. 2005). Fenfluramine and dexfenfluramine were withdrawn by the FDA in 1997 (Bowen 
et al. 1997) as their use is associated with cardiac valvulopathy caused by an agonist action at 
5-HT2B receptors expressed in cardiac tissue (Rothman et al. 2000).  
 
Sibutramine received approval from the FDA as a new anti-obesity drug in the same year that 
fenfluramine and dexfenfluramine were withdrawn. Sibutramine is a serotonin-noradrenaline 
reuptake inhibitor that reduces food intake by accelerating satiety in humans (Halford et al. 
2010). Agonist actions at 1 and 1 adrenoceptors and 5-HT2C receptors probably mediate 
this satiety enhancing effect (Jackson et al. 1997; Higgs et al. 2011). Sibutramine-induced 
reductions in food intake are modest averaging approximately a 4.5kg after 12 months 
treatment (Barkeling et al. 2003; Li et al. 2005). In 2010, sibutramine was withdrawn from 
the market as it was discovered that the drug was associated with an increased risk of 
cardiovascular events, such as heart attack and stroke (Sayburn, 2010).  
 
In 2006, the cannabinoid CB1 receptor inverse agonist rimonabant was approved by the 
European Medicines Agency (EMA). Rimonabant reduces hunger and caloric intake in 
humans (Heshmati et al. 2001) and it has been claimed to have a stronger effect on the 
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consumption of palatable foods in rats (Arnone et al. 1997); though a recent study failed to 
replicate this finding (Buckley and Rasmussen, 2014). Rimonabant produced a 4.7kg weight-
loss after 1 year (Christensen et al. 2007), which is similar in magnitude to the weight-loss 
caused by sibutramine. However, in January 2009 rimonabant was withdrawn from European 
markets due to adverse psychiatric effects including low mood, depression, and in some cases 
suicidal ideation (Butler and Korbonits, 2009). These side-effects prompted the FDA to issue 
a non-approvable letter for rimonabant for the US market.  
 
The anti-obesity drug orlistat was approved as a prescription drug in 1999 and marketed as 
Xenical®. More recently, orlistat was approved by the FDA as an over the counter drug and is 
marketed as AlliTM.  Unlike most previous anti-obesity drugs that primarily targeted the CNS, 
orlistat is a pancreatic lipase inhibitor that prevents the breakdown and absorption of fat in 
the intestinal system (Davidson et al. 1999). This produces unpleasant gastro-intestinal side-
effects, particularly for individuals consuming diets rich in fat (Finer, et al. 2000). In terms of 
efficacy, orlistat showed a weaker effect than sibutramine, reducing weight by approximately 
2.9kg at 12 months (Li et al. 2005). Orlistat is presently the only licensed anti-obesity drug in 
the UK. 
 
1.3.5.2. Future of Obesity Pharmacotherapy 
Recently, the FDA has approved two new anti-obesity drug treatments; the selective 5-HT2C 
receptor agonist lorcaserin (Belviq®) and a combination therapy of phentermine and 
topiramate (Qsymia®, formerly Qnexa). Lorcaserin is a full agonist at the 5-HT2C receptor, 
and is 18 times more selective for the 5-HT2C receptor than the 5-HT2A receptor (Thomsen et 
al. 2008). The drug is also >100 fold more selective for the 5-HT2C receptor than the 5-HT2B 
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receptor, and all other 5-HT receptors (Thomsen et al. 2008). Lorcaserin reduces food intake 
in rats and this effect can be blocked by treatment with a selective 5-HT2C receptor 
antagonist, but not a selective 5-HT2A receptor antagonist, confirming the role of 5-HT2C 
receptors in mediating the hypophagic effect (Thomsen et al. 2008). During an early clinical 
trial, 12 weeks treatment with lorcaserin 10mg twice daily produced weight-loss of 3.6kg in 
obese men and women (Smith et al. 2009). More recently, a meta-analysis of studies in which 
lorcaserin was administered for a year showed that lorcaserin produced a mean weight-loss of 
3.2kg (Chan et al. 2013); an effect that is probably due to enhanced satiety and reduced food 
intake though this remains to be confirmed. Hence, 5-HT2C receptor agonism remains a 
strategy to induce weight-loss pharmacologically. More broadly, there is likely to be 
continued interest in serotonergic drugs, as a recent study reported that serotonin transporter 
availability is associated with BMI (Hesse et al. 2014). Thus, the serotonergic system as a 
whole remains as an important target. 
 
Qsymia appears to be more efficacious than lorcaserin and previous anti-obesity agents, 
inducing moderate weight-losses of 8.1-10.2 kg after a year of treatment (Gadde et al. 2011). 
While the behavioural mechanism and pharmacology underpinning these effects have been 
extensively investigated for phentermine, mediation of the effects of topiramate (initially 
developed and approved for the treatment of epilepsy) is less clear. Work with rodents 
suggests that topiramate increases energy expenditure and decreases food intake (Richard et 
al. 2000; Picard et al. 2000). In obese men topiramate decreases energy intake, but in the 
absence of any changes in appetite or satiety (Tremblay et al. 2007); hence, the mechanism 
responsible for reducing food consumption might be distinct from previous anti-obesity 
drugs. One possible explanation relates to the ability of topiramate to inhibit excitatory 
pathways through antagonism at α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
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(AMPA) receptor sites (Gibbs et al. 2000; Zullino et al. 2003). Indeed, as topiramate reduces 
neurotransmission of the excitatory neurotransmitter glutamate (Kaminski et al. 2004), and 
this has previously been linked to decreased food intake (Zheng et al.2002), it is possible that 
this is the primary pharmacological mechanism by which the drug affects energy intake. 
However, topiramate also potentiates gamma-aminobutyric acid (GABA) transmission, both 
acutely and chronically (Kuzniecky et al. 2002) and there is evidence that 
intracerebroventricular injections of GABA in rats decrease food intake (Olgiati et al. 1980), 
while in humans,  the GABAB receptor agonist baclofen has been reported to produce a 
weight-loss (Arima and Oiso et al. 2010). Hence, the effect of topiramate on GABA 
neurotransmission might also play a significant role in its anti-obesity effects. 
 
Unfortunately, compliance with Qsymia is affected by unpleasant side-effects of the drug, 
including: paresthesia; dry mouth; constipation; dysgeusia; and insomnia (Alison et al. 2011). 
Less frequent are: depression; irritability; alopecia; anxiety; disturbance in attention and 
hypothesia (Alison et al. 2011). Although licensed in the United States, the drug has recently 
been rejected by the EMA due to concerns about cardiovascular and CNS side-effects (2013). 
Hence, Qsymia is not yet approved for sale in the UK market.  
 
Contrave, which is a combination of bupropion and naltrexone, has been submitted for FDA 
approval. Bupropion is a dopamine and noradrenaline reuptake inhibitor (Ferris et al. 1983) 
which enhances locomotor activity (Cooper et al, 1980), and decreases food intake in rats 
(Stairs and Dworkin, 2008) and induces weight-loss in humans (Anderson et al. 2002a). 
Naltrexone is an opioid receptor antagonist that reduces appetite and the rated palatability of 
foods by human volunteers (Speigel et al. 1987; Yeomans and Gray, 1997). Contrave 
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produces a more pronounced anorectic effect than either buproprion or naltrexone alone and 
appears to have fewer side-effects than buproprion when tested in rats (Wright and Rodgers, 
2013). In humans, contrave produced modest reductions in body weight of 4.3 - 7.9kg at 56 
weeks treatment (Apovian et al. 2013), suggesting it could be a useful anti-obesity agent.  
 
Empatic is a combination of buproprion and zonisamide that is in development for the 
treatment of obesity. Zonisamide is another anti-epileptic drug with a similar 
pharmacological mechanism of action to topiramate (Ueda et al, 2003). Zonisamide also 
increases dopamine and serotonin levels (Okada et al, 1995; Okada et al, 1999) but the 
mechanism by which the drug decreases body weight is unclear at present. Zonisamide is 
associated with modest weight-losses of 7.3kg after a year (Gadde et al, 2012), whereas 
Empatic produces 8.1kg of weight-loss after only 12 weeks of treatment (Gadde, 2007). 
 
There are also a large number of other compounds in earlier stages of preclinical and clinical 
development, targeting novel pathways (see Table 1.1. below). A number of neuropeptide 
receptors such as GLP-1, neuropeptide Y, and melanocortin are being investigated as 
potential targets, to treat obesity. Work on GLP-1 drugs has resulted in the GLP-1 agonist 
Exenatide (Byetta), and the GLP-1 analogue liraglutide (Victoza), which produces a 
sustained weight-loss of 7.8kg over 2 years, with minimal side-effects (Astrup et al. 2012). A 
neuropeptide Y receptor antagonist, Velneperit (George et al. 2014) and a melanocortin-4 
receptor agonist RM-493 (Kievit et al. 2013) have also been reported to show early promise 
as weight-loss agents. In addition, a novel µ-opioid receptor antagonist GSK1521498 is 
currently in early stage clinical trials in humans (Ziaudeen et al. 2013).  
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Table 1.1 Promising novel anti-obesity drugs under development 
Target Drug Mechanism of Action Status 
        
µ-opioid GSK1521498 µ-opioid antagonist Phase II 
        
Melanocortin  RM-493 Selective MC4R agonist Phase II 
        
GLP-1 Liraglutide (Victoza) GLP-1R Agonist Phase III  
  Exenatide (Byetta) GLP-1R Agonist Phase III  
        
Neuropeptide Y  Velneperit Y5 antagonist Phase III 
        
 
 
While the recent development and approval of new drugs to treat obesity is promising, the 
long term efficacy and safety of these compounds is still an area of ongoing research, and 
caution is clearly warranted (Li and Cheung 2009). For the development of future anti-
obesity drugs, an emphasis on ensuring efficacy and safety is paramount. Thus, it is essential 
to develop models to help identify safe and effective drugs at an early stage of development, 
so that regulatory approval is not rapidly followed by drug withdrawal as was the case with 
dexfenfluramine in the US and rimonabant in Europe. 
 
1.3.6. Summary 
Obesity is a global issue, and there is an urgent need to develop new treatments that are 
effective in producing and maintaining weight-loss as safely as possible. Unfortunately, 
current treatments are not ideal. Dietary and exercise interventions show some weight-loss 
utility, however, maintenance of these effects is very poor. Psychological therapies such as 
CBT and mindfulness training might be useful in conjunction with lifestyle interventions but 
further work is needed to examine their utility in the long term. Bariatric surgery produces 
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rapid weight-loss and maintains weight-loss. However, there are significant post-operative 
problems including surgery mortality, post-surgical complications and malnutrition. The 
eligibility criteria used by the NHS in the UK for bariatric surgery also means that many 
obese individuals are unable to be treated until their BMI increases to the eligibility 
threshold. Therefore, a treatment that can be used as an alternative to bariatric surgery is 
urgently needed. The most logical treatment to fill this demand would be a highly efficacious 
and safe anti-obesity drug. While the history of obesity pharmacotherapy has been one of 
limited success, the recent approval of new drugs, and the development of novel agents is 
more encouraging. There is a clear need for novel approaches early in clinical development to 
ensure that future drugs are both efficacious in terms of weight-loss and safe in terms of 
psychiatric side-effects. 
 
1.4. Experimental Medicine Model               
1.4.1. Introduction 
A barrier to successful development of new drug therapies for obesity is that the costs are 
high and the chance of a novel compound in Phase 1 trials reaching the market is very low, 
largely due to failure in late scale clinical trials or during the regulatory approval process 
(Kola and Landis 2004). Rimonabant is a prime example of a drug that was approved for use 
and then withdrawn shortly thereafter, resulting in a significant loss of time and money 
invested in its development (Butler and Korbonits 2009). 
 
It is increasingly recognised by the pharmaceutical industry that the introduction of 
translational Experimental Medicine models at the interface between Phase 1 and Phase 2 
clinical trials provides a more effective approach to assessing drug efficacy and safety before 
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large scale trials are undertaken (Dawson et al. 2011). Initial efficacy testing of novel 
compounds can also be conducted in healthy volunteers to assess safety issues that might 
pose risks for vulnerable patient populations (Dourish et al. 2008).  
 
At present, the potential clinical efficacy of a compound to treat obesity is primarily assessed 
by weight-loss during Phase 3 Clinical Trials. Studies must demonstrate that either: (1) 
participants lose at least 5% of their baseline body weight after 1 year compared to placebo 
or; (2) at least 35% of participants lose at least 5% of their baseline body weight (FDA, 
2007). Secondary efficacy measures that are also considered important include: blood 
pressure, pulse, lipoprotein lipids, fasting glucose and insulin, HbA1c in Type 2 diabetics and 
waist circumference. While these long term endpoints have obvious utility, they require 
lengthy periods of dosing, during costly and time-intensive studies. The ability to assess 
efficacy in shorter, acute studies could accelerate the development process. For example, 
sibutramine was marketed as an anti-obesity drug for over a decade, and induced weight-loss 
via a reduction in food intake (Barkeling et al. 2003). While the weight-loss effects take time 
to manifest, the effect of the drug on food intake are detectable after a relatively short period 
of dosing (7-14 days: Barkeling et al. 2003; Halford et al. 2010). As the sibutramine-induced 
reduction in food intake occurs acutely, and correlates with subsequent weight-loss 
(Barkeling et al. 2003), this suggests that measures of eating behaviour might provide an 
early/acute indicator of compound efficacy and assist in Go/No Go decisions during Phase 1 
Clinical trials. 
 
Studying the acute actions of anti-obesity agents can be useful in elucidating their 
behavioural mechanisms of action. This is important because there are many ways that drugs 
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can affect eating behaviour to induce weight-loss and some actions may be more effective 
than others. For example, a drug that enhances satiety may be preferable to a drug that has a 
general effect to decrease enjoyment of food and other rewarding stimuli.  Hence, a model 
that can differentiate these various pathways would be extremely useful. 
 
The requirements for ensuring psychiatric safety of compounds to treat obesity are less well 
defined by the regulatory authorities than those for weight-loss. The assessments that are used 
most commonly are validated neuropsychiatric questionnaires administered over lengthy 
weeks or months. The use of cognitive test batteries that measure emotional processing may 
offer an alternative approach to the assessment of psychiatric safety. These test batteries can 
be used in shorter term studies over days. For instance, the P1vital® Oxford Emotional Test 
Battery (ETB) is a computerised series of tasks that have been designed to assess cognition 
and emotional processing in human participants. In a study with rimonabant, the ETB 
detected negative effects of the drug on emotional processing after a single dose, in the 
absence of any change in standard questionnaire measures of mood, emotion, and psychiatric 
functioning (Horder, et al, 2009). Thus, the use of the ETB during phase 1 clinical trials 
might help to identify drugs with psychiatric safety concerns at an early stage of the clinical 
development process. 
 
With regard to both efficacy and psychiatric safety, the use of fMRI to examine the effects of 
psychopharmacological agents is growing rapidly. Recent work with sibutramine showed that 
the drug reduced activity in the hypothalamus and amygdala (Fletcher et al, 2010, see below 
for further discussion). This suggests that fMRI might be a useful technique to detect changes 
in brain activity that are related to changes in eating behaviour and the long term outcome of 
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weight-loss. In addition, fMRI might be useful to assess psychiatric safety, as previous work 
has reported that depression is related to deficits in reward (anhedonia) circuitry (McCabe et 
al. 2009). Hence, if potential biomarkers of anhedonia, depression, or other psychiatric 
effects, are detectable using fMRI, it might be possible to identify such undesirable drug-
induced effects at an early stage of testing. 
 
1.4.2. Novel Techniques for Assessing Drug Efficacy and Psychiatric Safety 
In developing an experimental medicine model to investigate anti-obesity drugs, there are a 
variety of potential methods and techniques that could be used to assess efficacy and 
psychiatric safety. Here, three specific methods will be reviewed: (1) Examining human 
eating behaviour using a Universal Eating Monitor (UEM) as an indicator of potential drug 
efficacy (2); Measuring emotional processing using the ETB as an indicator of psychiatric 
safety and; (3) Examining neural activity using fMRI as a potential indicator of both efficacy 
and psychiatric safety. 
 
1.4.2.1. Measuring Eating Behaviour using a UEM 
Total food intake is a key eating behaviour measure and could be a useful behavioural marker 
for anti-obesity drugs that aim to reduce food consumption. However, measurement of food 
intake alone does not provide any information on the behavioural mechanism by which 
anorectic drugs might exert their effects. Detailed microstructural examination of eating 
behaviour  in rats was carried out in the 1970s and 1980s by Blundell and Colleagues (1981; 
1985), who measured over various periods of time the amount of food consumed, latency to 
eat, duration of eating, number of eating bouts and local eating rate. This microstructural 
analysis of the individual components of a meal enables the detection of effects that are not 
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apparent at the macrostructural level. For instance, in a study in which rats were given five 
concentrations of sucrose, food deprivation did not affect the amount consumed of the two 
highest concentrations, however, it increased the duration of licking bouts, and decreased 
their number (Davis and Perez, 1993). Hence, changes can occur in the microstructure of 
ingestion patterns in the absence of changes in total food intake (Davis and Levine, 1977; 
Davis and Perez, 1993). 
 
The use of microstructural measures has also proven particularly useful in understanding the 
effects of different types of drug on eating behaviour. For instance, the dopamine D1 receptor 
agonist A-68930 and cocaine, reduce food intake due to selective reductions in the number of 
eating bouts (Cooper and van der Hoek, 1993; Al Nasar and Cooper, 1994). By comparison, 
amphetamine and fenfluramine reduce food consumption in rats via different microstructural 
actions: amphetamine increases inter-meal interval, whereas fenfluramine reduces eating rate 
(Blundell et al. 1976; Blundell, 1977; Blundell and Latham, 1978; Burton et al. 1981). More 
recently, it was reported that sibutramine selectively reduced consumption of glucose, by 
reducing the number of licking bouts (Higgs et al. 2011). Hence, different drugs can affect 
food intake via different microstructural actions. Therefore, it seems plausible that 
measurement of eating microstructure could be used to identify drugs that are effective anti-
obesity agents based on positive changes to eating microstructure such as a reduced eating 
rate.  
 
While the microstructural approach has been used in many rat studies to investigate the 
effects of anorexic drugs, there are fewer studies applying this approach to human volunteers. 
This is a key issue as effects in animal models do not always translate well to humans (see 
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Dourish et al. 2008; Dawson et al. 2011; Razafsha et al. 2013). A commonly used 
experimental setup is to present food buffets from which participants select a meal (Blundell 
et al. 1993; for a review of different experimental methods see Stubbs et al. 1998). These are 
particularly useful for examining the selection of different foods, however, they do not allow 
for microstructural analysis. 
 
The UEM was developed by Kissileff and colleagues (1980) to record human eating 
behaviour during the course of a meal. The basic setup consists of a balance placed under a 
table, projecting through the surface. A placemat rests on top of the table, disguising the 
balance and providing a surface on which to place a plate of food. The balance is connected 
to a computer that records the food weight every few seconds as participants eat so that the 
microstructure of a meal can be analysed. This procedure was further adapted by Yeomans 
(1996) who configured a UEM system to incorporate visual analogue scale (VAS) ratings 
throughout the meal. In the Yeomans UEM system (the Sussex Ingestion pattern Monitor or 
SIPM), participants are presented with a dish of 200g pasta. After each 50g of food 
consumed, the computer interrupts participant to ask them to complete VAS ratings. After the 
participant has eaten 150g (75%) of the total 200g provided to them the participant is asked to 
stop eating so that the dish can be replaced with another serving. The participants can 
continue to eat for as long as they wish.  
 
To date the UEM has been used to investigate various factors related to eating behaviour, 
including: the consumption of liquid versus solid meals (Kissileff et al. 1980); the effects of 
dietary restraint on eating (Westerterp-Plantenga et al. 1991); differences in eating patterns 
between bulimia nervosa patients and controls (Kissileff et al. 1996); the effects of food 
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palatability on eating (Yeomans, 1996); differences in eating patterns of lean and overweight 
individuals (Laessle et al. 2001); and as a test of the reliability of food intake measurement in 
the laboratory over time (Hubel et al. 2006). Yeomans (1996) also used the UEM to discover 
that when presented with highly palatable food, there is an initial stimulation of hunger and 
eating rate which occurs early within the meal, termed the ‘appetizer effect’. 
 
The UEM system has also been used to examine the actions of anorectic drugs. For instance, 
it has been reported that sibutramine treatment reduces the eating rate of obese women 
participants (Halford et al. 2010). Interestingly, 10 mg sibutramine significantly reduced 
intake after 12 minutes whereas 15mg sibutramine reduced intake after 4 minutes, suggesting 
that satiety was enhanced earlier in the meal at the higher dose. In addition, appetite VAS at 
the start and end of the meal were reduced by the 30mg and 15mg doses sibutramine 
respectively. In contrast, the opioid receptor antagonist naltrexone reduces food intake via a 
decrease in subjective ratings of food pleasantness and an abolition of the appetizer effect, 
suggesting a negative effect on food palatability (Yeomans and Gray, 1997). Hence, the UEM 
can distinguish drugs with different effects on appetite and satiety and has the potential to 
provide a behavioural marker of anti-obesity drug efficacy. However, further validation is 
needed to establish whether the UEM can be used successfully in acute single dose studies 
with healthy volunteers as most previous work has been carried out with clinical populations 
dosed for longer time periods. 
 
1.4.2.2. Measuring Emotional Processing using the ETB  
The ETB (see www.p1vital.com) comprises five validated cognitive tests that can be used to 
assess cognition and emotional processing (e.g. Murphy et al. 2008).  The Facial Expression 
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Recognition Task (FERT) displays faces that participants must categorise into one of six 
emotional categories based on their expression: happiness; fear; anger; disgust; sadness; 
surprise; and neutral. Response accuracy, reaction time, response bias (bias towards one 
emotion over another) and target sensitivity (ease in detecting the target stimulus from other 
stimuli) can be calculated. The Faces Dot Probe Task (FDOT) involves the presentation of 
two faces, which are replaced by a pair of dots. On some trials, one of the faces has an 
emotional expression. Participants must report the orientation of the pair of dots (i.e. vertical 
versus horizontal). For this task, accuracy, reaction time and vigilance (sustained attention) 
can be calculated. The Emotional Categorisation Task (ECAT) displays positive and negative 
self-referent personality descriptors (e.g. “cheerful” versus “hostile”, respectively) that 
participants must respond to, indicating whether they would like or dislike to be referred to as 
such. Accuracy and reaction times can be measured for this task. In the Emotional Recall 
Task (EREC) participants are asked to recall as many words as they can remember from the 
ECAT. This element is partly computerised: instructions given via computer, but words 
written down using pen and paper. The number of words recalled during this task can be 
calculated (both correct and incorrect). Finally, in the Emotional Recognition Memory Task 
(EMEM) words are re-presented from the ECAT, along with new distracter words, and 
participants are asked to report if they have previously seen the word. For this task, accuracy, 
reaction time, response bias and target sensitivity can be measured.  
 
 
The EMEM and EREC provide measures of emotional memory while the FERT, FDOT and 
ECAT provide a measure of emotion-guided attention. Effects consistent with a negative 
effect on emotional responding would include reduced responses to positive stimuli, and or, 
enhanced responses to negative stimuli. For instance, compared to control subjects, depressed 
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individuals show: reduced accuracy in identifying happy facial expressions (FERT); 
increased reaction times to respond to positive emotional words (ECAT); and reduced recall 
of positive words (EREC) (Harmer et al. 2009). 
  
Table 1.2 lists studies that have either used the ETB, or individual ETB tasks (e.g. FERT 
only). The ETB has been validated using a wide range of drugs, with different 
pharmacological mechanisms. Of the 28 studies listed, almost all showed drug-induced 
changes in either emotional processing or cognition, in the absence of any changes in 
standard measures of mood including VAS and standard psychiatric questionnaires, 
suggesting that the ETB is more sensitive to pharmacological manipulations than standard 
questionnaire measures. The ETB has also been used in several studies with clinical and 
clinical surrogate (e.g. dysphoric) populations, enabling the identification of behavioural 
markers of emotional processing. These include: individuals at risk of depression (Mannie et 
al. 2007; Chan et al. 2007; Le Masurier et al. 2007), anorexia nervosa (Jänsch et al. 2009), 
bipolar illness (Harmer et al. 2002b; Rock et al. 2010), panic disorder (Reinecke et al. 2013) 
and individuals exposed to postnatal depression (Douglas and Harmer, 2011). Hence, the 
ETB represents a single tool that can be used to identify markers of a number of relevant 
psychiatric disorders and test the potential of pharmacological agents to treat or exacerbate 
these conditions.  
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Table 1.2: Drugs studies using the ETB (or ETB Tasks) 
Study Drug(s) Tested 
Harmer et al. 2013 GSK424887 (NK₁ antagonist + 5-HT reuptake inhibitor) 
Mocking et al. 2013 Varenicline (Nicotinic acetylcholine receptor agonist) 
Harmer et al. 2012 Negative Ion Treatment 
Pringle et al. 2012 Memantine (NMDA antagonist) 
Horder et al. 2012 Rimonabant (CB1 inverse agonist) 
Harmer et al. 2011 Agomelatine (Melatonin receptor agonist) 
Browning et al. 2011 Citalopram (Selective serotonin reuptake inhibitor) 
Pringle et al. 2011 Aprepitant (NK₁ antagonist) 
Chandra et al. 2010 Aprepitant (NK₁ antagonist) 
Di Simplicio et al. 2009 Oxytocin 
Tranter et al. 2009 Citalopram and Reboxetine (Selective serotonin reuptake inhibitor and selective 
noradrenaline reuptake inhibitor) 
Horder et al. 2009 Rimonabant (CB1 inverse agonist) 
Arnone et al. 2009 Mirtazapine (Noradrenaline and serotonin antagonist) 
Murphy et al. 2009 Citalopram and Reboxetine (Selective serotonin reuptake inhibitor and selective 
noradrenaline reuptake inhibitor) 
Harmer et al. 2009 Reboxetine (Selective noradrenaline reuptake inhibitor) 
Murphy et al. 2008 Diazepam (benzodiazepine agonist) 
Harmer et al. 2008 Duloxetine (Serotonin-noradrenaline reuptake inhibitor) 
Scrutton et al. 2007 Alpha-Lactalbumin (protein with high tryptophan content) 
Murphy et al. 2006 Tryptophan supplementation 
Harmer et al. 2006 Ondansetron (5-HT3 receptor antagonist) 
Hayward et al. 2005 Tryptophan depletion 
Harmer et al. 2004 Citalopram and Reboxetine (Selective serotonin reuptake inhibitor and selective 
noradrenaline reuptake inhibitor) 
Bhagwagar et al. 2004 Citalopram (Selective serotonin reuptake inhibitor) 
Attenburrow et al. 2003 Tryptophan supplementation 
Harmer et al. 2003b Citalopram (Selective serotonin reuptake inhibitor) 
Harmer et al. 2003a Tryptophan depletion 
Harmer et al. 2002a Citalopram (Selective serotonin reuptake inhibitor) 
Harmer et al. 2001 Propranolol (Non-selective beta adrenoceptor blocker) 
 
An additional advantage of the ETB is that it can detect acute drug effects. For instance, 
several studies have reported that a single dose of the antidepressant citalopram in healthy 
volunteers produces changes in ETB task performance that are related to amelioration of 
clinical symptoms of depression (Harmer et al. 2002a; Harmer et al. 2003b; Bhagwagar et al. 
2004). In addition, there is evidence that acute effects of antidepressant drugs on ETB tasks 
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in patients with depression are associated with clinical improvement after several weeks of 
treatment, suggesting predictive potential of acute results (Tranter et al. 2009). Furthermore, 
recent studies have demonstrated that administration of rimonabant, produces an increase in 
negative emotional bias after a single dose (Horder et al. 2009) and after 7 days treatment 
(Horder et al. 2012), in the absence of any changes in subjective mood measures. Thus, the 
ETB can detect negative psychiatric side-effects after a single dose, thereby allowing a rapid 
assessment of psychiatric safety of pharmacological interventions. 
 
1.4.2.3. Measuring neural activity using fMRI 
There are a number of techniques that can be used to investigate human brain activity. These 
include electroencephalography (EEG), magnetoencephalography (MEG), positron emission 
tomography (PET) and fMRI. Each method has advantages and disadvantages. For instance, 
EEG and MEG provide good temporal resolution but poor spatial resolution, whereas fMRI 
provides the opposite. In addition, all three of these techniques are non-invasive. PET is an 
invasive technique requiring injection of a radionuclide and has very poor temporal 
resolution. However, it has reasonable spatial resolution, and can be used to investigate 
metabolically active brain regions, or, can be used to investigate the engagement of specific 
neurotransmitter receptors (Huettel et al. 2009; Kumar et al. 2013).  
 
For the investigation of anti-obesity drugs it is important that the neuroimaging technique 
provides a high spatial resolution of the neural circuitry affected by the drug. This is a key 
point because this level of detail is critical to interpret where the drug is affecting brain 
activity to produce changes in eating behaviour. It is also desirable to be able to assess 
specificity of responding to motivationally relevant stimuli (e.g. pictures or tastes of food) 
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versus control stimuli. Hence, currently the best available option to satisfy these requirements 
is fMRI as it provides good spatial resolution and the ability to examine neural responses to 
specific stimuli. 
 
fMRI measures brain activity indirectly via blood oxygen levels (Ogawa et al.1990). When 
neurones become active at rest or during a task, local blood flow to those brain regions 
increases and oxygen-rich (oxygenated) blood displaces oxygen-depleted (deoxygenated) 
blood.  Oxygen is carried by the haemoglobin molecule in red blood cells. Deoxygenated 
haemoglobin is more magnetic than oxygenated which is virtually nonmagnetic. This 
difference leads to an improved magnetic resonance signal, since the nonmagnetic blood 
causes less interference with the magnetic resonance signal. This improvement in resonance 
signal can be mapped using a magnetic resonance scanner to infer which brain regions are 
active at a particular time. By exposing participants to ‘events’ within the scanner such as 
pictures, tastes and smells, and recording the blood oxygen level dependent (BOLD) signal 
that encompasses this shift, it is possible to determine how exposure to specific stimuli 
affects brain activity (Huettel et al. 2009; Kumar et al. 2013). 
 
Previous work has reported that fMRI can be used to detect changes in BOLD activity in a 
number of regions involved in the processing of appetitive stimuli, including: insula; 
orbitofrontal cortex; anterior cingulate cortex; ventral striatum; caudate; putamen; amygdala; 
hippocampus; and hypothalamus (Simmons et al. 2005; Kringelbach et al. 2003; Cornier et 
al. 2009; Killgore et al. 2003; Goldstone et al. 2009; Porubska et al. 2006; Stoeckel et al. 
2008; Führer et al. 2008; LaBar. 2001). To date, neuroimaging has been used to: explore the 
effects of fasting on brain responses to food-related stimuli (St-Onge et al. 2005; Porubska et 
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al. 2006; Killgore et al.2003); compare the responses of lean and obese participants (Le et al. 
2006); examine the differences in restrained and unrestrained eaters (Coletta et al. 2009) and; 
examine the neural substrate of sensory specific satiety (Kringelbach et al. 2003; Smeets et al. 
2006).  
 
The effects of gastrointestinal peptides and hormones on neural activity have also been 
investigated in recent years. For example, fMRI has been used to investigate the effects of 
leptin administration on the BOLD response. In leptin deficient patients, leptin replacement 
therapy reduced striatal activity to the sight of food images, indicating an effect of leptin on 
reward circuitry (Farooqi et al. 2007).  The role of Peptide YY3-36 (PYY) has also been 
investigated in fMRI studies. In the presence of low concentrations of plasma PYY (that are 
associated with hunger) the hypothalamic BOLD signal predicts food intake. However, under 
high concentrations (that are associated with satiation) the OFC BOLD signal predicts food 
intake, potentially suggesting a switch from energy balance to reward mechanisms 
(Batterham et al. 2007). Ghrelin administration has also been reported to increase BOLD 
responses to the sight of food in the OFC, amygdala, insula, and striatum (Malik et al. 2008).  
 
The effects of a number of anorectic drugs have also been examined in fMRI studies. Fletcher 
and colleagues (2010) examined the effect of sibutramine on fMRI BOLD responses to 
pictures of food. Sibutramine attenuated activity in the hypothalamus and this effect was 
correlated with both ad-libitum food intake and subsequent weight-loss. These data suggest 
that reduced hypothalamic activity is a potential biomarker of enhanced satiation and future 
weight-loss (Halford et al. 2010). Cambridge and colleagues (2013) reported that the novel µ-
opioid receptor antagonist GSK1521498 decreased activation in the pallidum and putamen in 
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response to pictures of food. More recently, naltrexone was reported to reduce BOLD activity 
to rewarding chocolate stimuli in the dorsal anterior cingulate cortex and caudate (Murray et 
al. 2014). These data suggest that fMRI could prove useful in discriminating between 
anorectic drugs with different mechanisms of action. More broadly, the different patterns of 
activity observed for the opioid drugs and sibutramine suggests that fMRI data could be 
useful to investigate the neural mechanism of drug action, which for GSK1521498 and 
naltrexone implies an effect on reward processes, but for sibutramine suggests an effect on 
satiety processes. 
 
Rimonabant decreases activation in the OFC and ventral striatum (key reward areas) in 
response to rewarding chocolate stimuli, and increases activation in the lateral OFC in 
response to aversive mouldy strawberry stimuli (Horder et al. 2010). This pattern of activity 
suggests a dampening of reward and a bias towards negative aversive stimuli, which may 
reflect the anhedonia and depression-like effects induced by the drug and is consistent with 
the results of studies conducted with rimonabant using the ETB (Horder et al. 2009; Horder et 
al. 2012). Thus, fMRI has the potential to assess both efficacy and safety in acute studies of 
potential compounds to treat obesity. 
 
1.4.3. Summary 
Developing new anti-obesity drugs requires the early assessment of both efficacy and 
psychiatric safety. The use of experimental medicine models during Phase 1 trials provides a 
potential approach to accomplish this objective. The use of behavioural methods to examine 
eating behaviour and emotional processing can enable the evaluation of efficacy and 
psychiatric effects in acute study designs with healthy volunteers. The supplementation of 
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this approach with fMRI can provide additional biomarkers that may reveal information 
about drug mechanism(s) of action. 
 
1.5. Thesis Aims 
The experimental work in this thesis is aimed at the development of an experimental 
medicine model to determine the potential efficacy and psychiatric safety of novel anti-
obesity drugs. Thus, the thesis will aim to examine: (1) whether measures of eating behaviour 
provided by a UEM have utility as indicators of whether a drug will have a positive impact 
on eating behaviour, and elucidate a drug’s neural and behavioural mechanism of action; (2) 
the utility of using measures of emotional processing obtained from the ETB to detect 
negative psychiatric side-effects; (3) whether using the fMRI BOLD signal would provide 
indications of drug mechanism and whether these measures might prove predictive of eating 
behaviour. 
 
1.6. Thesis Hypotheses 
The following overarching hypotheses were tested: (1) The UEM will be able to detect acute 
decreases in food consumption and eating rate of healthy volunteers after the administration 
of an anorectic agent (mCPP). (2) The ETB will be able to detect changes in mood in healthy 
volunteers (e.g. increased anxiety) after administration of a drug that was previously shown 
to induce such effects (mCPP). (3) Satiation and anorectic agents which are hypothesised to 
enhance satiety will decrease BOLD responses in reward circuitry in the brain of healthy 
volunteers.  
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CHAPTER 2: Study 1: Effects of the 5-HT2C receptor agonist meta-
chlorophenylpiperazine on appetite, food intake and emotional processing in healthy 
volunteers 
2.1. Introduction 
The aim of Study 1 was to assess the validity of using the Sussex Ingestion Pattern Monitor 
(SIPM) and the ETB to detect the potential efficacy and psychiatric safety of anti-obesity 
drugs. Previous studies examining drug effects with such a model are limited. A UEM has 
been used to examine the effects of the serotonin-noradrenaline reuptake inhibitor 
sibutramine on eating behaviour in humans: sibutramine was reported to reduce eating rate 
and enhance satiety (Barkeling et al., 2003; Halford et al., 2010). Using the ETB, Horder and 
colleagues (2009) tested the effect of the cannabinoid CB1 receptor antagonist rimonabant on 
emotional processing in healthy volunteers. Rimonabant decreased positive emotional 
memory, which is a potential marker for the depressogenic effects (Butler and Korbonits, 
2009).  
 
To provide further validation of the UEM and ETB model it is necessary to test additional 
reference compounds. Here, the effects of the 5-HT2C receptor agonist mCPP will be tested. 
mCPP is a metabolite of the anti-depressant trazodone, and while it is not used clinically for 
appetite suppression, it reduces food intake in rats (Kitchener and Dourish 1994; Kennett et 
al. 1994; Hewitt et al. 2002) and in humans (Walsh et al. 1994; Cowen et al. 1995; Sargent et 
al. 1997). mCPP can also increase anxiety in healthy volunteers and in patients with panic 
disorder (Charney et al. 1987; Kahn et al. 1990). Thus, mCPP provides both an opportunity 
for the UEM to detect an effect on eating behaviour and for the ETB to detect an effect on 
emotional responding. 
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In humans, mCPP shows the highest affinity for the 5-HT2C receptor (compared to all other 5-
HT receptors) with a binding affinity (Ki) of 3.4nM (Nelson et al. 1999) where it acts as an 
agonist (Thomas et al. 1996). mCPP is also an agonist at the 5-HT1B receptor in rats, though it 
possesses a much lower affinity for 5-HT1B receptors (Hoyer, 1988). In mice, the 5-HT1B 
receptor agonist CP-94,253 suppresses food intake, but this effect is blunted or absent in 5-
HT1B knockout mice, or in animals pre-treated with a 5-HT1B receptor antagonist (SB224289) 
(Lee et al. 2004). When dosed with a 5-HT1B antagonist, mice show increased food intake 
(Lee et al. 2004). The effects of mCPP on food intake were compared to ORG 37684 (a 
relatively selective 5-HT2C agonist) and CP-94,253 on food intake by Schreiber and De Vry 
(2002) who showed that mCPP produced the greatest reduction in food intake of the three 
compounds. The 5-HT2C receptor antagonists metergoline and SB 242084 reversed the 
hypophagic effect of ORG 37684, but not the effect of mCPP or CP-94,253 (Schreiber and 
De Vry, 2002). Hence, at least part of mCPP’s hypophagic effect is likely to be mediated by 
5-HT1B receptors in rodents. Humans, however, do not express the 5-HT1B receptor in the 
brain. Therefore, it is likely that the hypophagic effects observed in humans are exerted via 
the 5-HT2C receptor and this is worth bearing in mind when comparing the effects of mCPP 
in rodents and humans. 
 
Participants were administered either a single dose of placebo, 15mg mCPP or 30mg mCPP, 
before consuming food from the UEM and then completing the ETB. Healthy volunteers 
were recruited and a between-subjects single-dose design was chosen. This is because in 
Experimental Medicine models it is more efficient to assess the potential efficacy of anti-
obesity drugs at an early stage of development by investigating the acute effects of drug 
administration on behaviour. Furthermore, testing in healthy volunteers allows the assessment 
of safety issues that might pose risks for vulnerable patient populations (Dourish et al. 2008). 
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It was predicted that mCPP would decrease food intake and enhance microstructural 
measures of satiety as well as increase anxiety and negative mood as measured by the ETB.  
 
2.2. Methods and Materials 
Participants 
48 healthy student volunteers (24 men and 24 four women) were recruited from the 
University of Birmingham; mean age 20.92 years (range 18-27), mean BMI 22.38 (range 
18.93-26.30). The study was advertised via posters as an ‘Appetite and Mood Study 
examining the effects of mCPP’. Participants received £80 compensation upon completion of 
the study. Informed consent was obtained and ethical approval was provided by the South 
Birmingham Research Ethics Committee (National Research Ethics Service). The study was 
conducted in accordance with the ethical standards laid down in the 1964 Declaration of 
Helsinki. Participants were screened to exclude the following: under 18 or over 65 years old, 
BMI under 18.5 or over 27.5, English not first language as determined by the National Adult 
Reading Test (NART – Nelson 1982), taking psychotropic medication, past or current Axis 1 
disorder as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders 
(SCID – Spitzer et al. 2004), pregnant or breast feeding, smoker, dyslexic, food allergies, 
vegan or vegetarian, diabetic, not using contraception (women), cognitive restraint score 
higher than 10 as measured by the Three Factor Eating Questionnaire (TFEQ - Stunkard and 
Messick 1985), and low rated pleasantness (<65) or low consumption of the test meal 
(<150g) on the food screening day. Women were not tested during their premenstrual week. 
 
Design 
The study used a parallel group, double-blind, placebo controlled design. A 30mg oral dose 
of mCPP was selected. Similar doses reduce appetite, and, in some cases, induce nausea and 
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anxiety (Sargent et al. 1997; Walsh et al. 1994; Cowen et al. 1995; Kahn et al. 1990). 
Therefore, a 15mg dose was also used, as this dose is not associated with nausea, but may 
still affect appetite (Smith et al. 1994a). The study had three conditions: placebo, 15mg 
mCPP, and 30mg mCPP. mCPP was supplied by the Guy’s and St Thomas’ NHS Foundation 
Trust Pharmacy Manufacturing Unit (GSTFT). Each group comprised 16 participants (8 men 
and 8 women). Both mCPP and placebo were prepared in identical capsules to maintain 
blinding.  
 
Universal Eating Monitor (UEM) 
Test meals were served on a UEM (the Sussex Ingestion Pattern Monitor - SIPM). This 
consisted of a balance (Sartorius Model CP4201; Sartorius Ltd, Epsom, UK; 0.1g accuracy) 
placed underneath, but protruding through, the surface of a table. A placemat on the table was 
used to hide the balance from view. The balance was connected to a laptop computer (refer to 
Figure 2.1). Using the procedure described by Yeomans (1996; 2000), plates containing 200g 
of pasta were placed on the mat and the amount of food eaten every 2 seconds was recorded 
covertly. The UEM software (SIPM Software version 2.0.8) was configured to interrupt 
participants each time they had eaten 50g of the meal and ask them to complete VAS ratings 
of hunger, fullness and pleasantness of the pasta. After 150g had been consumed, participants 
were interrupted and the plate was replaced with a fresh 200g plate of pasta. Participants were 
asked to eat in this manner until they felt ‘comfortably full’. The test meal consisted of pasta 
shells in a tomato and herb sauce, both Sainsbury’s U.K. own brand served at 55-60oC (233 
kcal per 200g serving).  
For each participant, a text file was produced containing the computerised VAS results and a 
time course indicating the balance weight every 2 seconds. The following variables were 
generated: total amount eaten (g), eating rate (g/min) and average mouthful weight (g). Total 
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amount eaten was calculated via decreases in plate weight over the course of the meal (with 
the exception of plate removal). This figure was divided by the number of minutes spent 
eating to derive the eating rate. For average mouthful weight, the total amount eaten was 
divided by the number of times the balance recorded a weight change (i.e. a decrease in 
weight indicating that a forkful of food had been removed). 
 
 
Figure 2.1 Left panel shows the UEM setup, featuring the laptop computer connected 
covertly to the balance underneath the red table mat with the dish for pasta placed on top. 
Right panel shows a standard 200g serving of the tomato-based pasta on the UEM setup. 
 
P1vital® Oxford Emotional Test Battery (ETB) 
The ETB is a computerised battery that comprises five validated cognitive tests see 
http://www.p1vital.com/Oxford%20Emotional%20Test%20Battery/index.html) which have 
been used in previous acute drug studies of emotional behaviour (e.g. Harmer et al. 2004; 
Murphy et al. 2008). The system produces an encrypted data file for each participant after 
they complete the test battery, which is then burned to a CD and sent to P1vital where it is 
decrypted and the data are processed (this procedure is used as security measure). The data 
processing generates all of the outcome measures, including: accuracy, reaction time, 
response bias, target sensitivity and vigilance score. 
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Accuracy is a measure of correct responses and is expressed as the percentage of correct 
responses of the total responses made. Reaction time is a measure of how long participants 
take to respond to a stimulus by pressing a button on the ETB button box and is expressed in 
milliseconds. Response bias measures the tendency to respond more or less to one stimulus 
than another (thus a bias can be positive or negative) and is calculated by taking into account 
the number of false alarms (when participants incorrectly respond that a stimulus is present) 
and misses (when participants incorrectly respond that a stimulus is not present). Target 
sensitivity measures the ease with which participants are able to detect a target stimulus 
against background distracter stimuli, by using accuracy and false alarms. Finally the 
vigilance score is a measure of sustained attention for a given stimulus, and is calculated by 
subtracting the reaction times from congruent trials (trials where the probe appears in the 
same location as the stimulus) from incongruent trials (trials where the probe appears in a 
different location from the stimulus).  
 
Facial expression recognition task (FERT): Faces with one of six emotional expressions 
(happiness, fear, anger, disgust, sadness and surprise) or a neutral expression were displayed. 
The pictures (from Ekman and Friesen 1976) were morphed from neutral to 100% 
expressions (Young et al. 1997) in 10% stages, producing 10 intensities for each emotion. 
Each intensity was presented four times for each emotion, along with 10 presentations of 
neutral expressions, yielding 250 stimuli. These were presented for 500ms, followed by a 
blank screen. Participants classified each expression as quickly and accurately as possible, 
using the button box provided. Accuracy, response bias (bias towards one emotion over 
another) and target sensitivity (ease in detecting the target stimulus from other stimuli) were 
calculated. 
 
60 
 
Faces dot probe task (FDOT): Pairs of photographs (from Matsumoto and Ekman 1988) 
were presented comprising either: one emotional (either happy or fearful) and one neutral 
facial expression, or two neutral expressions. Faces appeared above or below a central 
fixation point. For unmasked trials the pair was displayed for 100ms, whereas for masked 
trials, the pair was displayed for 16ms, and then replaced with a mask for 84ms; for both 
trials, the images were then replaced with a probe, located in the position of one of the faces 
(or masks). The probe consisted of a pair of dots, in either a vertical (:) or horizontal (··) 
orientation. Participants indicated the orientation as quickly and accurately as possible using 
the corresponding buttons on the button box. There were 192 trials: 32 happy + neutral; 32 
fear + neutral; 32 neutral + neutral for both masked and unmasked trials. Vigilance (sustained 
attention) scores were calculated. 
 
Emotional categorisation task (ECAT): Sixty positive and negative self-referent personality 
descriptors (e.g. “cheerful” versus “hostile”) (Anderson 1968), were displayed for 500ms. 
Words were matched for meaningfulness, length and frequency of occurrence. Participants 
indicated using the button box whether they would like or dislike to be described as such as 
quickly and accurately as possible. Accuracy and reaction times were measured. 
 
Emotional recall task (EREC): participants were asked to recall as many words as they could 
remember from the ECAT, within a four minute period. This task was partly computerised; 
instructions given via computer, but words written down using pen and paper. The number of 
correct words recalled and their valence was measured. 
 
Emotional recognition memory task (EMEM): Participants were presented with a series of 
words on a computer screen, containing the 60 personality descriptors from the ECAT, along 
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with 60 matching novel distracter words. Participants were instructed to use the button box, 
pressing ‘yes’ or ‘no’ to indicate whether the word had been presented during the ECAT. 
Accuracy, response bias and target sensitivity were calculated. 
 
Biological samples 
Salivary cortisol: Saliva was collected using salivettes (SARSTEDT). Participants abstained 
from drinking water for 30 minutes prior to giving the sample and then chewed on a synthetic 
cotton wool swab for 60 seconds. The sample was then taken to be centrifuged for 2 minutes 
at 1000g and then frozen at -80oC until analysed. Salivary cortisol was measured by liquid 
chromatography-mass spectrometry (LC-MS/MS) by the Clinical Laboratory Services, 
University Hospitals Birmingham NHS Foundation Trust. A Waters Aquity UPLC system 
was used for chromatography and was connected to a Waters Premier XE tandem mass 
spectrometer with an electrospray ion source. Intra-assay coefficients of variation (CVs) were 
<5.9% and inter-assay CVs <9.8% between 3 and 47 nmol/L. The lower limit of 
quantification, defined as the lowest concentration at which the CV is <20%, was 1.6 nmol/L.    
 
Procedure 
The experimental procedure is summarised in Figure 2.2. 
 
Figure 2.2 Flow diagram for screening process followed by an overview of key events and timings for test days 
in hours (hrs). 
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Screening Days: Participants underwent an initial screening at the School of Psychology, 
University of Birmingham for exclusions and completed the Eysenck Personality 
Questionnaire (EPQ - Eysenck and Eysenck 1975) to determine baseline personality traits. 
They returned approximately one week later for a trial run with the test meal served; those 
who liked and ate a sufficient amount of the pasta proceeded to the test day. 
 
Test Day: Participants arrived at the Welcome Trust Clinical Research Facility (WTCRF, 
University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital) at 
8.00, 9.00 or 10.00am. It was ensured that participants had eaten their normal breakfast two 
hours earlier by asking them to complete a breakfast questionnaire detailing their food intake 
that morning. Participants then completed a physical health check with a physician. This 
examination included blood pressure measurement and an electrocardiogram (ECG). They 
were then breathalysed and women completed a pregnancy test. All participants passed these 
checks. Participants also completed baseline VAS ratings of mood and appetite that 
comprised rated: ‘alertness’, ‘disgust’, ‘drowsiness’, ‘light-headed’, ‘anxiety’, ‘happiness’, 
‘nausea’, ‘sadness’, ‘withdrawn’, ‘faint’, ‘hungry’, ‘full’, ‘desire to eat’ and ‘thirst’. VAS 
scales comprised 100mm horizontal lines, anchored to the left and right with 0 and 10 
respectively. Participants were asked to place a vertical line on the scale to indicate how they 
felt at the moment, with 10 being the most they could ever imagine and 0 being completely 
absent. 1.5 hours after the start of the session, participants completed a pre-dose Beck 
Depression Inventory (BDI – Beck et al. 1961), Befindlichskeit scale of mood and energy 
(BFS - von Zerssen et al. 1974), and Positive and Negative Affective Schedule (PANAS – 
Watson et al. 1988), as measures of subjective mood and energy. They also completed a State 
Trait Anxiety Inventory (STAI – Spielberger, 1983) as an index of their anxiety, and another 
set of VAS as described above. After 2.5 hours, further VAS were completed and a saliva 
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sample was taken, after which participants were administered the test dose; either placebo, 
15mg mCPP or 30mg mCPP. VAS were completed every 30 minutes. 4.5 hours after the start 
of the session, participants were given ad-libitum access to the test meal on the UEM, and 
completed the computerised VAS during the meal. Following the meal, participants 
completed: BDI, BFS, PANAS, STAI and VAS. A saliva sample was taken an hour after 
lunch and participants then completed the ETB, which took approximately 90 minutes. A 
final set of VAS and a saliva sample were taken at the end of the session, along with a single 
blood sample. Participants were fully debriefed and questioned to determine if they were 
aware of the hidden balance or the aims of the study. 
 
Data Analysis 
General: One participant did not complete testing and so their data were removed from all 
analyses (woman 30mg mCPP group). For statistical analyses, effects and interactions with 
condition were determined by analysis of variance (ANOVA) and followed up with planned 
comparisons. Interactions with condition were also analysed if they approached statistical 
significance. Dunnett’s correction was used for all t-tests, and violations of sphericity were 
addressed using the Greenhouse-Geisser correction.  
 
VAS: To establish a factor structure for the VAS, a principal components analysis (PCA) was 
run with varimax rotation. All of the visual analogue scales data (i.e. all data points from all 
time points across the testing session – both between and within-subjects data) were entered 
into the PCA. Analysis of the 14 items provided 5 factors with eigenvalues > 1, accounting 
for 70.81% of the variance. Items that loaded > 0.5 onto a factor were included, resulting in 
four factors of 3 or more items: appetite (hunger, fullness and desire to eat), physical effects 
(lightheaded, nausea and faint), negative effects (disgust, anxiety, sadness, withdrawn and 
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thirst) and arousal (alertness, drowsiness and happiness). Scores for each of the factors were 
calculated by summing the scores for all items in that factor, and then dividing by the number 
of items. Items with a negative scale, were inverted to match the other items.  
 
UEM: For the UEM, microstructural data for 12 participants were lost due to technical issues 
with the balance and so the data for 35 participants were analysed. For total intake and 
correlational analysis, an estimate of intake was used. For instance, where intake data were 
missing for a plate, it was assumed that if the plate was finished, the individual had eaten 
approximately 150g.  
 
2.3. Results 
Participant Characteristics 
The groups did not differ in age, BMI or EPQ scores (all p > 0.05). There was a main effect 
of gender for the NART, with men scoring higher scores than women (F (1 41) = 5.12; p < 
0.05) and for the TFEQ factor cognitive restraint, with women showing higher restraint than 
men (F (1 41) = 4.19; p < 0.05), but there were no other main effects or interactions at 
baseline (Table 2.1).  
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Table 2.1 Participant characteristics, baseline means, and test meal intake (standard error of the mean) 
 
Men Women 
  Placebo 15mg 30mg Placebo 15mg 30mg 
Gender 8 8 8 8 8 7 
 
UEM Data 5 5 5 8 7 5 
Age 20.8 (0.4) 21.9 (0.8) 20.4 (0.5) 22.4 (1.0) 20.4 (0.5) 19.9 (0.7) 
BMI 23.8 (0.7) 22.1 (0.7) 22.8 (0.8) 21.5 (0.7) 22.0 (0.8) 22.4 (0.9) 
NART 114.9 (1.0) 114.6 (1.7) 112.6 (1.6) 112.9 (1.0) 111.9 (1.6) 109.7 (0.9) 
TFEQ CR 4.3 (1.4) 3.6 (1.0) 3.1 (1.0) 6.9 (0.9) 5.5 (1.1) 4.1 (1.2) 
EPQ N 4.0 (0.8) 4.0 (1.0) 4.0 (1.0) 7.9 (1.1) 3.3 (1.3) 4.1 (0.6) 
Test Meal  649.3 (90.1) 778.2 (111.6) 663.8 (107.7) 510.1 (60.2) 442.8 (31.1) 409.2 (66.9) 
              
       BMI - Body Mass Index; NART - National Adult Reading Test; TFEQ - Three Factor Eating Questionnaire (CR 
- Cognitive Restraint); EPQ - Eysenck Personality Questionnaire (N - Neuroticism) 
 
Salivary Cortisol 
Salivary cortisol was analysed by gender, condition, and time (baseline measure: t0; time 
after dosing: t60, t120, t180, t300). There was a main effect of time (F (4 164) = 7.07; p < 
0.001), condition (F (2 41) = 12.32; p < 0.001), an interaction between condition and time (F 
(8 164) = 2.49; p < 0.05), and an interaction between time and gender that was not analysed 
further (F (4 164) = 3.42; p < 0.05). Post hoc analysis showed there were main effects of 
condition for t60 (F (2 44) = 7.41; p < 0.01), t120 (F (2 44) = 8.37; p < 0.01) and t300 (F (2 
44) = 6.16; p < 0.01). Cortisol was significantly higher in the 15mg mCPP condition 
compared to placebo at t60 (t (30) -2.43; p < 0.05); while cortisol was higher in the 30mg 
mCPP condition compared to placebo for t60 (t (29) -4.18; p < 0.01), t120 (t (29) -3.86; p < 
0.01) and t300 (t (29) -3.36; p < 0.01) (Figure 2.3). There was no interaction between gender 
and condition (F (2 41) = 0.32; p > 0.05), or gender, condition and time (F (8 164) = 3.29; p > 
0.05), indicating that there was no differential cortisol response for men versus women to 
mCPP. 
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Figure 2.3 Salivary cortisol levels over time for placebo, 15mg mCPP, and 30mg mCPP. The 15mg group 
showed a significant increase in salivary cortisol compared to the placebo group at t60, and the 30mg group 
showed an increase at t60, t120 and t300. Error bars represent standard error of the mean. *p < 0.05; **p < 0.01 
 
Subjective State Questionnaires   
Data were analysed by gender, condition, and time (pre versus post-dosing). There were no 
main effects or interactions for the BDI, STAI Trait and State, or PANAS negative scores (all 
p > 0.05). There was, however, a main effect of time for PANAS Positive scores, with a 
small decrease in positive affect over the day (from 30.43 to 28.11; F (1 41) = 9.64; p < 
0.01). For the BFS, there a significant interaction between time and condition (F (1 42) = 
4.363; p < 0.05), whereby the placebo group BFS score decreased over time (t (15) 2.18; p = 
0.05). 
 
Visual Analogue Scales (VAS) 
Pre-dosing VAS scores were averaged for a pre-dose baseline. Each factor (negative effects, 
arousal, appetite, and physical effects) was analysed separately, by condition and gender, 
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showing no main effects or interactions (all p > 0.05). Post-dosing factors were then analysed 
by gender, condition and time (post-dosing in minutes: t30, t60, t90, t120, t150, t210).   
 
Negative effects and Arousal: There were no main effects or interactions for negative effects 
(all p > 0.05). For arousal, there were no main effects (all p > 0.05), but a significant two way 
interaction between time and condition (F (5 107) = 2.37; p < 0.05); follow up tests were not 
statistically significant (all p > 0.05), though there was a near significant effect of condition 
for t210 (F (2 44) = 2.67; p = 0.08), with mean arousal scores of; 64.69 for placebo, 75.79 for 
15mg mCPP and 75.22 for 30mg mCPP (see Figure 2.4). 
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Figure 2.4 Effect of mCPP on negative effects and arousal VAS ratings. For negative effects (Panel A) there 
were no main effects or interaction. For Arousal (Panel B), there were no main effects but a significant 
interaction between time and condition – post hoc tests did not show any significant differences in condition at 
any time points, though there was a trend for an effect at t210, with higher mean scores in the drug conditions 
compared to placebo. Error bars represent standard error of the mean.  
 
Physical Effects: There was a main effect of time (F (3 117) = 160.94; p < 0.01) and 
condition (F (2 41) = 5.97; p < 0.01 see Figure 2.5), and a significant two way interaction (F 
(6 117) = 3.25; p < 0.01). Main effects of condition were observed for: t60 (F (2 44) = 6.62; 
p < 0.01), t90 (F (2 44) = 7.83; p < 0.01) and t120 (F (2 44) = 4.69; p < 0.05), with physical 
effects rated significantly higher in the 30mg mCPP group than placebo (all p < 0.05 – Figure 
2.5).  
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 Appetite: There was a main effect of time (F (3 115) = 237.00; p < 0.001) and condition (F 
(2 41) = 3.78; p < 0.05 see Figure 2.5) but no significant interaction. For the effect of time, 
all comparisons were significantly different (all p < 0.05), and for condition, appetite was 
significantly lower in the 30mg mCPP group than placebo (t (29) 2.30; p < 0.05 - Figure 2.5).  
 
 
Figure 2.5 Effect of mCPP on appetite and physical effects VAS ratings. For appetite (Panel A) there was a 
main effect of condition (histogram on right panel) where appetite was significantly lower in the 30mg group 
compared to the placebo group, but no significant interaction (graph on left panel – post hoc t-tests showing a 
difference between placebo and 30mg at t30 only). Physical effects VAS scores (Panel B) showed a main effect 
of condition (histogram on right panel) and an interaction between condition and time (graph on left panel), 
where physical effects were significantly higher for the 30mg group at t60, t190 and t120, compared to placebo. 
Error bars represent standard error of the mean. *p < 0.05; **p < 0.01 
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Meal measures 
Test meal intake: There was a main effect of gender only, with men eating more than women 
(F (1 29) = 11.32; p < 0.01). There was no effect of condition, nor any interaction (Table 
2.1). 
 
Meal Intake quartiles: Amount eaten was analysed by quartile, gender, and condition, 
showing a main effect of quartile (F (3 87) = 8.18; p < 0.01), gender (F (1 29) = 11.32; p < 
0.01) and a two way interaction between quartile and condition (F (6 87) = 2.56; p < 0.05) 
although follow up tests were not significant (see Table 2.2 for means). Men ate more than 
women (174.09 grams versus 106.57 grams). Men had a faster eating rate than women 
(105.72g/min versus 67.23g/min; F (1 29) = 13.51; p < 0.01) and ate larger mouthfuls than 
women (12.06 grams versus 7.76 grams; F (1 29) = 6.56; p < 0.05). 
 
Table 2.2 UEM measures split by condition and quartile (standard error of the mean) 
      
                        Placebo     15mg       30mg       
                        Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 
                                                         Amount 
Eaten 
117.3 
(19.2) 
120.5 
(18.9) 
120.6 
(20.3) 
125.9 
(18.8) 
137.1 
(19.9) 
135.9 
(19.7) 
141.2 
(21.1) 
146.4 
(19.6) 
140.4 
(21.8) 
158.1 
(21.6) 
140.9 
(23.1) 
168.0 
(21.5) 
                      Eating Rate 
(g/min) 
84.7 
(8.7) 
78.8 
(12.9) 
76.5 
(9.8) 
79.0 
(12.7) 
74.8 
(8.9) 
84.1 
(13.3) 
81.6 
(10.1) 
61.8 
(13.1) 
98.2 
(9.6) 
124.7 
(14.3) 
95.0 
(10.9) 
98.4 
(14.1) 
                      Mouthful 
Weight (g) 
10.1 
(1.3) 
7.8 
(1.1) 
8.6 
(0.8) 
8.6 
(4.9) 
7.2 
(1.3) 
8.4 
(1.1) 
9.9 
(0.8) 
17.6 
(5.1) 
8.9 
(1.4) 
11.4 
(1.2) 
9.7 
(0.9) 
10.8 
(5.5) 
                       
 
Computerised VAS: Hunger decreased across quartiles (F (2 50) = 150.46; p < 0.001), and 
men were more hungry than women (47mm versus 38mm, respectively; (F (1 29) = 3.81; p = 
0.06) (all p < 0.001). Similarly, fullness increased across quartiles (F (2 47) = 176.78; p < 
0.001), and men were less full than women; (59mm versus 51mm, respectively; (F (1 29) = 
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4.46; p < 0.05)). For pleasantness, there was a main effect of quartile only (F (2 45) = 31.65; 
p < 0.001), with rated pleasantness decreasing across quartiles (all p < 0.05).  
 
Satiation Quotient 
The satiety quotient (Green et al. 1997 (pre-meal hunger – post meal hunger) / calories 
consumed) provides a measure of how satiating a given amount of calories is at various time 
points after an eating episode has finished. Adapting this, a satiation quotient (SQ) per 
quartile was calculated; a measure reflecting the satiating capacity of a food as it is eaten 
(quartile initial hunger – quartile ending hunger rating) / calories consumed during quartile). 
There was a main effect of quartile (F (3 87) = 11.62; p < 0.001) and gender (F (1 29) = 7.11; 
p < 0.05), a two way interaction between gender and condition (F (2 29) = 8.61; p < 0.01), 
and a three way interaction between quartile, gender and condition (F (6 87) = 2.50; p < 
0.05). For men, there was an effect of quartile (F (3 36) = 6.87; p < 0.01) and condition (F (2 
12) = 4.30; p < 0.05). SQs were significantly lower in the 30mg mCPP group compared to 
placebo (t (8) = 2.72; p < 0.05) and there was a significant increase in SQ from quartile 2 to 3 
(t (14) -2.86; p < 0.05). For women there was a main effect of quartile (F (3 51) = 6.53; p < 
0.01), condition (F (2 17) = 4.84; p < 0.05) and an interaction between quartile and condition 
(F (6 51) = 2.58; p < 0.05). Breaking down the interaction by quartile; for quartile 1, SQ was 
significantly higher for 30mg mCPP than placebo (t (11) = -2.44; p < 0.05); and for quartile 
2, SQ was significantly higher for both 15mg mCPP and 30mg mCPP, compared to placebo 
(t (13) = -3.07; p < 0.01; t (11) = -2.69; p < 0.05) (Table 2.3). 
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Table 2.3 Mean satiation quotients by quartile and condition for women 
participants (standard error of the mean) 
 
Condition 
Quartile Placebo 15mg 30mg 
1 0.04 (0.04) 0.04 (0.02) 0.20 (0.05)* 
2 0.10 (0.02) 0.21 (0.03)** 0.21 (0.04)* 
3 0.18 (0.05) 0.21 (0.05) 0.46 (0.16) 
4 0.17 (0.04) 0.20 (0.06) 0.09 (0.02) 
        
Compared to placebo: * p < 0.05; **p < 0.01 
 
Correlations  
To investigate the relationship between appetite, physical symptoms (both measured prior to 
lunch) and total food intake, correlations were performed on the three measures. A positive 
correlation was identified between appetite and intake (r (47) = 0.32, p < 0.05), but there was 
no association between physical symptoms and intake, or between physical symptoms and 
appetite (r (47) = -0.05, p > 0.05; (r (47) = -0.15, p < 0.05).  
 
Emotional Test Battery (ETB) Data  
Facial expression recognition task (FERT) and Faces dot probe task (FDOT): There were 
main effects of emotion (F (3 140) = 35.46; p < 0.001; F (6 246) = 130.28; p < 0.001) but no 
other significant effects or interactions for target sensitivity and response bias (all p > 0.05). 
There were no significant main effects or interactions for vigilance scores (all p > 0.05).  
Emotional categorisation task (ECAT): Accuracy data showed a main effect of gender only, 
with women showing greater accuracy than men (96.70% versus 89.34%, respectively; F (1 
40) 4.36; p < 0.05). Reaction time showed a main effect of valence only, with longer reaction 
times to negative versus positive stimuli (887.36ms versus 825.36ms, respectively; F (1 40) 
19.47; p < 0.001).   
 
73 
 
Emotional recall task (EREC): More positive than negative words were recalled (5.8 versus 
3.8 words; F (1 41) = 38.97; p < 0.001). There was also a main effect of condition (F (2 41) = 
4.77; p < 0.05) with more words correctly recalled in the 15mg mCPP and the 30mg mCPP 
groups than placebo (5.1 and 5.6 versus 3.6, respectively) (both p < 0.05 see Figure 2.6).  
Emotional recognition memory task (EMEM): Target sensitivity showed a main effect of 
condition only (F (1 41) = 5.87; p < 0.01), whereby target sensitivity was significantly higher 
in the 30mg mCPP group than placebo (t (23) -4.31; p < 0.001 see Figure 2.6). 
 
Figure 2.6 Mean number of words correctly recalled (left panel) and mean target sensitivity (right panel) for 
placebo, 15mg mCPP and 30mg mCPP groups in the emotional recall task. Word recall was enhanced in both 
the 15mg and 30mg groups compared to placebo and target sensitivity was enhanced in the 30mg group 
compared to placebo. Error bars represent standard error of the mean. *p < 0.05; ***p < 0.001 
 
2.4. Discussion 
The 5-HT2C receptor agonist mCPP at doses of 15mg and 30mg decreased appetite ratings of 
both healthy men and women, and enhanced within-meal satiation quotients (SQs) of women 
participants in a dose-related manner but had no significant effect on food intake. mCPP also 
dose-dependently increased ratings of negative physical effects, in particular nausea, but had 
no effects on ratings of negative mood or cognitive measures of anxiety and depression as 
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assessed by the ETB, for men and women participants. However, mCPP enhanced memory 
for emotional words independent of their valence.  
 
As expected, mCPP dose-dependently increased salivary cortisol, confirming activation of 5-
HT2C receptors. Peak effects for both doses occurred 60-180 minutes post dosing, which is 
consistent with previous reports (Kahn et al. 1990). UEM testing took place within this 
window at 120 minutes post dosing, while ETB testing took place later at 180 minutes post 
dosing. However, cortisol levels were still significantly raised for 30mg mCPP compared to 
placebo at 300 minutes post dosing. In addition, the 30mg dose of the drug, but not the 15mg 
dose, induced negative physical symptoms (nausea) in participants, a finding which also 
confirms the results of previous studies (Walsh et al. 1994). Taken together, these data 
suggest that mCPP activated 5-HT2C receptors at concentrations sufficient to exert effects on 
eating and emotional behaviour in the model. 
 
Appetite ratings were attenuated for men and women by 30mg mCPP, but not by 15mg 
mCPP, a finding that is consistent with previous reports (Cowen et al. 1995; Smith et al. 
1994a). Interestingly, the results for the SQ, showed a dose-dependent effect of mCPP, but 
only in women. Thus, SQs were enhanced in the first half of the test meal at both 15mg and 
30mg mCPP, with an earlier onset of action at the 30mg mCPP dose. mCPP failed to 
significantly decrease food intake compared to placebo suggesting that VAS ratings and the 
SQ measure derived from UEM microstructural data may be more sensitive to the effects of 
mCPP (at least in women) on eating than measurement of food consumption. The apparent 
acceleration of satiation by mCPP in lean women in the present study is similar to that 
observed with the 5-HT reuptake inhibitor sibutramine in obese women (Halford et al. 2010) 
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and may be part of a common behavioural mechanism by which 5-HT2C receptor activation 
reduces food intake.  
 
Differences between men and women in eating patterns and the response to mCPP were 
observed. Men ate more than women and at a faster rate. While both men and women had 
reduced appetite ratings after mCPP only women showed enhanced satiety. These differences 
are unlikely to be explained by gender differences in body weight, drug distribution, or 
metabolism because there were no gender effects observed for mCPP-induced increases in 
cortisol. One possibility is that although the men experienced an effect of mCPP on appetite 
they are less sensitive to the drug effects on actual food intake measured in the context of the 
laboratory. Several men ate close to or more than 1kg of pasta which suggests that they may 
have been eating larger amounts than usual. It would be informative to assess the response of 
men to the effects of mCPP on intake at usual meals taken in the home.  
 
It appears unlikely that the effects of 15mg mCPP on appetite and satiety were confounded 
by nausea as this dose did not induce significant physical effects. However, it is possible that 
nausea could have confounded the effects on appetite seen at the 30mg dose of mCPP. This 
does not seem plausible, however, as neither appetite nor food intake correlated with physical 
symptoms. This interpretation is consistent with the results of a previous study in which 
nausea also failed to correlate with food intake or appetite ratings (Walsh et al. 1994). In 
addition, the pattern of effects for appetite and nausea are distinct, as 30 mCPP attenuated 
appetite earlier, and for a longer duration, than the induction of nausea. 
 
On the basis of previous research (Charney et al. 1987; Kahn et al. 1990), it was predicted 
that mCPP might induce anxiety and or depression-like symptoms. The pattern of results 
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from the ETB, however, is not consistent with the induction of anxiety or depression-like 
responses by mCPP. Thus, there was no significant effect of mCPP administration on 
responses to fearful or angry facial expressions which are generally indicative of heightened 
anxiety (Mogg and Bradley 2002; Harmer et al. 2003). Nor were there any responses 
indicative of depression, such as the reduced recall of positive stimuli that has been observed 
after acute treatment with the CB1 receptor antagonist rimonabant (Horder et al. 2009). 
Previous studies that have reported anxiogenic effects of mCPP generally administered the 
drug as an intravenous bolus, and so it is possible that effects on anxiety are less evident with 
the oral route of administration used in the present study (Kahn et al. 1990; Silverstone and 
Cowen 1994; Cowen et al. 1995; Anderson et al. 2002b). The lack of an mCPP-induced 
depressogenic or anxiogenic effect on the ETB tasks is consistent with the general absence of 
effects on the questionnaire based measures of anxiety and mood; thus there is internal 
consistency within the model. 
 
mCPP dose dependently enhanced memory for emotional words, an effect that was 
independent of valance. This confirms that the ETB was capable of detecting effects of 
mCPP, even when testing was conducted after the predicted time for peak plasma levels and 
associated behavioural effects. Previous studies in rodents suggest that mCPP may impair 
memory function (Khaliq et al. 2012). However, studies in human volunteers have linked 
tryptophan depletion to memory impairment, and citalopram enhancement of serotonergic 
function with facilitation of memory consolidation (Hayward et al. 2005; Harmer et al. 2002). 
The present results are consistent with these findings and suggest that 5-HT2C receptors may 
mediate the facilatory effects of citalopram on memory.  
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Previous research has reported that enhancing memory of an eating episode decreases 
subsequent food intake (Higgs and Donohoe 2011). Thus, it is possible that long term use of 
mCPP and other serotonergic drugs could enhance memories of food consumption and reduce 
subsequent food intake. This theory of drug induced memory enhancement as a behavioural 
mechanism to reduce food intake (Higgs 2002) is supported by findings with the N-Methyl-
D-aspartate (NMDA) receptor antagonist memantine (Parsons et al. 2007; Foltin et al. 2008). 
This suggests that memory enhancement might play a role in enhanced satiation and could 
provide a novel target for future weight-loss drugs. 
 
In conclusion, the present results show that the UEM/ETB experimental medicine model is 
capable of measuring drug effects on eating, satiety and mood in healthy human volunteers. 
For the first time, this research shows that effects of a low 15mg dose of mCPP on appetite 
and satiety are detectable using a UEM to measure drug-induced enhancement of within-meal 
satiation, which appears to be a promising marker of an efficacious anti-obesity drug. The 
model can also detect drug induced changes in cognitive processing. Thus, an enhancement 
of memory for emotional stimuli by mCPP was observed for the first time supporting a role 
for 5-HT2C receptors in cognition. As the eating behaviour of men was highly variable, future 
studies will include women participants only, until experimental strategies to deal with this 
variability are developed. 
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CHAPTER 3: Study 2: Monitoring Eating Behaviour in the Laboratory: do we need to 
do it covertly? 
 
3.1. Introduction 
In Study 1, 26% of microstructural intake data were lost from the UEM due to participants 
unknowingly leaning on, or lifting the plate of pasta off the balance. Therefore, the aim of 
Study 2 was to assess whether participants could be made aware of the balance to reduce 
accidental interactions with it, without affecting their eating behaviour. In addition, an ad-
libitum cookie snack session was also included to evaluate both the consumption of a pasta 
meal and a snack of cookies. This could provide a model to detect selective effects of 
manipulations on responses to foods differing in palatability and energy density in future 
studies. 
 
The problem of UEM data loss during Study 1 has been reported in other studies. For 
example, Hubel and colleagues (2006) reported data loss due to participants manipulating a 
bowl of food situated on a balance. In addition, other researchers have reported excluding 
study data due to participants becoming aware of their UEM setup (Laessle et al. 2001). The 
UEM was designed as a covert measurement method (Kissileff et al. 1980), and has been 
consistently used in this manner by the majority of researchers for over three decades. 
However, Westerterp-Plantenga and colleagues (1991) reported that in a previous study, 
UEM awareness did not influence participants’ intake of a lunch (Westerterp-Plantenga et al. 
1990). However, in the Westerterp-Plantenga study (1990), fixed portions of food were 
provided to participants, which may have limited the ability to detect differences between 
groups. In addition, awareness of the UEM was only measured using a single food item 
(pasta).  
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It may be that awareness of being monitored by a UEM has an effect on consumption of 
certain foods but not others. For instance, there is evidence that observing participants while 
they are eating cookies reduces intake (Roth et al. 2001). In addition, if participants are not 
observed, but are told that the experimenter will know how many cookies they have eaten, a 
reduction in consumption is evident (Polivy et al. 1986). The key factor in most of these cases 
is often a desire to make a good impression on another individual, known as impression 
management (Herman, Roth and Polivy, 2003). Thus, actual or expected monitoring of food 
intake can reduce consumption, and it may be that eating energy dense or forbidden foods 
(e.g. cookies) is more susceptible to these effects, than staple foods (e.g. pasta), 
 
To explore this possibility, ad-libitum access to cookies and pasta was provided in Study 2. 
There is evidence that classifying the same food item as either a snack or a meal can 
influence intake with the snack classification enhancing intake (Capaldi et al. 2006). In 
addition, it has been reported that that obese individuals are more likely to snack than lean 
individuals (Berteus-Forslund et al. 2005) and that unhealthy snacking can impede weight-
loss (Kong et al. 2011). Therefore, ad-libitum cookies were added as a ‘snack session’ as this 
type of eating is associated with weight gain and obesity. 
 
The aim of the present study was to test whether explicit awareness of the UEM would affect 
intake of a lunch of pasta and/or a snack of cookies (more energy dense and palatable). 
Participants were given access to ad-libitum pasta and tomato-sauce, followed twenty 
minutes later by access to ad-libitum chocolate chip cookies. Participants in the aware 
condition were made explicitly aware of the UEM, while those in the non-aware condition 
were not told about the UEM. It was predicted that awareness of the UEM might decrease the 
consumption of pasta and cookies, having a larger effect on the latter. 
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3.2. Methods and Materials 
Participants 
A total of 72 healthy women student volunteers were recruited from the School of 
Psychology at the University of Birmingham. During testing, 3 participants in the non-aware 
condition became aware of the UEM, while 30 participants accidentally interacted with the 
balance during their test session. Therefore, 39 participants successfully completed testing 
and their data were used in the analysis. The 39 participants had a mean age of 19.67 years 
(SD 1.24) and a mean body mass index (BMI) of 21.84 (SD 2.17). Reimbursement for 
participation in the study took the form of course credits or a £10 cash payment. Informed 
consent was obtained from participants and ethical approval was provided by the University 
of Birmingham Research Ethics Committee. The study was conducted in accordance with 
Good Clinical Practice and the ethical standards laid down in the 1964 Declaration of 
Helsinki. Participants were not recruited if they: had food allergies; smoked cigarettes; took 
medication that affected appetite; were diabetic or had participated in a previous study using 
a UEM. All of these were assessed via questionnaire in the laboratory. 
 
Design 
A between-subjects design was used with a single factor of awareness with two levels: aware 
versus non-aware. Participants were randomly allocated to one of these conditions and order 
of testing within sessions was counterbalanced so that half of the participants completed a 
batch of questionnaires followed by a computer task, while the other half had the order 
reversed. As Yeomans (1996) had reported significant effects with 18 participants per group 
in a between-subjects design, the aim was to recruit at least 18 participants to each group. 
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Universal Eating Monitor (UEM) 
Food was served on a UEM (Sussex Ingestion Pattern Monitor; Sartorius Model CP4201; 
Sartorius Ltd, Epsom, UK; 0.1g accuracy). The UEM was connected to a computer, and 
relayed balance weights every 2 seconds (refer to Study 1 for a more detailed description). 
 
Lunch: The pasta was prepared and served in the same manner as Study 1, however, the total 
amount of pasta served was increased to 220g (253 calories per 220g serving). This was 
necessary, as some participants consume less of the pasta sauce than others, which if left on 
the dish in sufficient amounts (e.g. >50g), prevents the trigger for the automatic refill. Hence, 
the total amount was increased to eliminate this occurrence. All other aspects of the pasta 
meal were the same as for Study 1. 
 
Snack: Bowls were filled with 80g of Maryland chocolate chip cookies (390 calories per 80g 
serving; purchased from Sainsbury UK; refer to Figure 3.1). Each cookie was broken into 6-7 
pieces to reduce the likelihood that participants could track the number of cookies they ate, an 
approach used in previous research (Higgs and Woodward, 2009). The amount of cookies 
served ensured that participants were provided with more of the snack than they were likely 
to consume (Higgs and Woodward, 2009). The bowl was set on a placemat, and each time a 
participant ate 10g of cookies, the UEM software interrupted the participant to complete VAS 
ratings as described above for the pasta meal. After consuming 60g of cookies, the participant 
was interrupted and provided with a fresh bowl of 80g of cookies. Participants were asked to 
eat until they felt ‘comfortably full’.  
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Figure 3.1 Left panel shows a standard 80g serving of chocolate chip cookie pieces on the 
UEM setup. Right panels show the UEM setup (upper) and a serving of the tomato-based 
pasta on the UEM setup (lower).  
 
Stop Signal Reaction Time Task (SSRT) 
Impulsivity has been reported to affect the consumption of food (Guerrieri et al, 2007), 
hence, the SSRT was included to assess differences between groups on this measure. The 
SSRT (as described in Verbruggen et al. 2008) involves presenting participants with either a 
square or a circle shape on a screen that they are required to identify. On no-signal trials, a 
shape is presented and participants respond by identifying the shape. On stop-signal trials, an 
auditory stop signal alerts participants to withhold making a response to the presentation of 
the shape. The task consists of 32 practice trials followed by 192 experimental trials and takes 
20 minutes. Calculation of the stop signal reaction time provides a measure of inhibition of 
response (behavioural impulsivity). 
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Procedure 
Participants arrived in a pre-meal state having refrained from eating for 2 hours prior to 
arrival. They completed a consent form, and were screened using a lifestyle questionnaire 
which collected demographic information. After this, they completed the stop signal reaction 
time task as a measure of response inhibition and a series of questionnaires. The 
questionnaires comprised the Barratt Impulsivity Scale (BIS 11– Patton et al. 1995) and the 
Behavioural Inhibition/Approach Scales (BIS/BAS - Carver and White, 1994) as additional 
measures of impulsivity. Participants also completed the TFEQ, as a measure of dietary 
restraint, and the Power of food Scale (PFS, Lowe et al. 2009), as a measure of sensitivity to 
food to ensure no differences between groups. A breakfast questionnaire was used to ensure 
that no food was eaten within the previous two hours, and participants completed a set of 
baseline VAS for rated mood and appetite on a scale from 0-100mm (0mm anchor = not at 
all, 100mm anchor = extremely): ‘alertness’; ‘disgust’; ‘drowsiness’; ‘light-headed’; 
‘anxiety’; ‘happiness’; ‘nausea; ‘sadness’; ‘withdrawn’; ‘faint’; ‘hungry’; ‘full’; ‘desire to 
eat’ and ‘thirst’. 
 
Participants were taken to a room containing the UEM. Those in the aware condition were 
shown that there was a balance underneath the table. They were told that the balance would 
record the weight of their bowl and food as they ate during the meal and that this information 
would be stored on the computer it was connected to for later analysis. Those in the non-
aware condition were not given this information. After they had been given instructions 
regarding the procedure (i.e. that they could eat as many bowls of pasta as they wished until 
they were comfortably full), the participants were asked to eat lunch, as described above. 
After they had finished, they immediately completed another set of VAS, and were given a 
20 minute rest period in another room, where they were offered a home furniture magazine to 
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read. They then completed another set of VAS directly before being taken back to the UEM 
to eat the ad-libitum snack of cookies. Following this snack, participants completed a final set 
of VAS, and had their height and weight taken for BMI calculation. To assess awareness of 
the UEM they were then asked what they thought the study was about, and whether they had 
noticed the balance at any point, or whether they thought their intake was being recorded 
during the study. After this, participants were debriefed, thanked for their time, and 
compensated with course credits or a cash payment. 
 
Data Analysis 
General: Effects of awareness were determined with independent t-tests. Repeated measures 
analysis of variance (ANOVA) was used to examine temporal effects and interactions with 
awareness. Only significant effects of awareness, or temporal interactions with awareness, 
were followed up with planned comparisons and all post-hoc t-tests used the Bonferroni 
correction. Violations of sphericity were addressed using the Greenhouse-Geisser correction. 
 
VAS: To establish a factor structure for the VAS, a principal components analysis (PCA) was 
run with varimax rotation. Analysis of the 14 items provided 3 factors with eigenvalues > 1, 
accounting for 59.99% of the variance. Items that loaded > 0.5 onto a factor were included, 
resulting in three factors of 3 or more items: appetite (hunger, fullness and desire to eat); 
negative effects (sadness, nausea, disgust, faint, withdrawn, lightheaded) and arousal 
(alertness, happiness, drowsiness). Scores for each of the factors were calculated by summing 
the scores for all items in that factor, and then dividing by the number of items. Items with a 
negative scale, were inverted to match the other items. Anxiety and thirst did not load onto 
these factors and were analysed separately. 
 
85 
 
UEM: The following measures were calculated for UEM data: amount eaten, time spent 
eating, eating rate and pause between mouthfuls. The first three measures are standard 
measures of eating behaviour in microstructural studies, while the latter is a novel measure. It 
was included because it provides data on the time taken between mouthfuls, which may be a 
useful indication of motivation to eat. The pause measure also provides useful data on 
frequency of mouthfuls. For instance, if time is constant, then shorter pauses equate to more 
mouthfuls and vice versa. The data for each measure was also divided into quartiles for 
analysis (effects of quartile were not investigated further). 
 
3.3. Results 
Baseline Measures and Visual Analogue Scales 
To ensure there were no group differences in demographics and behaviours which might 
affect food consumption (e.g. impulsivity, food sensitivity, cognitive restraint, etc.) all scores 
were analysed using independent t-tests comparing aware and non-aware conditions. There 
were no significant differences for all scales and subscales: BMI; Age; TFEQ; BIS 11; PFS; 
BIS; BAS; and SSRT (all p > 0.05 – Table 3.1).  
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Table 3.1 Mean baseline scores for non-aware and aware groups (standard 
error of the mean) 
Measure Non-aware Aware 
BMI 21.9 (0.5) 21.8 (0.5) 
Age 20.0 (0.4) 19.4 (0.2) 
TFEQ Cognitive Restraint 8.3 (1.0) 9.1 (1.2) 
TFEQ Disinhibition 8.8 (0.7) 7.1 (0.8) 
TFEQ Hunger 7.3 (0.7) 7.2 (0.7) 
BIS 11 69.1 (2.7) 66.6 (2.1) 
PFS 40.8 (2.5) 43.7 (2.4) 
BIS 23.2 (1.0) 24.1 (0.6) 
BAS Drive 10.4 (0.5) 11.0 (0.5) 
BAS Fun seeking 12.0 (0.4) 11.7 (0.5) 
BAS Reward Responsiveness 16.7 (0.4) 17.4 (0.4) 
SSRT (milliseconds) 233.0 (7.0) 233.8 (5.0) 
      
      
BMI - Body Mass Index; TFEQ - Three Factor Eating Questionnaire; BIS 11 - 
Barratt Impulsiveness Scale; PFS - Power of Food Scale; BIS - Behavioural 
Inhibition Scale; BAS - Behavioural Activation Scale; SSRT - Stop Signal 
Reaction Time 
 
 
 
 
VAS data were analysed by condition (aware versus non-aware) and by time (pre-pasta, post-
pasta, pre-cookies and post-cookies). For appetite, arousal, anxiety and thirst there were main 
effects of time (all p < 0.01 – means displayed in Table 3.2) which were not analysed further, 
but there were no effects of condition (see Table 3.3 for means) and no interactions (all p > 
0.05). For negative effects, there was a main effect of time (F (3 99) = 18.48; p < 0.001), no 
effect of condition (F (1 33) = 0.10; p > 0.05) and a significant interaction between condition 
and time (F (3 99) = 3.36; p < 0.05). T-tests comparing negative effects between conditions 
for each time point did not show any significant differences (all p > 0.05); baseline difference 
(pre-pasta) for the non-aware versus aware was the closest to significance (18.06mm versus 
12.22mm, respectively; t (37) 1.29, p = 0.2). 
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Table 3.2 Mean VAS ratings over time (standard error of the mean) 
VAS Measure Pre-Pasta Post-Pasta Pre-Cookies Post-Cookies 
Appetite  72.5 (2.6) 15.3 (2.0) 17.2 (2.2) 9.7 (1.7) 
Negative Effects  15.1 (2.3) 9.7 (1.5) 8.8 (1.4) 7.6 (1.1) 
Anxiety  21.3 (3.5) 11.4 (2.3) 9.1 (1.6) 8.7 (1.7) 
Arousal  53.7 (2.5) 62.1 (2.4) 57.6 (2.1) 59.5 (2.1) 
Thirst  53.1 (4.4) 43.7 (3.8) 37.0 (4.2) 33.5 (4.2) 
          
 
 
 
  
Table 3.3 Mean VAS Measures separated by 
condition (standard error of the mean) 
VAS Measure Non-aware Aware 
Appetite 27.5 (2.1) 30.6 (2.1) 
Negative Effects 10.8 (2.3) 9.7 (2.3) 
Anxiety 12.9 (3.2) 13.2 (3.1) 
Arousal 60.6 (2.7) 55.8 (2.6) 
Thirst 42.3 (5.5) 42.7 (5.4) 
      
      
 
Universal Eating Monitor  
Two-factor repeated-measures ANOVA with the within-subjects factor quartile (quartiles 1, 
2, 3 and 4) and the between-subjects factor awareness (aware versus non-aware) were used to 
analyse the following measures: total amount eaten; time spent eating; pause between 
mouthfuls and eating rate.  
 
Pasta Lunch: There was a significant effect of quartile (both p < 0.05) but no effect of 
awareness and no significant interaction (all p < 0.05) for amount eaten, time spent eating and 
pause between mouthfuls (Table 3.4). There were there were no significant effects or 
interactions for eating rate (all p > 0.05).  
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Cookie Snack: There was a main effect of awareness for eating rate as participants in the 
aware condition ate cookies at a slower rate than those in the non-aware condition (F (1 37) = 
5.70; p < 0.05; 10.23 versus 13.40 g/min; Table 3.4). There was no main effect of quartile or 
a significant interaction (both p > 0.05).  There was a significant effect of quartile on amount 
eaten, time spent eating and pause between mouthfuls, (all p < 0.05 – Table 3.4) but no other 
main effects or interactions reached statistical significance (all p < 0.05).  
 
 
Computerised within-meal VAS  
VAS ratings made during the meal, were used to calculate the mean rating for each quartile 
of the meal. These were analysed using two-factor repeated-measures ANOVA, with the 
factors of quartile (within-subject) and condition (between-subject). 
 
Pasta: For the hunger VAS, there was a main effect of quartile (F (3, 86) = 150.44; p < 
0.001), and a trend for an effect of condition, with greater hunger in the aware versus non-
aware group when collapsing across quartiles (F (1 37) = 3.17; p = 0.08; 42.31 versus 
35.01mm, respectively); but no significant interaction (p > 0.05). For fullness there was a 
Measure Quartile 1 Quartile 2 Quartile 3 Quartile 4 Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Pasta 
Amount eaten (grams) 86.6 (5.1) 89.8 (5.2) 86.9 (6.4) 98.3 (5.3) 85.5 (7.8) 90.5 (8.2) 91.4 (7.6) 97.8 (8.1) 
Time spent eating (seconds) 89.0 (0.6) 96.7 (13.6) 99.4 (11.5) 137.4 (36.9) 97.9 (6.3) 82.7 (5.1) 91.9 (5.7) 114.4 (9.9) 
Pause between mouthfuls (secs) 8.0 (0.5) 7.8 (1.0) 7.9 (0.6) 9.8 (1.9) 9.3 (0.6) 7.5 (0.4) 8.1 (0.4) 9.6 (0.6) 
Eating rate (g/min) 61.1 (4.2) 66.1 (5.5) 64.6 (7.5) 60.3 (7.0) 52.8 (3.3) 66.0 (4.7) 61.0 (4.2) 55.7 (4.7) 
Cookies 
Amount eaten (grams) 7.9 (0.8) 9.98 (1.0) 10.5 (1.1) 11.9 (1.0) 7.6 (1.1) 9.1 (1.1) 9.1 (1.1) 11.0 (1.2) 
Time spent eating (seconds) 39.5 (4.2) 42.4 (4.0) 61.7 (9.0) 83.5 (15.5) 46.3 (6.1) 65.8 (7.1) 62.2 (7.5) 100.2 (14.2) 
Pause between mouthfuls (secs) 9.6 (1.1) 9.6 (1.5) 12.5 (2.7) 17.8 (5.4) 14.3 (1.7) 16.1 (1.9) 15.6 (1.6) 19.1 (2.7) 
Eating rate (g/min) 14.0 (1.8) 14.7 (1.1) 12.6 (1.3) 12.4 (1.7) 11.7 (1.5) 9.5 (1.2) 10.9 (1.5) 8.8 (1.2) 
Non-aware Aware 
Table 3.4  UEM Measures for Pasta and Cookies, split by non-aware versus aware groups and quartiles                                          
(mean with standard error of the mean in parentheses) 
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main effect of quartile (F (3 111) = 145.08; p < 0.001), and for condition, with lower fullness 
in the aware versus non-aware condition (55.07 versus 62.57; F (1 37) = 3.17; p < 0.05; 
Figure 3.2) but no significant interaction (p > 0.05). Finally, for the pleasantness ratings, 
there was a main effect of quartile (F (3 111) = 23.62; p < 0.001), but no effect of awareness, 
or a significant interaction (both p > 0.05). 
 
Cookies: For rated hunger, there was a main effect of quartile (F (3 111) = 6.97; p < 0.001), 
and a main effect of awareness with greater hunger in the aware group versus non-aware 
(18.39 versus 9.06; F (1 37) = 6.16; p < 0.05; Figure 3.2), but no interaction (F (3 111) = 
0.41; p > 0.05). For the fullness VAS, there was a main effect of quartile (F (3 111) = 11.24; 
p < 0.001), no effect of condition (F (1 37) = 0.68; p > 0.05), but a significant interaction 
between quartile and condition (F (3 111) = 2.80; p < 0.05); t-tests did not reveal any 
significant differences between the aware and non-aware group, for any quartile. For the 
pleasantness VAS, there was no effect of quartile, condition, or a significant interaction (all p 
> 0.05. 
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Figure 3.2 Mean fullness and hunger ratings whilst consuming pasta and cookies, respectively. Rated fullness 
whilst eating pasta (left) was significantly decreased when participants were aware (versus non-aware); mean 
rated hunger whilst eating cookies (right) was significantly increased when participants were aware. * p < 0.05 
 
Satiation Quotient 
Satiation quotients were calculated (refer to Study 1) and analysed. For pasta, there was a 
main effect of quartile (F (2 78) = 3.85; p < 0.05), but no effect of condition, nor an 
interaction (both p > 0.05). For cookies, there a main effect of condition, whereby 
participants in the aware group showed significantly lower satiation scores compared to the 
non-aware group (0.16 versus 0.44; (F (1 37) = 4.77; p < 0.05). There was no effect of 
quartile or interaction (both p > 0.05). 
 
3.4. Discussion 
Awareness of the UEM did not affect the total amount of pasta or cookies consumed. It also 
had no significant effect on the time taken to consume the food, or the pauses taken between 
mouthfuls. Awareness of the UEM did not affect the eating rate of pasta, however, it 
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significantly reduced the eating rate of cookies. Calculation of the satiation quotient showed 
that awareness did not affect the satiating capacity of the pasta, but weakened the effect of the 
cookies. Hence, awareness had a limited effect on eating behaviour. Overall, the effects of 
awareness are confined to the cookie snack, but do not affect total consumption. 
 
The decrease in cookie eating rate but not pasta eating rate supports the suggestion that the 
effects of awareness may be related to the type of food consumed. Thus, consumption of 
highly palatable, energy dense foods may be more susceptible to awareness of being 
monitored. As more energy dense foods such as cookies are often perceived as “unhealthy” 
and “dangerous” (Macht et al. 2003) and their consumption can be interpreted as a negative 
eating behaviour (Stevenson et al. 2007), it is plausible that consuming cookies was viewed 
by participants as a less acceptable behaviour than consuming the pasta. Therefore, as 
individuals are motivated to present themselves in a positive manner in an eating situation 
(Herman et al. 2003), individuals who were aware of the UEM might have reduced their rate 
of eating cookies, but not the pasta, to present a more positive social image of themselves. 
While it might be hypothesised that participants would have reduced their overall intake of 
cookies as well as eating rate, the presentation of cookies in small pieces could have made it 
difficult for participants to monitor and limit their intake. This suggestion is supported by 
evidence that participants eat more of the same food when it is presented amorphously, as 
numerous small pieces/parts, than as a whole item (Chang et al. 2012). 
 
The limited effects of awareness of the UEM on eating behaviour appear insufficient to 
justify continued use of a covert approach, which is associated with data loss (Study 1; 
Laessle et al. 2001; Hubel et al. 2006). It is simpler to ensure that participants remain aware, 
rather than non-aware of the UEM during test sessions. Once informed of the UEM, it is 
highly unlikely that participants will forget its presence during the test session. However, in a 
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non-aware study, participants may not remain non-aware, and some participants who become 
aware will not admit this during debrief due to demand characteristics. Therefore, an aware 
approach may ensure a more consistent experience for participants, and by extension, more 
robust data. 
 
The limited, but nonetheless selective decrease in the rate of cookie consumption reinforces 
the importance of assessing a range of food types. In addition, the observation that 
participants consumed a significant amount of cookies (36.7grams; approximately 4 cookies; 
179 calories) soon after lunch suggests that the UEM can be used to study the phenomenon of 
eating in the absence of hunger. This type of eating is associated with hedonically driven 
consumption of food and is more pronounced in overweight individuals (Shomaker et al. 
2010). This experimental design may therefore offer an opportunity to examine the potential 
behavioural mechanisms of anti-obesity drugs that reduce the hedonic value of food eaten in 
the absence of hunger. 
 
To conclude, the data from Study 2 suggest that the UEM may be used to assess eating 
behaviour without the need for participants to be unaware of its presence. In addition, the 
inclusion of a snack session as part of the UEM model may allow for testing of selective 
effects of drugs on hedonically driven eating. For future work with the model, it will be 
necessary to test other populations of interest, such as obese participants, where awareness 
could potentially interact with factors such as body image and self-esteem. More 
immediately, a direct test of whether awareness affects responses during a drug study, and 
whether an appetite suppressing drug has a selective effect within this setup, would help 
provide further data for the validity of a non-covert approach, and for the addition of a snack 
session (Study 6). 
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CHAPTER 4: Studies 3 and 4: The P1vital® Oxford Emotional Test Battery (ETB): 
does practice or satiety affect measures of cognition and emotional processing?  
 
4.1. Introduction 
To date, the ETB has been used in between-subjects designs (e.g. Murphy et al. 2008; 
Harmer et al. 2009) and has not been tested for repeated use. In many instances, cross-over 
paradigms are preferable, as they can control for individual differences, particularly with 
regard to eating behaviour. In addition, the effects of eating food prior to ETB testing are 
unknown but are important to determine for future ETB studies involving drugs that affect 
appetite. Therefore, the studies presented in this chapter investigated the influence of repeated 
testing and satiation on ETB performance. 
 
The aim of Study 3 was to investigate whether practice effects occur for any of the ETB tasks 
by testing the entire battery repeatedly. It is well documented that practice effects occur for 
many cognitive tasks (Hausknecht et al. 2007; Benedict and Zgaljardic, 1998). However, for 
some tasks, these effects plateau quickly and a stable level of performance is reached (Bartels 
et al. 2010). The factors that mediate this process probably relate to the cognitive function 
under investigation, the type of task being used, and the complexity of the task (Benedict and 
Zgaljardic, 1998). For instance, practice effects are more likely to occur for more complex 
tasks before stabilising (Falleti et al, 2006). Healthy women volunteers were tested on four 
occasions, with each test session separated by a 7 day interval; 7 days is a standard wash out 
interval in many crossover drug studies. Responses were compared across sessions to 
examine whether any practice effects occurred. Based on previous research (Benedict and 
Zgaljardic, 1998; Falleti et al, 2006), it was hypothesised that practice effects would occur for 
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the more complex tasks such as the facial expression recognition task and emotional recall 
task. 
 
The aim of Study 4 was to assess the effects of satiation on ETB performance. Much of the 
previous work investigating the effects of food intake on measures of cognition and mood has 
concentrated on the effects of meal composition on performance. For instance, ingesting a 
lunch high in protein or carbohydrates decreases mood, and produces selective impairments 
in different aspects of attention (Smith et al. 1988). Lunches with higher than usual levels of 
fat or carbohydrate also impair mood and cognitive efficiency (Lloyd et al.1994). In addition, 
large lunches are associated with more errors on attentional tasks (Smith et al. 1991). A 
number of  studies have compared the performance of fasted versus fed participants, showing 
that consumption of breakfast can improve cognitive performance on memory tasks (Benton 
and Parker, 1998; Smith et al. 1994b), and that consumption of palatable snack foods can 
enhance mood (Macht and Dettmer, 2006). However, these results are likely to be influenced 
by time of eating (breakfast versus lunch) and the palatability of the food consumed. In Study 
4 the effects of satiating participants before ETB testing was examined. It was hypothesised 
that participants satiated with lunch would show impaired cognitive performance, and 
possibly, a decrease in mood, compared to those who were not given lunch. 
 
4.2. Study 3 Overview and Design 
Study 3 tested whether repeated sessions on the ETB led to practice effects. A within-subjects 
design was used, with a single factor of session comprised of four levels: session 1; session 2; 
session 3; and session 4. Each session was run at the same time of day, one week apart and 
participants completed the ETB at all four sessions. The order of completing questionnaires 
and the ETB during sessions was counterbalanced across participants; half of the participants 
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always completed the questionnaires followed by the ETB, while the other half were tested in 
the reverse order each time. 
 
4.3. Study 3 Methods and Materials 
Participants 
30 healthy women student volunteers (mean age = 18.9 years; mean BMI = 21.48; mean 
NART score = 111) were recruited for the study from the University of Birmingham. 
Informed consent was obtained and participants were given either £20 cash or course credits 
upon completion. The study was approved by the University of Birmingham Research Ethics 
Committee and was conducted in accordance with the ethical standards laid down in the 1964 
Declaration of Helsinki. Participants were excluded from the study if they were under 18 or 
over 65 years of age and if they were not fluent English speakers as determined by the 
NART. Using a screening questionnaire, participants were excluded if they: had previously 
taken part in an ETB study; were dyslexic; smokers; taking medication; had consumed a high 
amount of caffeine ( > 750mg; Winston et al. 2005) or alcohol ( > 3 units; NICE, 2010) in the 
last 24 hours; or had current or past depression determined by use of the SCID.  
 
P1vital® Oxford Emotional Test Battery (ETB) 
The ETB is a computerised battery that comprises five validated cognitive tests (see 
www.p1vital.com), which has been used in previous drug studies (e.g. Harmer et al. 2004; 
Murphy et al. 2008; refer to Study 1 for full details). 
 
Procedure 
Participants completed a consent form before completing the screening measures. They had 
their height and weight taken for BMI calculation and then completed the NART, the SCID 
96 
 
(questions relating to depression only), a lifestyle questionnaire and an alcohol and caffeine 
questionnaire (documenting intake in the last 24 hours). Participants were then given VAS 
with the following mood and appetite items to rate on a scale from 0-100mm (0mm anchor = 
not at all, 100mm anchor = extremely): ‘alertness’; ‘disgust’; ‘drowsiness’; ‘light-headed’; 
‘anxiety’; ‘happiness’; ‘nausea’; ‘sadness’; ‘withdrawn’; ‘faint’; ‘hungry’; ‘full’; ‘desire to 
eat’ and ‘thirst’. After this, participants completed the ETB (which took approximately 60 
minutes) and then the TFEQ and the BDI questionnaire pack in a counterbalanced order. 
Finally, participants completed another VAS questionnaire.  
 
Participants returned for three further sessions, which were seven days apart from one 
another, and always at the same time of day. The procedure above was repeated for each 
session with the exception of: consent, BMI measurement, NART, SCID and the lifestyle 
questionnaire. On completing their last session, participants were debriefed, thanked for their 
time and compensated with either £20 cash or course credits. 
 
Data Analysis 
General: Within-subjects analysis of variance (ANOVA) was used to analyse the data. 
Bonferroni correction was used for all post-hoc t-tests and violations of sphericity were 
addressed using Greenhouse-Geisser correction.  
 
VAS: To establish a factor structure for the VAS, a principal components analysis (PCA) was 
run with varimax rotation. Analysis of the 14 items provided 4 factors with eigenvalues > 1, 
accounting for 66.64% of the variance. Items that loaded > 0.5 onto a factor were included, 
resulting in 4 factors of 3 or more items: appetite (desire to eat, hungry, fullness and thirst); 
negative physical effects (faint, lightheaded and nausea); arousal (alertness, happiness and 
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drowsiness); negative mood (anxiety, sadness and disgust). Withdrawn did not load > 0.5 
onto any of the factors and was analysed separately. Scores for each of the factors were 
calculated by summing the scores for all items in that factor and then dividing by the number 
of items. Items with a negative scale, were inverted to match the other items.  
 
ETB Data: Task specific effects that were relevant to the task but not to the experimental 
manipulation are presented to confirm the ability to detect effects of emotion and or valence. 
For main effects of emotion, t-tests were used to further analyse the data. Main effects of 
session and interactions between session and emotion or valence were also analysed. 
 
4.4. Study 3 Results 
Subjective Measures 
Questionnaires: ANOVA of scores from the BDI, TFEQ subscales (cognitive restraint, 
disinhibition and hunger) and the Alcohol and Caffeine questionnaire (ACQ) revealed no 
significant differences across the four test sessions, (all p > 0.05 – Table 4.1).  
Visual Analogue Scales (VAS): VAS scores were analysed with ANOVA using the factors of 
session (session 1, session 2, session 3 and session 4) and time (pre ETB and post ETB). For 
appetite, negative physical effects, negative mood and withdrawn, there were no main effects 
or interactions (all p > 0.05). However, for arousal, there were main effects of session (F (3 
87) = 3.12; p < 0.05) and time (pre ETB = 63.34mm versus post ETB = 55.64mm; F (1 29) = 
19.54; p < 0.001) but no significant interaction (F (3 87) = 0.52; p > 0.05). Following up the 
main effect of session with t-tests, none of the comparisons were significantly different, 
though the closest to significance was the decrease in arousal from session 1 to session 3 (t 
(29) 2.70; p = 0.07 – Table 4.1). 
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Table 4.1 Questionnaires and Visual Analogue Scale mean scores (standard error of the mean). VAS scores 
are averaged over each test session. 
 
Session 
Measure 1 2 3 4 
BDI 7.3 (1.0) 7.1 (1.1) 7.2 (1.3) 6.9 (1.3) 
TFEQ Cognitive Restraint  7.7 (1.1) 7.0 (1.1) 7.1 (1.2) 6.8 (1.2) 
TFEQ Disinhibition 7.1 (0.7) 7.3 (0.6) 7.4 (0.7) 7.3 (0.7) 
TFEQ Hunger 6.1 (0.5) 6.7 (0.6) 6.8 (0.7) 6.4 (0.6) 
Alcohol (units) 0.1 (0.1) 0.0 (0.0) 0.1 (0.0) 0.0 (0.0) 
Caffeine (mg) 186.5 (18.2) 179.7 (22.8) 207.0 (32.1) 175.7 (26.3) 
VAS Appetite 45.8 (1.4) 44.6 (1.3) 45.5 (1.5) 43.2 (1.4) 
VAS Negative Physical Effects 6.0 (1.3) 7.0 (1.8) 5.4 (1.2) 5.0 (1.2) 
VAS Negative mood 7.2 (1.1) 8.1 (1.4) 9.3 (1.9) 7.7 (1.6) 
VAS Withdrawn 7.5 (1.7) 6.6 (1.6) 7.0 (1.6) 8.4 (2.0) 
VAS Arousal 64.1 (2.7) 57.6 (2.8) 57.0 (2.9) 59.3 (3.1) 
          
 
 
 ETB Data   
Emotional categorisation task (ECAT): Accuracy data showed a main effect of valence with 
negative words categorised more accurately than positive words (F (1 26) = 8.14; p < 0.01; 
see Table 4.2). However, there was no effect of session nor an interaction between valence 
and session (both p > 0.05). For reaction time, there was no effect of valence, session, nor an 
interaction between valence and session (all p > 0.05). 
 
 
Emotional recognition memory task (EMEM): There was a main effect of valence for 
accuracy (F (1 29) = 80.33; p < 0.001) and for reaction time (F (1 29) = 21.68; p < 0.001) 
(see Table 4.2). However, there were no effects of session, nor an interaction between 
valence and session, either for accuracy or reaction time (all p > 0.05). For response bias, 
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there was an effect of valence (positive words = -0.138 versus negative words = 0.371; F (1 
28) = 140.99; p < 0.001 – see Table 4.2), but no effect of session, nor an interaction (both p > 
0.05). 
 
 
**p < 0.01; ***p < 0.001 
 
Emotional recall task (EREC): There were main effects of valence for the number of words 
correctly recalled (negative words = 8.03 versus positive words 9.93; F (1 29) = 16.36; p < 
0.001), and a main effect of session (F (3 87) = 44.66; p < 0.001 – Figure 4.1), but no 
significant interaction between valence and session (F (3 87) = 1.40; p > 0.05). Examining 
the effect of session, all sessions were found to be significantly different from one another 
(with the exception of session 3 versus session 4), with accuracy increasing over sessions (all 
p < 0.01 - Figure 4.1). For the number of incorrectly recalled words, there was a main effect 
of valence (F (1 29) = 7.42; p < 0.05), a main effect of session (F (3 87) = 8.21; p < 0.001), 
and an interaction between session and valence (F (2 70) = 3.84; p < 0.05). Breaking down 
the interaction by emotion, there was no effect of session for incorrectly recalled negative 
words (F (3 87) = 0.61; p > 0.05), but there was an effect of session for incorrectly recalled 
positive words (F (2 67) = 9.43; p < 0.001 – Figure 4.1). T-tests showed significant decreases 
in falsely recalled positive words from session 1 (2.60 words) to session 3 and session 4 (1.30 
ETB Task Measure Positive Negative
Emotional Categorisation Accuracy   92.6 (1.4)   94.8 (1.0)**
Emotional Recognition Accuracy   82.6 (1.9)   67.7 (2.3)***
Reaction Time   964.0 (43.5)   1086.2 (53.3)***
Response Bias  -0.14 (0.06)    0.37 (0.05)***
Valence
Table 4.2 ECAT Accuracy and EMEM Accuracy, Reaction Time and 
Response Bias scores, split by valence (standard error of the mean)
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and 1.07 words: t (29) 4.04; p < 0.01; t (29) 3.89; p < 0.01 – Figure 4.1). There was also a 
trend for a decrease from session 1 to session 2 (2.60 to 1.77 words; t (29) 2.71; p = 0.07). 
 
 
Figure. 4.1 Emotional recall task (EREC): Correctly recalled words (left) and falsely recalled positive words 
(right), for the four test sessions. Number of words correctly recalled increased across each session, with the 
exception of session 3 to session 4. For positive words, there was a significant decrease from session 1 to 
sessions 3 and 4. Error bars represent standard error of the mean. **p < 0.01 
 
Facial expression recognition task (FERT): There were main effects of emotion (F (3 98) = 
18.88; p < 0.001) and session (F (3 87) = 6.44; p < 0.01) on accuracy, but no significant 
interactions (p > 0.05). T-tests on the effect of emotion showed that facial expressions of 
anger, disgust, fear, sadness and surprise were categorised significantly less accurately than 
neutral faces (all p < 0.01), while accuracy for happy faces was not significantly different 
from neutral faces (p > 0.05) (see Table 4.3). Accuracy was significantly higher during 
session 2 and session 4 (57.90% and 58.83%) than session 1 (55.27% - Figure 4.2) (t (29) -
3.16; p < 0.05; t (29) -4.39; p < 0.01).  
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There were main effects of emotion (F (4 102) = 32.87; p < 0.001) and session (F (3 84) = 
6.30; p < 0.01) for reaction time but no interaction (p > 0.05). For the effect of emotion, 
reaction times to anger, disgust, fear, sadness and surprise expressions were significantly 
slower than to neutral faces (all p < 0.01) (see Table 4.3), while reaction times to happy faces 
and neutral faces did not differ (p > 0.05) (see Table 4.3). Reaction times were significantly 
different between all sessions (with the exception of session 3 versus session 4), with reaction 
times decreasing over sessions (Figure 4.2 - all p < 0.01).  
 
For response bias, there was a main effect of emotion (F (3 100) = 96.02; p < 0.001), a 
marginal effect of session (F (2 69) = 2.94; p = 0.05) and a trend towards a significant 
interaction between emotion and session (F (5 135) = 2.26; p = 0.06). For the effect of 
emotion, participants were more biased to all emotional faces compared to neutral 
expressions (all p < 0.001 – Table 4.3). Breaking down the interaction by emotion, there was 
only an effect of session for surprise (F (3 87) = 3.30; p < 0.05). Comparisons between 
sessions showed a trend towards an increase in response bias from session 1 (0.704) to 
sessions 2, 3 and 4 (7.16, 7.61, and 7.60), however, these differences were not statistically 
significant (all p > 0.05). 
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Figure. 4.2 Facial expression recognition task (FERT): mean accuracy (left), and mean reaction time (right), 
averaged over all emotions, for the four test sessions. Accuracy increased from session 1 to session 2 and 
session 4, while reaction time decreased across each session, with the exception of session 3 to session 4. Error 
bars represent standard error of the mean. *p < 0.05; **p < 0.01 
 
 
 
Table 4.3 FERT Accuracy, Reaction Time, and Response Bias scores, 
for each emotion vs. neutral faces (standard error of the mean) 
Emotion Reaction Time Accuracy Response Bias 
Anger 1335.7 (57.1)*** 45.4 (2.4)*** 0.7 (0.0)*** 
Disgust 1244.2 (44.9)*** 52.4 (2.2)*** 0.7 (0.0)*** 
Fear 1483.2 (48.5)*** 50.4 (2.5)*** 0.7 (0.0)*** 
Happy 1060.5 (15.8) 69.2 (1.4) 0.9 (0.0)*** 
Neutral 1076.9 (30.0) 71.2 (2.7) -0.1 (0.0) 
Sad 1216.9 (35.5)** 53.7 (2.8)** 0.7 (0.0)*** 
Surprise 1257.8 (34.3)*** 59.2 (1.6)*** 0.7 (0.0)*** 
 
**p < 0.01; ***p < 0.001 
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Faces dot probe task (FDOT): There was a main effect of masking (masked faces= 96.23% 
versus unmasked faces = 95.25%; (F (1 29) = 7.40; p < 0.05) on accuracy, but no effect of 
session, emotion (fear versus happy) or congruence (congruent versus incongruent probe 
location) nor any interactions (all p > 0.05). For reaction time, there was a main effect of 
session (F (3 87) = 6.11; p < 0.01), whereby reaction times significantly decreased from 
session 1 to session 4 (616.32ms to 579.39ms - t (29) 4.73; p < 0.001) (Figure 4.3). No other 
main effects or interactions were observed for reaction time (all p > 0.05).  
 
 
Figure. 4.3 Faces dot probe task (FDOT): Mean reaction times, averaged over both emotions, for the four test 
sessions; reaction time decreased significantly from session 1 to session 4. Error bars represent standard error of 
the mean. **p < 0.01 
 
4.5. Study 3 Discussion  
Repeated testing with the ETB revealed that the emotional categorisation task (ECAT) and 
emotional memory recognition task (EMEM) were free from practice effects. Performance on 
the facial expression recognition task (FERT), faces dot probe task (FDOT) and emotional 
recall task (EREC) was subject to practice effects; however, these effects plateaued before the 
final test session. 
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For the ECAT, it is perhaps not surprising that accuracy was stable (i.e. individuals 
consistently liked and disliked to be described by positive and negative words, respectively), 
because self-concept is relatively stable over time (Demo, 1992). While it might have been 
expected that participants would have become faster at selecting these descriptors over 
repeated sessions, evidence shows that self-referent stimuli are processed automatically and 
faster than non-self-referent stimuli (Bargh, 1992; Geller and Shaver, 1976). Therefore, it is 
possible that participants were performing at maximal speed from the first test session. As the 
EMEM task also showed a lack of practice effects for accuracy and reaction times, it is 
possible that participants were also responding as quickly and accurately as possible on this 
task from the first session to the same self-referent stimuli.  
 
For the FDOT, accuracy was high and did not change over test sessions, most likely due to 
the simplicity of the task and its low cognitive demand. Reaction time decreased from the 
first to the last session, but was stable across the last three sessions. Consequently, in future 
studies the first session could be a training day, and subsequent sessions could use be used for 
repeat testing. This is similar to the dual-baseline approach in which if there is a change 
between session 1 and session 2, but no changes thereafter, session 2 can be used as a 
baseline for comparison with subsequent sessions (McCaffrey and Westervelt, 1995). 
 
The FERT results showed that accuracy was stable after the first session. Compared to the 
results from this study (in parentheses) healthy volunteers in previous ETB studies showed 
the following accuracy: 48% (45%) to anger, 50% (52%) to disgust, 52% (50%) to fear, 62% 
(69%) to happy, 51% (54%) to sad, 56% (59%) to neutral, and 58% (59%) to surprise 
(Harmer et al. 2003; Harmer et al. 2004). Hence the accuracy levels observed in this study are 
comparable with those reported in published research.  
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FERT reaction times were only stable across the last two sessions. This reaction time pattern 
may relate to the complexity of this task. It has been reported that tasks with complicated 
instructions are associated with increased practice effects (Powers, 1986). However, using the 
duel-baseline approach, this task could have utility in repeated-measures experiments if the 
first two sessions are used as practice sessions.  
 
In the EREC, the number of correctly recalled words increased across the first two sessions, 
but then stabilised across the final two sessions. As participants did not recall all of the words 
it is possible that a ceiling effect in memory performance was reached at this point, though 
there are also other reasons why participants might have stabilised at this level of 
performance. For the incorrect words, recall was stable after the first session, suggesting 
quicker learning of incorrect words. Therefore, as with the FERT task, the EREC task 
appears suitable for repeat testing, after two initial training sessions.  
 
It is possible that using different stimuli for each session would help to reduce practice 
effects. However, while the use of alternative stimuli reduces practice effects in some studies, 
the evidence remains inconsistent, and is likely to be task specific (Benedict and Zgaljardic, 
1998; Hinton-Bayre and Geggen, 2005). Perhaps more problematic is the issue of whether 
training on the ETB could bias responding, for example, by training participants to respond 
according to a response set. Hence, if these tasks are to be used in within-subjects designs, a 
necessary first step would be to ensure that training will not result in fixed responding. This 
could be examined by investigating whether responses can be increased or decreased via an 
experimental manipulation known to produce such effects after several practice trials. 
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In conclusion, both the ECAT and EMEM are suitable for within-subjects designs, while the 
FDOT requires a single training session, and the FERT and EREC require two training 
sessions, if they are to be used repeatedly. Therefore, it may be possible to use the entire 
battery repeatedly after two initial training sessions. Future work should explore the value of 
using alternate stimuli across sessions to reduce the effects of practice, and investigate 
whether repeated testing induces a response set. This would further validate the ETB for use 
with cross-over designs in experimental medicine models. 
 
4.6. Study 4 Overview and Design 
To investigate whether satiety affected performance on the ETB, a between-subjects design 
with a single factor (condition) and two levels (satiated versus non-fed) was used. 
Participants were randomly allocated to a condition with 15 participants in each group. Group 
size was based on previous work in which 12-16 participants per group yielded significant 
effects on the ETB (Murphy et al. 2008; Harmer et al; 2004; Browning et al. 2007). Based on 
prior research indicating that mood effects can be reliably detected 60 minutes after food 
consumption (Smith et al. 1988; Macht and Dettmer, 2006), participants were tested on the 
ETB 60 minutes after consuming lunch or in a non-fed state. 
 
4.7. Study 4 Methods and Materials 
Participants 
30 healthy women psychology students (mean age = 21.41 years; mean BMI = 19.97; mean 
NART = 117) were recruited from the University of Birmingham. Informed consent was 
obtained from all participants, who were compensated after the study with either course 
credits or £10 cash. The study was approved by the University of Birmingham Research 
Ethics Committee and was conducted in accordance with the ethical standards laid down in 
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the 1964 Declaration of Helsinki. Participants were excluded if they were not: between 18-65 
years of age; fluent English speakers as determined by the NART; and of a body mass index 
(BMI) between 18.5 and 24.9. Participants were also excluded if they had taken part in a 
previous ETB study, were dyslexic, smokers, currently taking medication, had consumed a 
large amount of caffeine (> 750mg) or alcohol in the last 24 hours, had food allergies, 
diabetes, or past or present depression as determined by the SCID. Participants who scored 
more than 10 on restraint scale of the TFEQ were not recruited. This is because high levels of 
dietary restraint have been associated with impaired cognitive performance (Green et al. 
1994). 
 
Test Meal Setup and Cheese Sandwiches 
For lunch, participants were served a platter of cheese sandwiches; sixteen quarters, arranged 
in two rows of eight quarters each. Each quarter sandwich serving contained 92.3 calories and 
weighed approximately 31g. Participants were provided with a plate to eat from, and asked to 
eat as much as they wanted until they felt comfortably full. The platter was weighed before 
and after serving (along with any remnants left on the participant’s plate) to determine total 
food intake in grams. Participants were also provided with a glass of water. 
 
Procedure 
Prior to attending the test session, participants were sent the TFEQ via email to ensure they 
were eligible for the study. Those who attended the test day completed a consent form, before 
they were screened with a lifestyle questionnaire, a breakfast questionnaire (to ensure they 
had not consumed food since 8pm the prior day) the SCID and the NART. Participants also 
completed an alcohol and caffeine screening questionnaire to assess their intake over the last 
24 hours, before completing a set of VAS. VAS items were placed above the centre of a 
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100mm line, anchored with “not at all” (0mm) and “extremely” (100mm), and included the 
items: alert; disgusted; drowsy; light-headed; anxious; happy; nauseated; sad; withdrawn; 
faint; hungry; thirsty; full; and desire to eat. 
 
Participants in the satiated condition were served cheese sandwiches after which they 
completed another VAS and a sandwich rating questionnaire. This questionnaire assessed 
liking of the sandwich, whether the meal was a typical size, and whether participants ate 
beyond comfortable fullness, using VAS scale items. Participants were then asked to wait in a 
test cubicle for an hour before proceeding to the ETB test; as noted above, mood effects have 
previously been detected an hour after eating. During this time they completed a VAS after 
30 minutes and 60 minutes, the latter immediately prior to ETB testing. Participants were 
then asked to complete the ETB tasks, followed by a batch of questionnaires, including the 
PFS, BIS, and BDI. Participants then had their height and weight measured for calculation of 
BMI, were asked what they thought the aims of the study were, debriefed and thanked for 
their time. Participants in the non-fed condition completed a similar procedure, but consumed 
the lunch of cheese sandwiches after completing the ETB tasks.  
 
Data Analysis 
General: Between-subjects and mixed analysis of variance (ANOVA) were used to analyse 
the data. Bonferroni correction was used for all post-hoc t-tests, and violations of sphericity 
were addressed using the Greenhouse-Geisser correction.   
VAS: Items were analysed separately to investigate individual profiles of satiation.  
ETB Data: As with Study 3, task specific effects are presented first (e.g. effects of emotion, 
or valence), followed by main effects of condition, and interactions between condition and 
emotion or valence. 
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4.8. Study 4 Results 
Participant Characteristics and Subjective State Questionnaires 
Using independent t-tests (non-fed versus satiated) no significant differences were observed 
between groups for age, BMI, NART, BIS, PFS, BDI, TFEQ (cognitive restraint, 
disinhibition and hunger) and amount eaten (all p > 0.05; see Table 4.4). Hence, it appears 
that the groups were well matched. 
 
Table 4.4 Participant Characteristics and Subjective State Questionnaires 
(standard error of the mean) 
               Condition 
Measure Non-fed Satiated 
Age 19.7 (0.3) 20.3 (0.5) 
Body Mass Index (BMI) 21.5 (0.6) 21.4 (0.5) 
National Adult Reading Test (NART) 116.3 (1.1) 117.1 (1.3) 
Barratt Impulsivity Scale (BIS) 63.3 (2.0) 68.2 (3.0) 
Power of Food Scale (PFS) 38.2 (2.4) 37.4 (3.1) 
Beck Depression Inventory (BDI) 5.8 (0.9) 7.8 (1.5) 
TFEQ Cognitive Restraint 6.2 (0.8) 6.3 (0.8) 
TFEQ Disinhibition 5.3 (0.7) 7.1 (1.0) 
TFEQ Hunger 5.4 (1.0) 7.3 (0.9) 
Amount Eaten (grams) 193.6 (16.7) 188.5 (15.5) 
      
 
Three factor eating questionnaire (TFEQ) 
 
Visual Analogue Scales 
VAS scores were entered into mixed ANOVAs, with the factor of condition (satiated versus 
non-fed) and time (pre versus post-manipulation). 
 
Appetite items: Hunger, desire to eat, fullness and thirst showed a main effect of time and a 
main effect of condition (all p < 0.001; see Table 4.5). For hunger, fullness and desire to eat 
(but not thirst), there were significant interactions between condition and time (all p < 0.001; 
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see Table 4.5). Comparing pre versus post-manipulation ratings separately for each group, 
rated hunger decreased over time in the satiated (p < 0.001; see Table 4.5), but did not change 
over time in the non-fed group (p > 0.05). Desire to eat also decreased over time in the 
satiated group (p < 0.001; see Table 4.5), but increased over time in the non-fed group (p < 
0.05). Finally, fullness significantly increased over time in the satiated group (p < 0.001; see 
Table 4.5), but did not change in the non-fed group (p > 0.05). 
 
Mood items: For alertness and anxiety there were main effects of time whereby alertness and 
anxiety decreased over time (both p < 0.05; see Table 4.5). There was no effect of condition 
or interaction for either rating. For faint, there was no effect of time or condition (both p < 
0.05), however, there was a significant interaction between time and condition (p < 0.01). 
Comparing pre versus post-manipulation ratings separately for each group, neither t-test 
survived significance (both p < 0.05), however, the means showed a trend for increased faint 
ratings in the non-fed group over time, and decreased faint ratings in the satiated group over 
time. For disgust, drowsiness, light-headed, happiness, nausea, sadness, and withdrawn, there 
was no effect of time or condition, or a significant interaction (all p > 0.05).  
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Table 4.5 Visual Analogue Scale mean scores split by condition and time (standard error of the 
mean) 
  Non-fed Satiated 
VAS Item 
Pre-
Manipulation 
Post-
Manipulation 
Pre-
Manipulation 
Post-
Manipulation 
     Appetite 
    
Hunger a,b,c 74.5 (3.7) 79.7 (5.6) 81.6 (3.9) 15.3 (5.7) 
Desire to Eat a,b,c 71.0 (4.0) 81.8 (3.9) 78.9 (4.2) 14.4 (4.0) 
Fullness a,b,c 14.7 (3.3) 7.2 (4.5) 5.9 (3.4) 64.4 (4.7) 
Thirst a,b 66.3 (5.1) 52.3 (7.3) 69.4 (5.3) 24.0 (7.5) 
     
Mood 
    
Alertness a 64.5 (5.6) 51.3 (5.6) 59.9 (5.6) 55.8 (5.6) 
Disgust 6.6 (1.6) 4.5 (2.1) 2.6 (1.6) 4.6 (2.1) 
Anxiety a 17.4 (4.8) 10.9 (2.9) 12.0 (4.8) 2.9 (2.9) 
Drowsiness 33.4 (7.4) 43.2 (6.5) 36.0 (7.4) 40.5 (6.5) 
Lightheaded 25.1 (5.6) 26.7 (5.2) 19.5 (5.6) 8.9 (5.2) 
Happiness 60.9 (3.1) 58.7 (3.2) 65.5 (3.1) 67.8 (3.2) 
Withdrawn 17.2 (4.7) 18.6 (4.2) 13.3 (4.7) 9.5 (4.2) 
Faint c 12.1 (5.4) 19.9 (4.7) 19.1 (5.4) 5.5 (4.7) 
Sad 11.4 (2.4) 10.5 (3.3) 3.9 (2.4) 6.8 (3.3) 
Nausea 10.3 (3.1) 10.1 (4.1) 7.0 (3.1) 5.8 (4.1) 
               
a = Main effect of time; b = Main effect of condition; c = Interaction between time and condition 
 
Emotional Test Battery (ETB) Data 
Emotional categorisation task (ECAT) and Emotional recognition memory task (EMEM): 
There was no effect of valence, condition, nor an interaction between condition and valence 
(positive versus negative words) for ECAT accuracy (all p > 0.05; see Table 4.6). Analysis of 
ECAT reaction time showed a trend towards a main effect of valence with quicker times for 
positive versus negative words (F (1 28) = 4.16; p = 0.05), but no effect of condition, and no 
interaction (both p > 0.05; see Table 4.6). EMEM accuracy scores showed a main effect of 
valence with better accuracy for positive versus negative words (F (1 28) = 33.87; p < 0.001), 
but no effect of condition nor a significant interaction (both p > 0.05; see Table 4.6). Analysis 
of reaction time also showed an effect of valence with quicker times for positive versus 
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negative words (F (1 28) = 54.24; p < 0.001), but no effect of condition, nor a significant 
interaction (both p > 0.05; see Table 4.6).  
 
Emotional recall task (EREC): For words correctly recalled, there was a main effect of 
valence with more positive words recalled versus negative (F (1 28) = 27.80; p < 0.001; see 
Table 4.6), but no effect of condition nor a significant interaction (both p > 0.05). For words 
incorrectly recalled, there was also an effect of valence with more positive words recalled 
versus negative (F (1 28) = 12.27; p < 0.01; see Table 4.6), but no effect of condition nor a 
significant interaction (both p > 0.05). 
 
Facial expression recognition task (FERT): For accuracy, there was a main effect of emotion 
(F (4 99) = 30.60; p < 0.001 – Table 4.7), but no effect of condition, or an interaction 
between emotion and condition (both p > 0.05; see Table 4.8). T-tests on the effect of 
emotion showed that all facial expressions were categorised significantly less accurately than 
neutral faces (all p < 0.01; see Table 4.8). Analysis of reaction time data also revealed a main 
effect of emotion (F (4 117) = 19.68; p < 0.001 – Table 4.7), but no effect of condition, nor 
an interaction between emotion and condition (both P > 0.05; see Table 4.8). For the effect of 
emotion, reaction times to anger, disgust, fear, sadness and surprise expressions were 
significantly slower than to neutral faces (all p < 0.01) (see Table 4.7), while reaction times to 
happy faces were not significantly different from those to neutral faces (p > 0.05; see Table 
4.7). 
 
Faces Dot Probe Task (FDOT): For FDOT accuracy and reaction times, there was no main 
effect of condition (non-fed versus satiated; see Table 4.6), emotion (fear versus happy 
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faces), masking (masked versus unmasked), or congruency (congruent versus incongruent 
probe location) and no significant interactions between these factors (all p > 0.05). 
 
 
 
Table 4.7 Accuracy and Reaction Times for FERT Task split by 
emotion (standard error of the mean) 
  Measure   
Emotion Accuracy Reaction Times 
      
Anger 46.0 (2.4)*** 1504.8 (82.7)*** 
Disgust 54.8 (1.46)*** 1300.2 (55.3)** 
Fear 46.7 (2.2)*** 1614.5 (67.9)*** 
Happy 61.8 (1.7) 1179.6 (35.5) 
Neutral 78.3 (2.7)*** 1124.6 (54.3) 
Sad 46.8 (2.9)*** 1414.6 (60.0)*** 
Surprise 58.0 (1.6)*** 1387.5 (70.2)** 
      
 
Significance values are for each emotion versus neutral  
**p < 0.01; *** p < 0.001 
ETB Task  Measure Non-fed Satiated Non-fed Satiated 
Accuracy 96.7 (1.3) 96.0 (1.3) 96.2 (1.2) 95.3 (1.2) 
Reaction Time 834.7 (41.7) 819.1 (41.7) 785.2 (37.5) 805.0 (37.5) 
Accuracy 65.3 (4.4) 62.7 (4.4) 79.8 (2.7) 85.8 (2.7) 
Reaction Time 1081.3 (62.5) 1093.1 (62.5) 915.7 (44.0) 912.1 (44.0) 
Correct Words 5.1 (0.7) 4.7 (0.7) 7.2 (0.7) 7.0 (0.7) 
Incorrect Words 0.6 (0.3) 0.7 (0.3) 1.7 (0.5) 2.7 (0.5) 
Accuracy 95.4 (1.2) 93.2 (1.2) 94.5 (1.5) 92.9 (1.5) 
Reaction Time 630.8 (17.4) 655.5 (17.4) 631.9 (18.1) 656.3 (18.1) 
Emotional Categorisation  
(ECAT) 
Emotional Recognition  
Memory (EMEM) 
Table 4.6 Accuracy, Reaction Time, and Number of Correct and Incorrect words recalled for ETB  
tasks, split by negative and positive stimuli and non-fed and satiated state (standard error of the mean) 
Emotional Recall    
(EREC) 
Faces Dot Probe   
(FDOT) 
Positive Negative 
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Table 4.8 Accuracy and Reaction Times for FERT Task, split by emotions and non-fed 
and satiated state (standard error of the mean) 
  Accuracy Reaction Times 
Emotion Non-fed Satiated Non-fed Satiated 
          
Anger 44.0 (3.5) 48.0 (3.5) 1355.6 (112.2) 1654.0 (112.2) 
Disgust 54.8 (2.1) 54.7 (2.1) 1291.9 (79.6) 1308.4 (79.6) 
Fear 45.8 (3.2) 47.5 (3.2) 1602.3 (97.6) 1626.7 (97.6) 
Happy 60.5 (2.4) 63.0 (2.4) 1117.4 (48.3) 1241.9 (48.3) 
Neutral 80. (3.8) 76.7 (3.8) 998.3 (70.4) 1250.9 (70.4) 
Sad 48.3 (4.1) 45.2 (4.1) 1372.3 (85.6) 1456.9 (85.6) 
Surprise 58.8 (2.2) 57.2 (2.2) 1274.9 (96.4) 1500.1 (96.4) 
          
          
 
4.9. Study 4 Discussion 
Participants who were asked to eat a sandwich lunch until satiated reported a decrease in 
appetite, compared to participants who were not given lunch. Satiation did not significantly 
affect questionnaire based measures of mood, nor did it affect performance on the ETB. 
Hence, the successful induction of satiation did not affect any measures of emotional 
processing or cognition in this paradigm. 
 
The lack of a satiation-induced effect on mood in the present study might be partly due to the 
type of food used. The study by Macht and Dettmer (2006) reported that both apple and 
chocolate consumption elevated mood in healthy women, but the effect of chocolate 
consumption was greater than the effect of apple consumption. Hence, it is possible that 
palatable or energy dense foods have greater effects on mood than less palatable or energy 
dense foods. This suggestion is supported by evidence that foods with a high energy content 
have greater effects on mood than food with a lower energy content (Macht et al. 2003).  
Thus, the use of a food that is more palatable or energy dense than bland cheese sandwiches 
might have elicited effects on emotion, which might then have been detected by the ETB.  
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Another possible explanation of the lack of effect of lunch consumption on mood might be 
that any effect was transient and did not persist long enough to be detected by the ETB, 
which can take up to 90 minutes to complete. Alternatively, satiation may not affect the 
emotional processing tasks that comprise the ETB. It should be noted that significant effects 
were observed using the ETB including significant differences between neutral and emotional 
faces and differences in responding according to valence. Hence, it was possible to detect 
significant effects on performance in this battery in the laboratory. 
 
The absence of an effect of satiation on cognitive measures from the ETB is not necessarily 
unexpected. While there is evidence that consumption of food can affect memory (Benton 
and Parker, 1998), recent work suggests that the type of food consumed is important. For 
instance, consuming a breakfast of oatmeal enhances cognitive performance compared to a 
ready-to-go cereal (Mahoney et al. 2005). It is thought that this may be due to oatmeal 
providing a slow sustained energy release of glucose to the brain, and suggests that the 
composition of the food consumed is likely to mediate temporal effects on cognition. In 
addition to evidence suggesting that food consumption has no effect on effect on cognitive 
performance (Müller et al. 2013), there is also evidence that eating food can directly impair 
cognitive performance in some tasks (Smith and Miles, 1987). Such effects might be 
attributable to the well-known “postprandial dip”, the effects of which can be worsened by 
consuming heavier meals (Reyner et al. 2012).  
 
 
 
In conclusion, satiation did not affect questionnaire-based measures of mood nor performance 
on the ETB. Therefore, it seems unlikely that variations in appetitive state due to hunger, 
eating or drug administration will confound the results of ETB studies. However, further 
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work with other types of foods such as high calorie cookies given at varying intervals prior to 
ETB testing would help to confirm this conclusion. 
 
4.10. General Summary 
To summarise, after two training sessions the ETB appears to be suitable for use in within-
subjects designs, enabling greater control of individual differences which may be particularly 
important for consistent effects in eating studies.  The ETB also appears to be insensitive to 
the satiety state of participants, which reduces concern about satiety state acting as a potential 
confound in ETB studies and reinforces the robust nature of the test battery.  
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CHAPTER 5: Study 5: Natural satiation attenuates blood oxygen level dependent 
(BOLD) activity in brain regions involved in reward and increases BOLD activity in an 
inhibitory control centre: a functional magnetic resonance imaging (fMRI) study in 
healthy volunteers 
 
5.1. Introduction 
The use of fMRI has the potential to provide information on brain functional biomarkers of 
satiation and response to anti-obesity drugs. For instance, recent fMRI work with sibutramine 
revealed that the drug attenuated BOLD activity in response to viewing of food cues in the 
hypothalamus and amygdala (Fletcher et al. 2010). Suppression of BOLD activity in the 
hypothalamus was associated with a greater reduction in ad-libitum food intake and body 
weight (Fletcher et al. 2010). However, this pattern of activity was different to that observed 
when comparing BOLD responses in a fasted versus fed state, which suggests that distinct 
modulation of neural activity might underlie responses to feeding versus drug-induced 
changes in appetite. Therefore, further work is required to elucidate brain responses to 
feeding to provide a template against which the actions of anti-obesity drugs can be 
compared.  
 
Hunger associated with food deprivation increases the incentive value of food, which is 
reflected in enhanced responses to appetitive stimuli in reward-related brain areas as assessed 
by fMRI (Goldstone et al. 2009; Führer et al. 2008; LaBar et al. 2001; Haase et al. 2009; 
Fletcher et al. 2010; Siep et al. 2009). Previous studies have assessed the effects of fasting on 
brain responses to food-related stimuli (St-Onge et al. 2005; Porubska et al. 2006; Killgore et 
al.2003), compared the responses of lean and obese participants to eating (Le et al. 2006) or 
examined differences in brain activation between restrained and  unrestrained eaters (Coletta 
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et al. 2009).  Studies that have examined the effects of eating on neural activity have tended 
to focus on sensory specific responses rather than the effects of satiation per se (Kringelbach 
et al. 2003; Smeets et al. 2006). To date no study has assessed the effects of a standard meal 
on BOLD responses and compared this to natural inter-meal hunger levels rather than 
prolonged fasting.  Furthermore, previous studies have only assessed responses to either taste 
or visual stimuli and did not investigate modality specific effects of satiation on neural 
responses.   
 
Recently, a role for frontal inhibitory neural circuitry in the control of food intake has been 
highlighted (see Moran and Westerterp-Plantenga, 2012). For example, dorsolateral 
prefrontal cortex (dlPFC) activation has been associated with higher levels of self-control 
over food choices and cognitive restraint of intake (Hare et al. 2009; Hollmann et al. 2012). 
This raises the possibility that reduced motivation to eat associated with consumption of food 
(satiation) is mediated in part by enhanced activity in prefrontal brain regions involved in 
executive control. Interestingly, obese patients with Prader Willi syndrome show 
hyporeactivity in dlPFC following a meal which has been suggested to be related to the 
satiety deficit associated with this syndrome (Holsen et al. 2012).  Activity in the dlPFC may 
affect food motivation by modulating reward value signals encoded by the vmPFC (Hare et 
al. 2009; 2011) suggesting that interactions between dorsolateral and ventromedial PFC may 
be particularly important in satiation.  
 
In Study 5, an fMRI paradigm was used that was developed to investigate neural responses to 
both primary and secondary rewarding and aversive appetitive stimuli in the human brain 
(McCabe et al. 2010). The effects of satiety were assessed by scanning participants after a 
brief 4 hour fast or following the consumption of a lunch of cheese sandwiches. The use of 
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this bland food ensured that participants were satiated while minimising sensory specific 
satiety effects (Kringelbach et al. 2003). 
 
It was predicted that compared to a pre-meal state, consuming a satiating lunch would reduce 
neural activity in reward and appetitive areas such as ventromedial prefrontal cortex, 
orbitofrontal cortex, ventral striatum, midbrain, hypothalamus, insula, amygdala, 
hippocampus and brainstem. It was also predicted that satiation would  increase neural 
responses in the dorsolateral prefrontal cortex (inhibitory control), which would be negatively 
correlated with activity in the vmPFC, based on recent research showing an inverse 
relationship between these two areas in a food task (Hare et al. 2009).   
 
5.2. Materials and methods 
Participants 
16 healthy volunteers (8 men, 8 women; mean age = 21.7 years; mean BMI = 21.1) who met 
the inclusion criteria were recruited via posters and advertisements on websites.  The study 
was advertised as a chocolate experiment involving fMRI scanning, with a free lunch of 
cheese sandwiches and £50 compensation. Ethics approval was provided by the Oxford 
Research Ethics Committee B (National Research Ethics Service) and informed consent was 
obtained from all participants. Participants were excluded if they had a past or present Axis 1 
disorder, as determined by the SCID, or a score over 10 on the BDI. Other exclusion criteria 
were taking medication, left-handed, smoker, food allergies, diabetic, under 18 or over 60 
years of age, outside a BMI range of 18.5 - 24.9 or any contraindications to fMRI scanning 
such as the presence of a pacemaker. 
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Design 
A within-subjects design was used, with participants taking part in both experimental 
conditions: pre-meal and satiated. For both conditions, each run on a separate test day, 
participants were scanned twice, an hour apart. In the satiated condition, participants received 
lunch between scans, whereas those in the pre-meal condition received lunch after the second 
scan of the test day, and had a one hour break between scans (Figure 5.1). Participants were 
tested within a month of screening, and test days were either one or two weeks apart, with 
scans at the same time and on the same day of the week as the first sessions (+/- half an 
hour). Order of completing the satiated and pre-meal test days was counterbalanced across 
participants and gender.  
 
 
Figure 5.1 Overview of experimental procedure; pre-meal condition and satiated condition with approximate 
timings. 
 
Scanner Stimuli 
Taste stimuli were delivered to participants via three Teflon tubes held between their lips; one 
tube each for a tasteless rinse control, a chocolate taste and an unpleasant strawberry taste, 
each of which were liquid at room temperature. The tubes were connected to their own 
individual reservoir, which was capable of delivering 0.5ml of a given stimulus via a syringe 
and a one-way syringe activated check valve. Stimulus delivery was provided manually with 
liquid release over a period of seven seconds in response to computer generated times. The 
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tasteless rinse control was 0.5 ml of a saliva-like rinse solution (25 X 10-3 mol/L KCl and 2.5 
X 10-3 mol/L NaHCO3 in distilled H2O), used between trials, and subtracted from the effects 
of the other taste stimuli. The aversive strawberry taste stimulus was an unpleasant 
strawberry drink (Rosemount Pharmaceuticals, Leeds, UK), matched in intensity, sweetness 
and texture to the chocolate taste stimulus, which was a Belgian Chocolate Milk Drink 
(Marks & Spencer, UK). 
 
Scanner Task 
Based on the experimental paradigm used by McCabe et al. (2010), a total of six conditions 
(presented nine times) were utilised in the scanner task: chocolate taste; chocolate picture; 
chocolate taste with chocolate picture; strawberry taste; strawberry picture; strawberry taste 
with strawberry picture. For trials with oral stimuli, 0.5ml of the appropriate liquid was 
delivered to the participant’s mouth while they were inside the scanner. Simultaneously, a 
visual stimulus was presented either of chocolate, mouldy strawberries or a gray control 
image for seven seconds. Participants were instructed to move their tongue once, as soon as 
the liquid was administered to disperse it throughout the mouth, and then to remain still until 
a green cross was shown, signalling to the participant to swallow the liquid.  
 
After a 2 second delay, participants rated each of the stimuli on that trial for: “pleasantness” 
(anchored at +2 for very pleasant, 0 for neutral, and -2 for very unpleasant); “intensity” (0 to 
4, with 4 being most intense); and for “wanting” (using the same scale as pleasantness). They 
did this by moving a bar vertically along a scale, using a button box. The ratings were 
followed by presentation of the visual gray control stimulus and the tasteless control solution, 
in the same manner as the test stimuli. The tasteless control solution was always administered 
whilst displaying the gray control stimulus. On trials where only the chocolate or strawberry 
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image was presented, the rinse was not used but the gray control image was shown to allow a 
contrast. This sequence was followed by a two second delay for swallowing, followed by a 
one second gap between trials. This procedure was repeated for each of the six conditions, 9 
times. 
 
Lunch 
The lunch consisted of a glass of water and an ad-libitum meal of cheddar cheese sandwiches 
on oatmeal bread. A single sandwich weighed approximately 120g (358 calories) and 
participants were able to eat a maximum of eight sandwiches (960g). Four sandwiches were 
initially provided to each participant, and they were given free access to additional 
sandwiches if they wished to consume more. 
 
Procedure 
Screening Day: Participants were screened with the Medical Screening Sheet, SCID and BDI, 
to determine eligibility. They were also given the: Fawcett-Clarke Pleasure Scale to examine 
their capacity for pleasure (FCPS – Fawcett et al., 1983), Snaith-Hamilton Pleasure Scale as 
an indicator of anhedonia (SHAPS – Snaith et al., 1995), Eating Attitudes Test questionnaire 
as a measure of disordered eating (EAT – Garner et al., 1982), and the TFEQ. Participants 
also completed an fMRI screening sheet to ensure they were eligible to take part. Their height 
and weight was taken to allow calculation of BMI and they completed a trial run of the 
scanner task to ensure they liked and disliked the chocolate and strawberry liquids, 
respectively. Participants also ate a sample of the cheese sandwiches to ensure they would be 
willing to eat the same sandwiches on the test days. A Sandwich Rating Questionnaire (SRQ) 
was used to assess liking of the cheese sandwich; the questionnaire used 100mm VAS and 
asked participants to rate the sandwich on how enjoyable it was and whether they would 
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choose to eat it. A Chocolate Questionnaire (CQ) was also used to assess chocolate craving, 
liking, frequency of consumption and amount consumed. 
 
Testing Day: Participants were asked not to eat chocolate for 24 hours before the scan and 
this was checked verbally on the morning of the test. They were also asked not to eat food for 
at least 2 hours prior to scanning to ensure a pre-meal state and this was checked by having 
participants complete a breakfast questionnaire detailing when they last ate. Scanning took 
place either between 11.30am – 2.30pm or 12.30pm – 3.30pm. On arrival, participants filled 
out a breakfast form, the STAI and VAS, before completing the first scan of the day. Each 
VAS questionnaire used 100mm scales, and contained mood and appetite related items: 
alertness; disgust; drowsiness; anxiety; happiness; nausea; sadness; withdrawn; faint; hungry; 
full; desire to eat; thirst. After this, participants completed another set of appetite VAS. 
Participants in the satiated condition were invited to consume their lunch and asked to eat to 
the nearest half sandwich to facilitate estimating the amount of food eaten, either at 12.30pm 
or 1.30pm, depending on starting time. After they had finished eating, participants were 
asked to fill in a sandwich rating form and appetite VAS, before completing the second scan. 
After the second scan, participants completed a final set of appetite and mood VAS and a 
STAI.  Participants in the pre-meal condition, completed appetite VAS after the first scan and 
were then given a one hour break outside the scanner instead of eating lunch. During this 
time, participants were allowed to read a book or a newspaper in an adjacent room. This 
break was followed by an appetite VAS and the second scan. Subsequently, participants were 
given an appetite VAS and lunch as above, with the same sandwich rating, before completing 
a final set of mood and appetite VAS, along with a STAI. Participants then returned for a 
second scanning day, and underwent the entire procedure again, for the condition they did not 
complete the first time.  
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fMRI Scan  
An event-related interleaved design utilised the six scanner task stimuli described above in 
random permuted sequence. A 3.0 T Magnetom Verio (Siemens) whole body scanner was 
used at the Oxford Centre for Functional Magnetic Resonance Imaging of the Brain 
(FMRIB), acquiring T2*weighted echo planar imaging (EPI) slices every 2 seconds (TR = 2). 
36 Axial slices (in-plane resolution of 3 x 3 x 3 mm - no gap) were acquired, the matrix 
size was 64 x 64 and field of view was 192 x 192 mm. Acquisition took place during the task, 
resulting in a total of 976 volumes, the first four being dummy scans. A whole brain T2*-
weighted EPI volume of these dimensions and an anatomic T1 volume with axial plane slice 
thickness of 1 mm and in-plane resolution of 1.0 x 1.0 x 1.0 mm were also obtained. 
 
fMRI Analysis 
FMRIB software library (FSL; FMRIB, Oxford, www.fmrib.ox.ac.uk/fsl) was used for pre-
processing and statistical analyses of the data. For pre-processing, the following were used: 
high pass filter cut off of 60s; motion correction using FMRIB's Linear Image Registration 
Tool (MCFLIRT); interleaved slice timing correction; spatial smoothing with a 6mm full-
width-half-maximum kernel; high pass temporal filtering and film pre-whitening. Functional 
data were registered to their corresponding structural images and transformed to Montreal 
Neurological Institute (MNI) space using a reference brain (12 DOF linear transformation). 
Multivariate Exploratory Linear Optimized Decomposition into Independent Components 
(MELODIC) was also used to remove artefacts; mean percentage of components removed = 
4.98%; SE = 0.27%.   
 
Following this, the MELODIC filtered scans were entered into a first level analysis, to 
produce contrasts of the 6 experimental stimuli from the task, minus the corresponding 
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control stimuli (control rinse, control gray image and combination of both). Motion 
correction parameters from MELODIC for each of the 6 experimental stimuli were entered as 
regressors of no interest and orthogonalised to the total of 9 experimental and control stimuli. 
To account for baseline, a second level analysis (Fixed Effects) was run on these first level 
outputs for each participant to subtract baseline scans from the post manipulation scans (i.e. 
pre-meal minus baseline and satiated minus baseline). Subsequently, all second level outputs 
were entered into a third level mixed effects (FMRIB's Local Analysis of Mixed Effects 1+2; 
FLAME 1+2) group analysis, producing f-tests for the following main effects and 
interactions: condition; stimuli; modality; condition x stimuli; condition x modality; stimuli x 
modality and condition x stimuli x modality. Using a backwards elimination process, non-
significant variables were removed one at a time (interactions first, followed by main effects) 
until only variables that were significant remained.  
 
Group Z statistic images were subsequently corrected for multiple comparisons by means of 
family wise error (FWE) correction to control for false positives using the AlphaSim 
program, part of the AFNI toolkit (Cox, 1996). To control the FWE rate, the program takes 
the particular voxel-wise threshold, voxel dimensions and spatial smoothing kernel size used 
in the fMRI analysis and, by means of a Monte Carlo simulation, computes the probability of 
a cluster of specific size arising by chance. Based on our data, with a voxel-wise threshold of 
p < 0.001 (Z > 3.1) only clusters with more than 24 contiguous voxels were significant with a 
FWE corrected p < 0.05. As the hypothalamus is difficult to image accurately due to its 
proximity to sinuses and susceptibility to artefacts (Ojemann et al. 1997) and it is a 
particularly small region yielding small cluster sizes in other appetite-fMRI studies (Haase et 
al. 2009), a more conservative voxel-wise threshold (p <0.0005; Z>3.3) producing a smaller 
FWE cluster threshold (19 or more contiguous voxels; p < 0.05) was used to balance the risk 
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of Type 1 versus Type 2 errors. Effects of stimuli and modality were not reported unless they 
interacted with satiation. For clarity, local maxima are reported in the tables of activation 
results. Brain regions were anatomically identified using FSL’s integrated Harvard-Oxford 
Cortical and Subcortical Atlases. For regions not covered by these the Duvernoy Atlas 
(Duvernoy, 1999) was used. To display brain regions of interest, group Z statistic images 
were masked using a mask of the brain region (derived from cluster parameters) and then 
entered into MRIcro (Rorden & Brett, 2000) to visualise BOLD signal % change. 
 
Behavioural Data Analysis 
Appetite VAS taken pre- and post-lunch and break for those who were satiated and pre-meal 
respectively, were averaged over time for hunger, desire to eat and fullness. All three items 
were correlated significantly (Pearson’s correlations, all p < 0.01) and so they were averaged 
into the composite measure ‘appetite’ for analysis. Scanner task ratings were averaged across 
the scanning session and, along with region of interest data, were analysed by condition (pre-
meal versus satiated), stimuli (chocolate versus strawberry) and modality (taste, picture, and 
taste and picture). Only main effects of condition and interactions with condition were 
followed up with planned comparisons. All t-tests used Bonferroni correction and violations 
of sphericity were addressed using the Greenhouse-Geisser correction. 
 
5.3. Results 
Participants 
All participant scores for the TFEQ, STAI, FCPS, SHAPS, BDI and EAT questionnaires 
were within the normal range, and liking and craving ratings of chocolate were sufficient to 
ensure chocolate would be a robust reward stimuli (see Table 5.1). In addition, the food 
intake of participants in the pre-meal condition, who ate 336.9g (SE = 40.5g; lunch =1004 
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calories), did not differ from that of participants in the satiated condition, who ate 398.1g (SE 
= 41.8g; lunch = 1186 calories) (p > 0.05).  
 
    
Table 5.1: Participant characteristics and baseline means (standard error of 
the mean) 
Measure Mean (SE) 
TFEQ Restraint Scale 3.8 (0.8) 
TFEQ Disinhibition Scale 4.6 (0.6) 
TFEQ Hunger Scale 3.9 (0.8) 
STAI State 30.1 (1.7) 
STAI Trait 30.4 (1.7) 
FCPS 131.5 (3.7) 
SHAPS 22.3 (1.0) 
BDI 0.8 (0.4) 
EAT 2.4 (0.5) 
Chocolate Liking 8.4 (0.3) 
Chocolate Craving 6.1 (0.4) 
Pre-meal Condition Intake (grams) 336.9 (40.5) 
Satiated Condition Intake (grams) 398.1 (41.8) 
    
  TFEQ, Three Factor Eating Questionnaire; STAI, State and Trait Anxiety 
Inventory; FCPS, Fawcett Clarke Pleasure Scale; SHAPS, Snaith-Hamilton 
Pleasure Scale; BDI, Beck Depression Inventory; EAT, Eating Attitudes Test 
questionnaire. 
 
 
Appetite VAS 
There was a main effect of condition (F (1 15) = 95.91; p < 0.001), and of time (F (1 15) = 
9.63; p < 0.01) and an interaction between condition and time (F (1 15) = 59.13; p < 0.001.) 
There were no significant differences between baseline appetite for the satiated and pre-meal 
conditions (52.9mm versus 55.9mm; t (15) = -0.55, p > 0.05), but appetite was significantly 
higher in the pre-meal than the satiated condition (73.3mm versus 11.1mm; t (15) = 13.37, p 
< 0.001). 
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Scanner Task Subjective Ratings 
Pleasantness: Mean ratings from the scan during which participants were in the pre-meal or 
satiated state were analysed by condition, stimuli (chocolate versus strawberry) and modality 
(taste, picture, and taste and picture). There was a main effect of condition (F (1 15) = 8.59; p 
< 0.05), stimulus (F (1 15) = 270.36; p < 0.001) as well as interactions between condition and 
stimuli (F (1 15) = 11.34; p < 0.01) and between stimulus and modality (F (1 20) = 5.66; p < 
0.05). Chocolate stimuli were rated significantly less pleasant when satiated than in the pre-
meal state (t (15) = -3.79, p < 0.01, see Figure 5.2). In contrast, there were no significant 
differences for ratings of strawberry stimuli between the pre-meal and satiated conditions (t 
(15) = 1.63, p > 0.05). 
 
 
 
Figure 5.2. Mean pleasantness ratings for chocolate and strawberry stimuli, split by modality and condition 
(with standard error bars). **p < 0.01 
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Wanting: There was a main effect of condition (F (1 15) = 25.97; p < 0.001), stimulus (F (1 
15) = 268.13; p < 0.001) and interactions between condition and stimulus (F (1 15) = 26.52; p 
< 0.001) and stimulus and modality (F (2 30) = 6.96; p < 0.01). Chocolate stimuli were rated 
significantly less wanted in the satiated condition compared to the pre-meal condition (0.55 
versus 1.22; t (15) = -6.15, p < 0.001, see Figure 5.3). There were no significant differences 
between ratings in the pre-meal and satiated conditions for strawberry stimuli (t (15) = 0.39, p 
> 0.05). 
 
 
Figure 5.3. Mean intensity ratings for chocolate and strawberry stimuli, split by modality and condition (with 
standard error bars). ***p < 0.001 
 
Intensity: There was a main effect of stimulus (F (1 15) = 15.07; p < 0.01 – Figure 5.4) with 
the strawberry stimuli rated more intense than the chocolate stimuli and of modality (F (1 15) 
= 20.14; p < 0.001). There was also a trend towards an effect of condition (F (1 15) = 3.45; p 
= 0.08), with higher intensity ratings when in the pre-meal state compared to satiated. 
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Figure 5.4. Mean intensity ratings for chocolate and strawberry stimuli, split by modality and condition (with 
standard error bars). **p < 0.01 
 
fMRI Whole Brain Analysis 
Contrast of parameter estimates (COPEs) for each of the six experimental stimuli (chocolate 
taste, chocolate picture, chocolate taste and picture, strawberry taste, strawberry picture, and 
strawberry taste and picture) had the corresponding control stimuli subtracted at the first level 
(control rinse, control gray image and combination of both). At the second level, baseline 
scans at the start of the day were subtracted from scans taken during the pre-meal (e.g. pre-
meal – baseline scan) and satiated state (e.g. satiated state – baseline scan). These contrasts 
were then entered into a higher level analysis with the following factors: condition (pre-meal 
versus satiated); stimulus (chocolate versus strawberry) and modality (taste versus picture 
versus taste and picture). There was a main effect of condition and a main effect of modality; 
however, there was no main effect of stimulus and nor any significant interactions between 
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any of the factors. Local maxima for the main effect of condition are reported for key 
appetitive/reward areas (see Table 5.2). Additional areas showing an effect of condition are 
reported in Table 5.3 for reference. Satiation attenuated BOLD activity in the ventromedial 
prefrontal cortex (vmPFC), orbitofrontal cortex, nucleus accumbens (ventral striatum), 
hypothalamus and insula (see Figures 5.5 and 5.6). Activity was not attenuated in the 
amygdala or hippocampus at this statistical threshold. Stimulus-evoked BOLD activity was 
enhanced in the satiated state; bilaterally in the dorsolateral prefrontal cortex (dlPFC) and the 
insula (see Figures 5.7 and 5.8). To investigate the relationship between the vmPFC (reward) 
and dlPFC (inhibitory control), percentage signal change values for the local maxima were 
extracted and correlated using SPSS for the left vmPFC and dlPFC while satiated. A 
Pearson’s correlation coefficient, revealed a significant negative correlation (r = -0.580, n = 
16, p < 0.05, see Figure 5.9). 
 
As additional checks, there were no significant differences in BOLD response between men 
and women, and BOLD response to the stimuli did not change over time (baseline scan day 1 
compared to baseline scan day 2). 
 
 
 
 
 
 
 
 
 
132 
 
Table 5.2. Local maxima of key appetitive and reward areas showing main effect 
of condition (satiation versus pre-meal state) averaged over stimuli and modality. 
Brain Region (Hemisphere) 
Montreal 
Neurological Institute 
(MNI) Coordinates 
Estimated 
Brodmann 
Area 
 
Z 
Score 
  
X Y Z 
            
Reduced activation when satiated (versus pre-meal state) 
 
            
Ventrolateral PFC (R)   50 42 -12 47 4.0 
Ventromedial PFC (L) -12 52 -22 11 4.0 
Nucleus Accumbens (L)  -8 4 -12 -- 3.5 
Orbitofrontal Cortex (R)  46 32 -12 47 3.5 
Anterior Medial PFC (R)  8 68 12 10 3.4 
Hypothalamus (L) * -8 -6 -18 -- 3.4 
Insula (L) -42 2 -12 48 3.1 
Ventrolateral PFC (L) -44 48 -18 47 3.1 
            
Increased activation when satiated (versus pre-meal state) 
 
      
 
    
Dorsolateral PFC (R)  46 46 16 46 4.8 
Anterior Lateral PFC (L) -44 56 0 46 4.3 
Parahippocampal G (L) -16 -30 -10 30 4.3 
Dorsolateral PFC (L)  -42 50 16 46 4.1 
Insula (R) 38 -6 14 48 4.0 
Parahippocampal G (R) 20 -18 -24 35 3.7 
Anterior Medial PFC 0 56 0 -- 3.4 
            
            
FWE cluster corrected (voxel p < 0.001; cluster > 24 contiguous voxels – p < 0.05). 
Prefrontal Cortex (PFC); Gyrus (G); Left side (L); Right side (R). 
  *Hypothalamus FWE cluster corrected (voxel p <0.0001; cluster > 15 contiguous voxels - p < 0.05). 
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Table 5.3. Local maxima of other brain areas showing main effect of condition (satiation versus pre-
meal state) averaged over stimuli and modality. 
Brain Region (Hemisphere) 
Montreal Neurological 
Institute (MNI) 
Coordinates 
Estimated 
Brodmann 
Area 
  
Z 
Score 
X Y Z   
            
Reduced activation when satiated (versus pre-meal state) 
 
  
    
Frontal G (R)  16 18 62 8 4.5 
Temporal Pole (L) -36 8 -22 38 3.3 
            
Increased activation when satiated (versus pre-meal state) 
 
  
          
Superior Parietal Cortex (R) 30 -44 68 1 5.6 
Temporal G  (R) 48 -50 -12 20 5.5 
Occipital Cortex (R) 50 -74 -2 19 5.5 
Occipital Cortex (L) -40 -80 -8 19 5.4 
Postcentral G  (L) -66 -14 22 43 5.2 
Superior Parietal Cortex (L) -38 -42 54 40 5.2 
Heschl's G  (R) 52 -22 8 48 5.0 
Supramarginal G  (L) -66 -28 32 2 4.9 
Lingual G  (R) 4 -66 0 18 4.7 
Precuneous Cortex (L) -2 -58 32 -- 4.6 
Occipital Fusiform G  (L) -24 -66 -12 19 4.4 
Temporal G  (L) -50 -48 -24 20 4.4 
Precuneous Cortex (R) 24 -52 6 19 4.3 
Supramarginal G  (R) 62 -32 44 40 4.1 
Lingual G  (L) -10 -50 0 18 4.1 
Postcentral G  (R) 52 -16 40 3 4.1 
Precentral G (R) 32 -6 70 6 4.1 
Thalamus (R) 14 -24 12 -- 4.0 
Occipital Fusiform G  (R) 40 -66 -12 19 3.9 
Frontal G  (R) 36 32 44 9 3.8 
Precentral G (L) -42 -14 62 4 3.5 
            
 
FWE cluster corrected (voxel p < 0.001; cluster > 24 contiguous voxels – p < 0.05). Gyrus (G); Left side (L); 
Right side (R). 
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Figure 5.5 Brain regions in blue showed a reduced BOLD signal when satiated compared to pre-meal. Insula; 
Ventromedial prefrontal cortex (VMPFC); Nucleus Accumbens (N.ACC); Hypothalamus (HYPO); 
Orbitofrontal Cortex (OFC). 
 
 
 
Figure 5.6 Percentage change in areas showing a reduced BOLD signal when satiated (compared to pre-meal). 
Insula (INS); Ventromedial prefrontal cortex (VMPFC); Nucleus Accumbens (NACC); Hypothalamus (HYPO); 
Orbitofrontal Cortex (OFC). 
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Figure 5.7 Areas in yellow (Dorsolateral Prefrontal Cortex (DLPFC) and Insula) showed enhanced stimulus-
evoked BOLD activity when satiated (versus pre-meal).  
 
 
 
Figure 5.8 Percentage signal change in left and right dorsolateral prefrontal cortex (DLPFC) and insula when 
satiated. 
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Figure 5.9 Negative correlation between percentage change values in BOLD signal in left dorsolateral 
prefrontal cortex (DLPFC) and ventromedial prefrontal cortex (vmPFC) while satiated.   
 
5.4. Discussion 
A novel fMRI paradigm was used to assess the effects of satiation on brain responses to 
aversive and rewarding food-related tastes and pictures. Satiation of healthy volunteers 
attenuated stimulus-evoked BOLD activity across key reward areas and enhanced stimulus-
evoked BOLD activity in areas associated with inhibitory control. Activity in the vmPFC was 
negatively correlated with activity in the dlPFC. Importantly, this pattern of results was 
observed during normal eating patterns and therefore the profile of activity is likely to reflect 
brain patterns associated with natural satiation; this can be used as a benchmark in the 
experimental medicine model for future fMRI studies examining the neural profiles of 
satiation enhancing drugs. 
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Multiple reward areas were attenuated by satiation and the model appears to be sensitive to 
changes across the striatal-cortical pathway. Attenuation of the nucleus accumbens, 
ventromedial prefrontal cortex and orbitofrontal cortex is consistent with satiety induced 
decreases in reward (Small et al. 2001; Fletcher et al.2010; Kringelbach et al. 2003), 
reinforcing the involvement of these reward areas in energy balance. This is a significant 
finding, as previous paradigms typically report more limited profiles of attenuation: e.g. 
orbitofrontal cortex (Kringelbach et al. 2003) or ventral striatum (Fletcher et al.2010). 
Increased stimulus-evoked BOLD activation in these areas has been reported in obese versus 
healthy individuals (Stoeckel et al. 2008; DelParigi et al. 2005). Therefore, the results of the 
present study reinforce the suggestion that reduced appetitive reward value is likely to be part 
of usual satiation.  
 
We also observed that satiation increased stimulus-evoked dlPFC BOLD activity after a 
meal, and this was negatively correlated with vmPFC activity. Although we did not measure 
inhibitory control directly in this study, previous work has reported that increased dlPFC 
activity reflects increased cognitive/inhibitory control (MacDonald et al. 2000). Hare and 
colleagues (Hare et al. 2011) have reported that the dlPFC modulates vmPFC reward 
responses to food, suggesting that enhancement of inhibitory control is a mechanism of 
limiting further food intake by blunting reward. Interestingly, it has been reported that the 
strength of the connection between the dlPFC and vmPFC is associated with dietary success 
in obesity (Weygandt et al. 2013). Furthermore, such a mechanism may underlie overeating 
in obesity. Obesity is associated with reduced behavioural inhibition and reduced neural 
activity in inhibitory control areas when satiated (Le et al. 2006; Appelhans et al. 2011; 
Martens et al. 2013). This suggests that restoration of the dlPFC response to food stimuli may 
be a potential target for obesity treatment. Indeed non-invasive stimulation of this region 
reduces craving for highly palatable foods (Jansen et al. 2013). Recent studies with the 
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selective noradrenaline reuptake inhibitor atomoxetine have reported enhanced dlPFC 
activation in children with attention deficit hyperactivity disorder (ADHD) (Cubillo et al. 
2013) and weight-loss in obese individuals (Gadde et al. 2006). The behavioural mechanism 
of this effect has not been delineated but it could be concluded, based on the results of the 
present study, that the drug may enhance satiation by increasing dlPFC control over the 
reward response in the vmPFC. Further studies with atomoxetine in the current model are 
required to test this hypothesis. 
 
For the first time, a satiation-induced decrease in hypothalamic activity was identified in 
response to food taste and food pictures that was not confounded by sensory specific satiety 
or overeating (Smeets et al. 2006; Cornier et al. 2009). It has been reported previously that 
administration of the anorectic drug sibutramine reduces hypothalamic responses to pictures 
of high calorie foods (Fletcher et al. 2010). However, these authors did not observe a 
reduction in hypothalamic activity after participants consumed a standard breakfast following 
an overnight fast. It is possible that the effects of satiety on hypothalamic responding are 
dependent upon the baseline level of hunger and whether participants are allowed to eat to 
fullness.  
 
Insula activity showed a more complex pattern of response, with increased superior activity 
and decreased inferior activity, when satiated. Increased activation of the superior insula may 
represent an aversion to further food ingestion associated with satiation (Krolak-Salmon et al. 
2003; Wicker et al. 2003) while decreased inferior insula activity may relate to bodily 
sensations of fullness (Wang et al. 2008).  
Participants showed a decrease in wanting and pleasantness of the rewarding chocolate 
stimuli but not the aversive strawberry stimuli when satiated. This finding is consistent with 
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the idea that eating-related declines in rated food pleasantness are more pronounced for 
hedonically positive than aversive stimuli (Scherr et al. 1982). The hedonic valence of 
aversive tastes may be more resistant to change because avoidance of tastes such as sour and 
bitter, which normally signal the presence of toxins in food, has adaptive value (Capaldi et al. 
1997). Although this interaction was not observed for the BOLD signal, there are several 
reasons why this might be the case. For instance, Berridge (1996) argues that subjective 
ratings of reward can be distorted by conscious awareness of stimuli (i.e. cognitive 
processes). Hence, it is possible that the subjective ratings are not a true reflection of 
underlying brain activity related to hedonic responses. Alternatively, it might be that the brain 
regions in which satiation interacts with stimulus type (chocolate versus strawberry) are 
difficult to image. For instance, the brainstem in decerebrate rats is responsive to aversive and 
rewarding stimuli (Grill et al. 2002), but is very difficult to image accurately in humans 
(Brooks et al. 2013b).  
 
Intensity ratings were also recorded, and the lack of significant reductions when satiated 
supports evidence that the intensity of the stimulus, and potentially the neural circuitry 
underlying it, are dissociable from rated pleasantness and wanting (Small et al. 2003).  
 
In conclusion, the effect of natural satiation on brain responses to food stimuli has been 
profiled for the first time using a novel fMRI paradigm. Satiation was associated with 
attenuated stimulus-evoked BOLD activity in reward-related areas and enhanced BOLD 
activity in an area associated with inhibitory control. The model provides behavioural and 
neuronal markers of satiety that may be compared with the effects of putative satiety 
enhancing agents to facilitate the development of novel treatments for appetite control and 
obesity.  
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CHAPTER 6: Study 6: Effect of acute administration of meta-Chlorophenylpiperazine 
(mCPP) on appetite and fMRI BOLD signals in healthy women. 
 
6.1. Introduction 
The results from Study 1 demonstrated that it was possible to detect the effect of a single 
dose of mCPP on eating behaviour using a UEM. The results from Study 5 showed that it was 
possible to detect the effects of satiation on brain activity, using fMRI. The aim of the present 
study was to extend this work by examining the effects of a single dose of mCPP on brain 
responses to appetitive stimuli using fMRI, and to extend the experimental medicine model to 
include the capacity to detect selective neural and behavioural responses to foods which vary 
in energy density and palatability. 
 
fMRI provides a useful method for exploring the neural basis of food preferences, and their 
modulation by various appetitive states. Thus, high calorie compared to low calorie food 
images induce greater activity in reward and appetitive brain regions, including: frontal 
cortex; insula; striatum; midbrain; hypothalamus; amygdala; hippocampus; and anterior 
cingulate cortex (Frank et al. 2010; Fletcher et al. 2010; Haase et al. 2009; van der Laan et al. 
2011). Further, this increased response to high calorie foods is modulated by appetitive state, 
with fasting/hunger selectively increasing activation to high calorie foods compared to low 
calorie foods in ventral striatum, amygdala, insula, orbitofrontal cortex, caudate, putamen and 
cingulate cortex (Goldstone 2009; Siep 2009).  
 
It is possible that drugs affecting appetitive state also have a selective effect on brain 
responses to food images that is dependent on the caloric value of the food. This idea is 
supported by recent work showing that administration of the satiety enhancing anti-obesity 
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drug sibutramine selectively attenuated activity in response to high but not low calorie foods 
in the hypothalamus and amygdala (Fletcher et al. 2010). Cambridge and colleagues (2013) 
also reported that the anti-obesity/binge eating novel µ-opioid receptor antagonist 
GSK1521498 decreased activation in the pallidum/putamen to high calorie, but not low 
calorie, food images. Other anti-obesity drugs may also have selective effects on high versus 
low calorie foods; such an effect might be helpful in reducing the consumption of highly 
palatable energy dense foods.  
 
Brain responses to food images are associated with food intake (Fletcher et al. 2010), which 
suggests that selective neural effects detected by brain imaging might be reflected in eating 
behaviour. This is consistent with the recent finding that sibutramine selectively reduced the 
binge eating of lard by rats (Popik et al. 2011). Using a UEM it is possible to detect drug 
induced effects on eating behaviour in both obese and lean individuals (Halford et al. 2010; 
Study 1). Therefore, by adapting this method to include a food which is energy dense and 
highly palatable and a staple food which is less energy dense and palatable, it may be 
possible to investigate selective drug effects on eating microstructure for these foods.  
 
Recent work examining the effect of mCPP on the BOLD response in humans has reported 
that intravenous administration of mCPP increases activity in the: choroid plexus, substantia 
nigra, hypothalamus, caudate, pallidum, amygdala, pyriform cortex and anterior cingulate 
gyrus (Anderson et al. 2002b; McKie et al. 2011). 5-HT2C receptors have been identified in 
the human brain in the choroid plexus, substantia nigra, hypothalamus, basal ganglia, 
amygdala, hippocampus and prefrontal cortex (Marazziti et al. 1999; Pazos, 1987). Hence, 
there is clear overlap between the brain distribution of 5-HT2C receptors, and the effect of 
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mCPP on the fMRI BOLD signal. Thus mCPP is an appropriate compound to probe the 
effects of 5-HT2C receptor stimulation on neural activity, using fMRI. 
 
The present study examined the effects of a single dose of mCPP versus placebo on BOLD 
fMRI responses to images of low and high calorie foods in healthy women volunteers. The 
effects of mCPP on ad-libitum consumption of a tomato based pasta meal, followed by ad-
libitum intake of a chocolate chip cookie snack (high energy density/palatability) were also 
examined. It was hypothesised that mCPP would reduce the BOLD response to food images 
in key reward and appetitive areas (frontal cortex, insula, hypothalamus, amygdala, 
hippocampus, nucleus accumbens, caudate, putamen, cingulate cortex and brainstem), and 
that these effects would be more pronounced or selective for high calorie foods, than low 
calorie foods. It was also hypothesised that there would be a parallel effect on eating 
behaviour measured by the UEM, whereby mCPP would decrease eating behaviour measures 
for pasta and cookies, but have a greater or selective effect on cookie intake.  
 
In addition, behavioural responses to anti-obesity drugs often vary with some individuals 
responding and showing decreases in food intake while others show no effect (Barkeling et 
al. 2003). Therefore, as a secondary aim, the study aimed to differentiate drug responders 
from non-responders and to investigate differences in behavioural and neural responses to 
food stimuli that might account for any differential responses. 
 
6.2 Methods and Materials 
Participants 
24 healthy women volunteers (mean age 22.71 (SE: 1.19); mean BMI 21.79 (SE: 0.32); mean 
cognitive restraint score 5.71 (SE: 0.49) were recruited from the University of Birmingham. 
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Posters advertised the study as an “Appetite & fMRI study”, and participants were 
compensated with £100 upon completion. Psychology students were also able to complete the 
study for credits as part of their course requirement. Informed consent was obtained for all 
participants and ethical approval was provided by South Birmingham Research Ethics 
Committee (National Research Ethics Service). The study was conducted in accordance with 
the ethical standards laid down in the 1964 Declaration of Helsinki. Participants were 
screened to exclude the following: under 18 or over 65 years old; BMI under 18.5 or over 
24.9; English not first language as determined by the NART; taking psychotropic medication; 
past or current Axis 1 disorder as determined by the SCID; pregnant or breastfeeding; 
smoker; dyslexic; food allergies; diabetic; cognitive restraint score higher than 10 as 
measured by the TFEQ. Participants were also excluded if they had previously taken part in 
an mCPP study, were left-handed, or had any contraindications to fMRI scanning such as 
pacemakers assessed via an fMRI Screening Form (FSF). Women were asked to participate 
in test days that fell outside their premenstrual week.  
 
Design 
A repeated-measures, double-blind, placebo controlled design was used. There was one 
factor: drug condition was a within-subjects factor with two levels consisting of mCPP 30mg 
and placebo administration on separate test days. mCPP was supplied by the Guy’s and St 
Thomas’ NHS Foundation Trust Pharmacy Manufacturing Unit (GSTFT). The 30mg dose 
was selected on the basis of the results of Study 1. To maintain blinding, mCPP and placebo 
were prepared in identical capsules. Awareness of the UEM was investigated as a secondary 
aim in this study: the first 12 participants were not made aware of its presence (non-aware) 
while the second 12 participants were made explicitly aware that it was being used (aware). 
For the analysis of responders versus non-responders, individuals were identified as 
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responders if they showed more than a 10% decrease in food intake for the mCPP versus 
placebo condition. Non-responders were classified as those showing less than a 10% decrease 
in intake for mCPP versus placebo. 
 
Universal Eating Monitor (UEM) 
Food was served on a UEM (see Study 1 for details). 
Pasta Lunch: Dishes filled with 220g of pasta were placed on the placemat. Each time the 
participant ate 50g of the pasta, the SIPM software (version 2.0.13) interrupted the participant 
to complete computerised VAS ratings (hunger, fullness and pleasantness of the pasta). After 
consuming 150g, participants were interrupted and provided a fresh dish of 220g of pasta. 
Participants were asked to eat in this manner until they felt ‘comfortably full’. The lunch 
consisted of pasta shells in a tomato and herb sauce (Sainsbury’s UK), served at 55-60oC 
(207kcal per 220g serving).  
 
Cookie Snack: Bowls containing 80g of cookie pieces were set on the placemat. Each time 
the participant ate 10g of cookie pieces, the SIPM software interrupted the participant to 
complete VAS ratings as described above for pasta. After consuming 60g, participants were 
interrupted and provided with a fresh bowl containing 80g of cookie pieces. Participants were 
asked to eat until they felt ‘comfortably full’. The cookies were Maryland Chocolate Chip 
Cookies, with each cookie being broken into 6-7 pieces (390kcal per 80g serving). 
 
Biological samples 
Salivary cortisol: Saliva samples were collected and analysed as described for Study 1.    
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Scanner Task and Stimuli  
The scanner task was originally created for use with diabetic patients and consisted of 
pictures of foods that varied in fat and sugar content (relevant to a diabetic population). The 
task was run with E-Prime (build 2.0.8.90) in three separate blocks, with each block taking 
approximately 8 minutes 30 seconds. Each block consisted of 40 food pictures (10 Low Fat / 
Low Sugar – LL, 10 High Fat / Low Sugar – HL, 10 Low Fat / High Sugar – LH, 10 High Fat 
/ High Sugar – HH), 40 non-food control pictures and 5 smiley face images (see Figure 6.1). 
Presentation order of food picture types (LH, HF, HS and LL) was fixed, however, the 
pictures within these sub-groups were presented in random order. For instance, an LH 
presentation would randomly select one of the 10 available LH images available, without 
repeating the picture. Each of the three blocks used variations of the same food stimuli (e.g. a 
different picture of an apple was shown in each block). Stimuli (food + non-food images) 
were displayed for 2500ms, fixation points were displayed for 3500ms, and smiley face 
images were displayed for 1500ms. Participants were asked to imagine eating the foods they 
saw during the task and to press a button on a button box whenever they saw a smiley face to 
ensure they were maintaining attention. The HH images used high calorie foods 
(approximately 400kcal per 100g of food shown) and the LL images used low calorie foods 
(approximately 100kcal per 100g of food shown). 
 
 
Figure 6.1 Scanner task stimuli consisting of fixation cross, example food images from each food category and 
smiley face target. 
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Food Image Ratings 
The food ratings task also ran on E-Prime (build 2.0.8.90), and displayed the 120 food images 
that were shown in the scanner task (30 HH, 30LL, 30 LH and 30 LL). For each image, 
participants were asked “How appetising does this food look to you?” and “how much do you 
want to eat this food now?” Participants were instructed to respond as quickly as possible, 
selecting a number between 0-7 on the keyboard (0 = not at all; 7 = very much).  
 
Procedure 
The experimental procedure is summarised in Figure 6.2. 
 
Figure 6.2 Flow diagram for screening process followed by an overview of key events and timings for test days 
in hours (hrs). 
 
Screening and Test Days:  
Screening Days: Participants were sent an email containing: an information sheet detailing 
the study; key exclusion criteria; and a copy of the TFEQ to complete. Those who met the 
study criteria were invited to a screening day at the School of Psychology at which they 
completed a consent form and various screening measures: FSF; Medical Screening Sheet; 
SCID; NART; EPQ; and a Breakfast and Lunch Questionnaire. Their height and weight was 
also taken to calculate BMI. Participants returned after a week for two trial runs, both a week 
apart, with the UEM setup at the WTCRF. Those in the aware group were explicitly told 
about and shown the UEM balance during each trial, while those in the non-aware condition 
were not. On both occasions participants ate an ad-libitum lunch of pasta followed 20 
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minutes later by an ad-libitum snack of cookies (as described above). All participants 
completed VAS ratings before and after access to each food. These contained mood and 
appetite items: ‘alertness’; ‘disgust’; ‘drowsiness’; ‘light-headed’; ‘anxiety’, ‘happiness’; 
‘nausea’; ‘sadness’; ‘withdrawn’; ‘faint’; ‘hungry’; ‘full’; ‘desire to eat’; and ‘thirst’.  
 
Test Days: Participants arrived at the WTCRF at 9.00am with prior instructions to consume 
their normal breakfast before arriving. On their first test day, but not their second, they 
underwent a blood pressure test, electrocardiogram and a physical check with a physician. If 
a participant passed these checks, they were then breathalysed and completed a pregnancy 
test each test day, before completing the first batch of questionnaires: Breakfast Form; BDI; 
BFS; PANAS; STAI; PFS; BIS; and FSF.  
 
Participants also completed baseline VAS. Participants were then escorted to the Birmingham 
University Imaging Centre (BUIC) for their first scan at 10.00am, after which they completed 
a set of VAS, provided a saliva sample (all samples were taken using a salivette), and took 
the test dose (mCPP or placebo) at 11.00am. At 30 minutes post-dosing they completed 
another set of VAS. After an additional 30 minutes, participants provided a saliva sample and 
completed VAS immediately prior to their second scan, which occurred at approximately 
12.00pm. After completing the scan, participants completed a set of VAS and provided 
another saliva sample, before being escorted back to the WTCRF.  
 
Immediately prior to lunch at 1.30pm, participants completed VAS and were then given ad-
libitum access to a pasta lunch via the UEM; participants in the aware condition were 
reminded of the presence of the UEM before eating. After finishing lunch, participants 
completed VAS. This was followed by a 20 minute break after which a further set of VAS 
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was completed directly before participants were given ad-libitum access to the cookie snack. 
Immediately after finishing, participants filled out VAS. At 3.00pm (approximately 30-
40minutes later) participants completed a second batch of questionnaires: VAS; BDI; BFS; 
PANAS; STAI; PFS; and BIS. Participants then provided a final saliva sample, rated the 
scanner task food images, and had a single blood sample taken. Participants returned for a 
second visit, and the procedure described above was repeated with the only difference being 
dosing with placebo or drug. At the end of their second session, participants in the non-aware 
group were questioned to determine whether they became aware of the UEM during the 
study, were then fully debriefed and given the opportunity to ask questions. They were 
thanked for their time, and reimbursed for participation. 
 
fMRI Scan  
An event-related design was used, utilising the task stimuli described above in pseudo 
random sequence. A 3.0 T Achieva (Philips) whole body scanner was used at BUIC. 
T2*weighted echo planar imaging (EPI) slices were acquired every 2.5 seconds (TR = 2.5). 
33 axial slices (in-plane resolution of 2.5 x 2.5 x 3 mm - no gap) were acquired, with a matrix 
size of 96 x 96 and field of view of 240 x 240 mm. 200 volumes were acquired for each block 
of the task with two dummy scans. A whole brain T2*-weighted EPI volume (resting state) 
was also acquired, along with an anatomic T1 volume: sagittal plane slice thickness of 1 mm 
and in-plane resolution of 1.0 x 1.0 x 1.0 mm. 
 
fMRI Analysis 
Analysis 1: Effect of placebo versus mCPP on BOLD signals to Low and High Calorie Foods 
FSL was used to pre-process and analyse the data as described for Study 5. MELODIC 
filtered data were entered into a first level analysis, to produce contrast of parameter estimate 
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(COPE) images for high calorie (high sugar + high fat = HH) and low calorie (low sugar + 
low fat = LL) food images. These COPES were then averaged across each of the scanning 
blocks for each participant (i.e. averaging across blocks 1-3 for each scan) in a second level 
analysis. A subsequent analysis was run on these outputs for each participant to subtract 
baseline scans from post-dosing scans (i.e. post-placebo minus pre-placebo and post-mCPP 
minus pre-mCPP). Following this procedure, the outputs were entered into the final mixed 
effects (FLAME 1+2) group analysis, producing contrasts between placebo and mCPP 
conditions for BOLD signal activity in response to the low calorie food images and the high 
calorie food images separately. Group Z statistic images were generated using two level 
voxel and cluster thresholding to control for error rates (z threshold > 2.3; P threshold < 
0.05). To explore the main effect of condition, local maxima are reported. The same FWE 
correction from Chapter 5 was applied here, with a voxel-wise threshold of p < 0.001 (Z > 
3.1) only clusters with more than 24 contiguous voxels were significant with a FWE 
corrected p < 0.05. The same adjusted correction was also used for the hypothalamus: p < 
0.0005; Z>3.3) producing a smaller FWE cluster threshold (19 or more contiguous voxels; p 
< 0.05). Brain regions were anatomically identified using FSL’s integrated Harvard-Oxford 
Cortical and Subcortical Atlases. For regions not covered by these the Duvernoy Atlas 
(Duvernoy, 1999) was used. To display brain regions of interest, group Z statistic images 
were masked using a mask of the brain region (derived from cluster parameters) and then 
entered into MRIcro (Rorden & Brett, 2000) to visualise BOLD signal % change. This 
procedure was also used for the analyses below. 
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Analysis 2: Correlation between BOLD response to high calorie foods and amount of cookies 
consumed 
To examine whether differences in BOLD response to high calorie foods between the placebo 
and mCPP condition were associated with differences in amount of cookies consumed, 
correlational analyses were performed. Data were processed as above, up to the final mixed 
effects group analysis. At this point, each participant’s data were entered into individual 
analyses to produce contrasts for placebo versus mCPP activity for the high calorie food 
images. Consumption data (total amount of cookies eaten) were also used to produce 
corresponding difference scores between placebo and mCPP conditions for cookie 
consumption. The fMRI contrasts were then entered into a mixed effects (FLAME 1+2) 
higher level analysis with the amount of food consumed differences. Contrasts were produced 
to investigate positive and negative linear associations between the BOLD signal and these 
values. Group Z statistic images were generated using two level voxel and cluster 
thresholding to control for error rates (z threshold > 2.3; p threshold < 0.05). Local maxima 
that survived the FWE correction described in analysis 1 and were correlated with intake data 
were followed up with 3mm radius spherical ROIs. BOLD percentage signal change values 
were extracted and correlated with behavioural data using SPSS for visualisation.  
 
Analysis 3: Difference in Baseline BOLD response to High Calorie foods between 
Responders versus Non-responders  
Baseline scan data were pre-processed as described above in analysis 1. The same first and 
second level analyses as for analysis 1 were then applied to produce high calorie COPES and 
to average across scanning blocks 1-3 for each scan. These data were then entered into an 
analysis to subtract placebo day scans from test day scans (i.e. pre-mCPP minus pre-placebo). 
Following this analysis, the outputs were entered into a mixed effects model (FLAME 1+2), 
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to produce contrasts between non-responders and responders for BOLD signal activity in 
response to the high calorie food images. Group Z statistic images were generated using two 
level voxel and cluster thresholding to control for error rates (z threshold > 2.3; P threshold < 
0.05). To explore the main effect of group (responders versus non-responders), local maxima 
are reported. The FWE correction described for analysis 1 was applied.  
 
Data Analysis 
General: One participant was unable to complete both test days due to nausea during the first 
test day and so their data was removed from all analyses. Two participants were unable to 
complete both post-dosing scans also due to nausea and to light-headedness; therefore, 
complete imaging data is only available for 21 participants.  For statistical analyses, effects 
and interactions with condition were examined with analysis of variance (ANOVA). Effects 
of condition, or interactions with condition, were followed with planned comparisons; 
Bonferroni correction was used on all t-tests unless otherwise stated. Violations of sphericity 
were addressed using the Greenhouse-Geisser correction. 
UEM: Microstructural data were lost for 7 pasta sessions and 2 cookie sessions due to 
technical issues, such as participants leaning on the balance, thus analyses were conducted on 
pasta and cookie data for 17 and 21 data sets respectively. Microstructural data were analysed 
by quartile, however, as they concord with the overall analysis of UEM data, they are not 
presented here for conciseness. 
 
6.3 Results 
Salivary Cortisol 
Cortisol levels at baseline (pre-drug) and immediately prior to the test meal (120mins post 
dosing) were analysed with ANOVA, which showed no main effects of condition or time 
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(both p > 0.05), but a significant interaction between condition and time (F (1 22) = 8.85; p < 
0.01). T-tests revealed that there were no baseline differences between mCPP and placebo 
conditions (4.98 versus 5.59nmol/L; t (22) = -1.14, p > 0.05), however, immediately prior to 
food, cortisol was significantly higher in the mCPP than the placebo condition (6.62 versus 
2.77nmol/L; t (22) = -2.62, p < 0.05), confirming a response to mCPP. 
 
Subjective state questionnaires: 
Questionnaire scores were analysed by within-subjects ANOVAs using condition (placebo 
versus mCPP) and time (pre versus post dosing) as factors. For the STAI State there was a 
main effect of condition (F (1 22) = 5.89; p < 0.05), with elevated state anxiety in the mCPP 
(27.72) versus placebo (25.52) condition (see Table 6.1). There was no effect of time (F (1 
22) = 1.23; p > 0.05) and no significant interaction between condition and time for STAI 
State (F (1 22) = 3.49; p > 0.05). For the BFS there was no effect of condition (F (1 22) = 
0.58; p > 0.05), but a main effect of time (F (1 22) = 12.10; p < 0.01) and an interaction 
between condition and time (F (1 22) = 5.61; p < 0.05). For the interaction, t-tests revealed 
no significant change from pre-dosing for placebo (11.65 versus 13.61; t (22) = -1.71, p > 
0.05), but a significant increase in BFS scores from pre-dosing for mCPP (10.52 versus 
18.43; t (22) = -3.26, p < 0.01), indicating lower mood and energy after dosing. For the 
following questionnaires and subscales, there were no effects of time or condition, or 
interactions between time and condition: BDI; BIS; PFS; PANAS POS; PANAS NEG; and 
STAI TRAIT (all p > 0.05). 
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Table 6.1 Questionnaire Scores for mCPP and Placebo conditions, split by time 
(standard error of the mean) 
  Placebo mCPP 
Measure Pre-drug Post-drug Pre-drug Post-drug 
BDI 1.38 (0.58) 1.30 (0.54) 2.38 (1.03) 1.74 (0.50) 
BIS-11 58.48 (1.71) 58.35 (1.87) 58.75 (1.95) 58.04 (1.92) 
BFS 11.65 (3.10) 13.61 (3.02) 11.17 (2.55) 18.43 (3.65)** 
PFS 33.09 (2.31) 32.48 (2.36) 33.79 (2.42) 32.52 (2.36) 
PANAS-Positive 30.96 (1.85) 31.00 (1.68) 30.79 (1.59) 28.57 (1.75) 
PANAS-Negative 10.87 (0.25) 11.09 (0.37) 11.63 (0.76) 11.57 (0.44) 
STAI-State 25.78 (1.11) 25.26 (1.09) 26.96 (1.05) 28.65 (1.29) 
STAI-Trait 29.65 (1.73) 28.35 (1.46) 31.42 (1.62) 29.87 (1.30) 
          
          
BDI - Beck Depression Inventory; BIS 11 - Barratt Impulsiveness Scale; BFS- 
Befindlichskeit scale of mood and energy; PFS - Power of Food Scale; PANAS - 
Positive and Negative Affective Schedule; STAI -  State Trait Anxiety Inventory.               
** p < 0.01 (difference versus pre-drug) 
 
VAS 
Pre-dosing VAS scores were averaged across each item, for a pre-dose baseline. These were 
then analysed using paired t-tests by condition, which showed no significant differences at 
baseline (all p > 0.05). Post-dosing VAS items were then analysed by condition and time 
(post-dosing in minutes: t30, t60, t120, t150, t170, t190, t200, t240). For the following VAS 
items there were main effects of condition, with elevated scores in the mCPP condition 
compared to placebo: faint = 8.83mm versus 3.20mm (F (1 18) = 5.08; p < 0.05); light-
headed = 11.22mm versus 3.32mm (F (1 18) = 13.79; p < 0.01); nausea = 8.17mm versus 
2.87mm (F (1 18) = 15.68; p < 0.01). There were no main effects of time or interactions 
between condition and time for these items (all p > 0.05). For hunger, fullness, desire to eat, 
alertness, thirst, drowsiness and happiness, there was a main effect of time (all p < 0.05), but 
no effect of condition, or interactions (all p > 0.05). For anxiety, disgust, sadness and 
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withdrawn, there were no main effects of condition or time, or significant interactions (all p > 
0.05).  
To account for the different time durations between VAS questionnaires (which varied more 
than in Study 1), area under the curve scores (trapezoid method) were calculated for all VAS 
items. Uncorrected paired t-tests were used. A Bonferroni correction operates on the 
assumption that tests are statistically independent (these VAS items are highly 
intercorrelated) and would also have been prohibitively conservative in this instance. T-tests 
showed increased scores for faint, light-headed, and nausea (all p < 0.01), along with 
decreased hunger and desire to eat (both p < 0.05) in the mCPP condition compared to 
placebo (Table 6.2). All other items were not significantly different (all p > 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
  *p < 0.05; **p < 0.01 
 
 
Table 6.2 Area under the curve scores for VAS items, split by 
mCPP and Placebo conditions (standard error of the mean) 
VAS Item Placebo mCPP 
Alertness 14520.22 (892.65) 13252.39 (912.46) 
Disgust 601.52 (74.80) 912.17 (198.66) 
Drowsiness 3346.52 (672.08) 3450.87 (606.22) 
Nausea 606.09 (90.63) 2158.04 (317.22)** 
Faint 706.30 (105.49) 2254.13 (582.79)** 
Lightheaded 751.09 (121.85) 2938.26 (514.16)** 
Anxiety 603.04 (82.50) 717.61 (141.54) 
Happiness 15632.17 (447.76) 14662.39 (712.02) 
Sadness 740.22 (128.02) 731.74 (128.88) 
Withdrawn 787.83 (124.36) 787.17 (170.62) 
Hunger 8172.39 (502.31) 6596.30 (718.66)* 
Desire to Eat 7830.65 (599.53) 6168.04 (726.58)* 
Fullness 10401.74 (650.88) 10176.96 (829.69) 
Thirst 4685.46 (582.40) 4594.13 (635.99) 
      
155 
 
Universal Eating Monitor  
For all measures of eating behaviour (e.g. amount eaten), each measure was computed for the 
entire eating episode (e.g. total amount of pasta eaten) and analysed by condition (placebo vs. 
mCPP 30mg) and food type (pasta vs. cookies) to explore potential interactions. T-tests were 
then performed for each measure (separately for each food) to explore a priori hypotheses of 
differential effects of condition on these foods. 
 
Interactions  
There was no significant two-way interaction between condition and food type for total 
amount eaten, time spent eating or eating rate (all p > 0.05). However, there was a significant 
interaction for pauses between mouthfuls (F (1 13) = 10.49; p < 0.01). Individual analyses of 
each measure separated by food type are listed below. 
 
Pasta  
Rate of pasta consumption during the meal was significantly reduced in the mCPP condition 
compared to placebo (t (16) = 2.27, p < 0.05, see Table 6.3), and pauses between mouthfuls 
was significantly increased by mCPP (t (16) = -2.32, p < 0.05, see Table 6.3). There was no 
main effect of condition for total amount eaten (t (16) = 1.43, p > 0.05) or for time spent 
eating (t (16) = -1.43, p > 0.05).  
 
Cookies 
Participants ate less cookies in the mCPP condition than in the placebo condition (t (20) = 
3.09, p < 0.01; see Table 6.3), ate at a slower rate in the mCPP condition (t (18) = 4.12, p < 
0.01, see Table 6.3), and took longer pauses between mouthfuls in the mCPP condition than 
in the placebo condition (t (18) = -3.82, p < 0.01, see Table 6.3). No significant differences 
were observed between conditions for total time spent eating (t (20) = -0.98, p > 0.05).  
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Table 6.3 UEM measures for Pasta and Cookies, split by placebo and mCPP conditions (standard error of 
the mean) 
  Pasta Cookies 
UEM Measure Placebo mCPP 30mg Placebo mCPP 30mg 
Amount eaten (grams) 441.0 (45.0) 389.8 (51.1) 38.1 (2.9) 26.6 (3.8) ** 
Time spent eating (seconds) 402.2 (33.3) 528.2 (70.4) 235.1 (32.6) 269.9 (35.9) 
Eating rate (g/min) 64.2 (5.7) 47.7 (6.6) * 11.0 (1.4) 6.6 (1.2) *** 
Pause between mouthfuls (seconds) 10.4 (0.8) 15.5 (2.5) * 12.2 (1.7) 25.5 (3.8) ** 
          
          
*p < 0.05; **p < 0.01;*** p < 0.001         
 
Awareness 
To investigate whether the awareness manipulation had any effect on eating measures the 
same analyses above were repeated with the addition of the factor ‘awareness’ (aware versus 
non-aware). There were no significant effects of awareness, nor any interactions with 
condition for any measures (all p > 0.05 – see Table 6.4 for means). 
 
Table 6.4 UEM measures for Pasta and Cookies, split by condition and awareness (standard error of the 
mean) 
  Placebo mCPP 30mg 
UEM Measure Non-aware Aware Non-aware Aware 
Pasta         
Amount eaten (grams) 490.2 (70.7) 400.7 (57.9) 434.8 (65.4) 349.3 (78.2) 
Time spent eating (seconds) 382.9 (43.8) 418.0 (50.2) 467.4 (74.5) 582.9 (117.1) 
Eating rate (g/min) 73.8 (8.9) 56.4 (6.9) 56.8 (10.0) 39.4 (8.5) 
Pause between mouthfuls (seconds) 9.4 (1.1) 11.1 (1.2) 12.1 (1.6) 18.5 (4.4) 
          
Cookies         
Amount eaten (grams) 38.5 (4.4) 37.7 (4.1) 29.7 (5.8) 23.2 (5.0) 
Time spent eating (seconds) 221.1 (51.2) 247.8 (43.3) 299.6 (50.4) 237.5 (51.7) 
Eating rate (g/min) 13.0 (2.7) 9.1 (1.1) 6.9 (2.0) 6.2 (1.3) 
Pause between mouthfuls (seconds) 12.6 (3.4) 11.8 (1.5) 26.7 (4.6) 23.9 (6.8) 
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Within-Meal VAS Pleasantness Ratings 
Within-meal pleasantness ratings for the pasta and cookies were used to calculate mean 
scores for each eating episode (lunch and snack). Paired t-tests were used to analyse the data 
by condition. For pasta, there was no significant effect of condition (t (16) = 1.99, p > 0.05). 
However, for cookies there was an effect of condition (t (19) = 2.46, p < 0.05), whereby those 
in the mCPP condition rated the cookies as less pleasant than those in the placebo condition 
(78.36 versus 84.84mm, see Figure 6.3).  
 
 
Figure 6.3 Pleasantness ratings for cookie session, split by condition. Pleasantness ratings significantly decrease 
in whilst consuming cookies, for those in the mCPP condition, compared to placebo. * p < 0.05 
 
 
Correlations between subjective ratings and intake 
To investigate the relationship between food intake and subjective ratings (nausea, hunger, 
and rated pleasantness of the food), correlations were performed on the measures, separately 
for pasta and cookies, during the mCPP condition. Hunger and nausea ratings were taken 
directly before the food that was eaten, and pleasantness ratings were used after participants 
had consumed a first mouthful of the test food. For pasta intake, hunger, but not nausea or 
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pleasantness, was positively correlated with food intake (r = -0.52, n = 19, p < 0.05). For 
cookie intake, neither nausea nor hunger significantly correlated with amount eaten (both p > 
0.05), however, there was a trend for a weak positive correlation with pleasantness (r = -0.17, 
n = 17, p = 0.07).  In addition, pasta intake did not significantly correlate with cookie intake 
(r = 0.03, n = 19, p > 0.05). 
 
fMRI 
Effect of placebo versus mCPP on BOLD signals to Low and High Calorie Foods 
The higher level analysis revealed a main effect of condition for activity to both high and low 
calorie foods pictures, in several key appetitive and reward regions (local maxima are 
displayed in Table 6.5; local maxima for other regions are displayed in Table 6.6 for 
reference). mCPP attenuated activity to the sight of high calorie food images in the insula 
(bilaterally), hippocampus, anterior cingulate, and dorsolateral prefrontal cortex (dlPFC) 
(Figure 6.4). For the low calorie food images, mCPP bilaterally attenuated activity in the 
orbitofrontal cortex (OFC) only (Figure 6.5). Dosing with mCPP increased activity to high 
calorie food images bilaterally in the ventromedial prefrontal cortex (vmPFC) and in the 
ventrolateral prefrontal cortex (vlPFC) (Figure 6.7), while for low calorie images, mCPP 
increased activity in the amygdala and midbrain (Figure 6.8). 
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Table 6.5 Local maxima of key appetitive and reward areas showing main effect of condition 
(placebo versus mCPP), split by activity to high and low calorie food images 
Brain Region (Hemisphere) 
Montreal Neurological 
Institute (MNI) Coordinates 
Estimated 
Brodmann 
Area 
Z-Score 
X Y Z 
            
Reduced activation after mCPP (compared to placebo)       
            
High Calorie Food Images           
Insula (L) -42 8 -6 48 3.5 
Hippocampus (R) 30 -10 -22 20 3.4 
Anterior Cingulate Cortex (R)  2 24 28 24 3.3 
Dorsolateral Prefrontal Cortex (R)   32 38 26 46 3.3 
Insula (R)   42 10 -10 48 3.1 
            
Low Calorie Food Images           
Orbitofrontal Cortex (R)    22 24 -20 11 3.3 
Orbitofrontal Cortex (L) -16 26 -18 11 3.2 
            
            
Increased activation after mCPP (compared to placebo)     
            
High Calorie           
Ventromedial Prefrontal Cortex (R)     20 50 -24 11 3.3 
Ventrolateral Prefrontal Cortex (L) -44 46 -18 47 3.1 
            
Low Calorie           
Midbrain (R)    8 -12 -16 35 3.4 
Amygdala (L) -22 -6 -16 34 3.3 
            
            
FWE cluster corrected (voxel p < 0.001; cluster > 24 contiguous voxels – p < 0.05). Left side (L); 
Right side (R). 
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Table 6.6 Local maxima of other brain areas showing main effect of condition (placebo versus 
mCPP), split by activity to high and low calorie food images 
Brain Region (Hemisphere) 
Montreal Neurological 
Institute (MNI) Coordinates 
Estimated 
Brodmann 
Area 
Z-Score 
X Y Z 
            
Reduced activation after mCPP (compared to placebo)       
            
High Calorie Food Images           
Thalamus (R)    16 -26 14 -- 4.0 
Lateral Occipital Cortex (L) -40 -86 -10 19 4.0 
Occipital Fusiform G (L)  -30 -70 -16 19 3.9 
Occipital Fusiform G (R)    26 -76 -16 18 3.9 
Temporal pole (L) -50 10 -8 48 3.8 
Temporal G (R)    56 -20 -8 21 3.8 
Lateral Occipital Cortex (R)    42 -88 -12 19 3.8 
Precentral G (L) -28 -8 52 6 3.7 
Occipital Pole (L)  -28 -90 22 19 3.7 
Supplementary Motor Cortex (L)  -6 -4 62 6 3.6 
Temporal Occipital Fusiform G (R)    34 -56 -18 37 3.6 
Planum polare (L) -48 -4 -2 48 3.4 
Central Opercular Cortex (R)    46 2 10 48 3.3 
Thalamus (L) -16 -24 16 -- 3.3 
Superior Parietal Lobule (L) -36 -54 62 7 3.2 
Planum Polare (R)     46 -6 -12 48 3.2 
            
Low Calorie Food Images           
Subcallosal Cortex 0 22 -16 11 3.4 
Thalamus (R)    20 -24 6 -- 3.3 
Lateral Occipital Cortex (L) -38 -64 56 7 3.3 
Supplementary Motor Cortex (L) -2 -8 60 6 3.2 
Frontal G (L) -24 0 68 6 3.2 
            
Increased activation after mCPP (compared to placebo)     
            
High Calorie           
Angular G (R)    48 -54 42 40 3.2 
Lateral Occipital Cortex (L) -54 -74 26 39 3.1 
            
Low Calorie           
Precuneous (L) -6 -48 56 5 3.8 
Precuneous (R)   6 -46 56 5 3.7 
Frontal G (R)   42 4 44 6 3.4 
Supramarginal G (R)    68 -38 38 40 3.3 
            
            
FWE cluster corrected (voxel p < 0.001; cluster > 24 contiguous voxels – p < 0.05). Gyrus (G); 
Left side (L); Right side (R). 
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Figure 6.4 Brain areas showing decreased BOLD signal to high calorie food images when dosed with mCPP 
compared to placebo (dlPFC = dorsolateral prefrontal cortex) 
 
 
 
Figure 6.5 Brain areas showing decreased BOLD signal to low calorie food images when dosed with mCPP 
compared to placebo (OFC = orbitofrontal cortex) 
 
 
 
Figure 6.6 Brain areas showing increased BOLD signal to high calorie food images when dosed with mCPP 
compared to placebo (vlPFC = ventrolateral prefrontal cortex; vmPFC = ventromedial prefrontal cortex) 
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Figure 6.7 Brain areas showing increased BOLD signal to low calorie food images when dosed with mCPP 
compared to placebo. 
 
Correlations between BOLD response to high calorie foods and amount of cookies consumed 
To further examine the relationship between the apparent preferential effect of mCPP on 
amount of cookies consumed, and BOLD signal activity to high calorie food images, 
difference scores between the placebo and mCPP condition for amount of cookies consumed 
and BOLD signals were correlated in a whole brain analysis using FSL. Analyses revealed 
significant positive correlations between amount of cookies eaten and BOLD signal to the 
sight of high calorie foods in the orbitofrontal cortex (20, 12, -28; Z = 3.1; r = 0.475, n-20, p 
< 0.05), and ventrolateral prefrontal cortex (34, 64 -8; Z = 3.4; r = 0.552, n = 20, p < 0.05) 
(see Figure 6.8). Although the local maxima for the hypothalamus did not survive the 
adjusted FWE voxel threshold of p < 0.0005 (p = 0.0013), a trend for a similar effect was 
noted (2, 4, -18; Z = 3.0; r = 0.510, n = 20, p < 0.05) (see Figure 6.8).  
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Figure 6.8 Correlations between difference scores for BOLD % Signal and the amount of cookies consumed, 
between placebo and mCPP conditions. Negative values represent drug induced decreases in BOLD signal and 
amount of cookies consumed, whereas positive values represent drug induced increases. mCPP attenuated 
BOLD signal is associated with significant decrease in cookie consumption in the (A) orbitofrontal cortex and 
(B) ventrolateral prefrontal cortex. A trend was also noted for (C) the hypothalamus. 
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Responders versus Non-responders Analysis 
mCPP had a significant effect on cookie but not pasta intake and therefore analyses of 
responders versus non-responders was conducted on cookie consumption data. Participants 
were classified as responders if they showed a > 10% decrease in food consumption after 
mCPP versus placebo, and non-responders if they showed a < 10% decrease in consumption 
after mCPP versus placebo. This analysis revealed 12 responders and 8 non-responders. 
 
Behavioural Data 
Mixed ANOVA with condition (placebo and mCPP) and response (responder and non-
responder) were used to examine cookie intake. There was a main effect of condition (F (1 
18) = 14.62; p < 0.01), a main effect of response (F (1 18) = 5.77; p < 0.05), and a significant 
interaction between condition and response (F (1 18) = 38.70; p < 0.001). Responders ate 
significantly less cookies after mCPP than placebo (13.9g versus 38.4g; p < 0.001), whereas 
non-responders ate significantly more cookies after mCPP than after placebo (41.9g versus 
36.1g; p < 0.05). 
   
To explore whether differences in rated hunger or food pleasantness might underlie the 
differential effect of mCPP on food intake, these measures were analysed with t-tests. Initial 
ratings for both measures (from the UEM computerised VAS) for the mCPP condition were 
compared between responders and non-responders. Hunger ratings prior to consuming 
cookies were not significantly different between responders and non-responders (21.6mm 
versus 21.1mm; p > 0.05). For the rated pleasantness, the non-responder group rated cookies 
as significantly more pleasant than the responder group (87.6mm versus 70.1mm; p < 0.05). 
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Difference in Baseline BOLD response to High Calorie foods between Responders and Non-
responders 
During baseline scans (pre-mCPP), cookie non-responders exhibited greater BOLD activity 
to the sight of the high calorie images than responders across a wide range of key 
reward/motivational areas, including: orbitofrontal cortex, putamen, posterior cingulate 
cortex, midbrain, amygdala, parahippocampal gyrus, pons and dorsomedial prefrontal cortex. 
Brain activity was lower in cookie non-responders (versus responders), only in the 
ventromedial prefrontal cortex (Table 6.7; Figure 6.9). Other areas showing differences in 
BOLD signal between responders and non-responders are included in Table 6.8 for reference.  
 
 
 
 
X Y Z
HIGH CALORIE IMAGES
Higher activation in Non-Responders vs. Responders
Pons (R) 6 -28 -26 -- 4.0
Midbrain (R) 8 -28 -22 35 3.6
Midbrain (L) -14 -20 -16 35 3.6
Posterior Cingulate Gyrus (R) 2 -20 36 23 3.2
Amygdala (L) -24 -10 -12 34 3.2
Putamen (L) -28 -4 4 -- 3.2
Orbitofrontal Cortex (L) -26 16 -22 38 3.1
Parahippocampal Gyrus (L) -20 -22 -24 30 3.1
Dorsomedial Prefrontal Cortex (R) 12 64 32 10 3.1
Lower activation in Non-Responders vs. Responders
Ventromedial Prefrontal Cortex  (R) 22 72 -6 11 3.5
Table 6.7 Local maxima of key appetitive & reward areas showing differences in BOLD signal between non-
responders vs. responders to the sight of high calorie food images.
Brain Region (Hemisphere)
Montreal Neurological 
Institute (MNI) Coordinates
Estimated 
Brodmann 
Area
Z-Score
FWE cluster corrected (voxel p < 0.001; cluster > 24 contiguous voxels – p < 0.05). 
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Figure 6.9 Differences in baseline BOLD responses to high calorie food pictures between cookie 
responders and non-responders. Orange highlights areas in which non-responders showed a greater 
BOLD signal compared to responders. Blue highlights the single area in which non-responders 
showed a lower BOLD signal compared to responders. OFC = Orbitofrontal Cortex; PHG = 
Parahippocampal Gyrus; dmPFC = dorsomedial Prefrontal Cortex; PCC = Posterior Cingulate Cortex; 
vmPFC = ventromedial Prefrontal Cortex 
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6.4 Discussion 
The 5-HT2C receptor agonist mCPP at a dose of 30mg decreased salivary cortisol measured 
120mins post dosing, confirming activation of 5-HT2C receptors. mCPP reduced ratings of 
hunger and desire to eat, confirming previously observed effects (see Study 1). However, 
there was no significant effect of mCPP on pasta intake, which is again consistent with the 
results of Study 1. In contrast, mCPP induced a significant decrease in cookie intake. The 
drug also decreased brain activity to the sight of high calorie foods, while exerting a more 
limited effect on responses to low calorie foods. Correlations between food consumption and 
BOLD signal showed significant positive associations between high calorie foods and cookie 
intake whereby the BOLD response to high calorie foods in the orbitofrontal cortex and 
ventrolateral prefrontal cortex significantly predicted cookie consumption. A further analysis 
to investigate the behavioural and neural differences between drug responders and non-
X Y Z
HIGH CALORIE IMAGES
Higher activation in Non-Responders vs. Responders
Temporal Pole (L) -62 6 -22 21 4.0
Temporal Pole (R) 38 26 -34 38 3.6
Thalamus (R) 8 -2 4 -- 3.6
Frontal Gyrus (R) 54 28 -6 45 3.2
Angular Gyrus (R) 60 -50 32 40 3.2
Temporal Occipital Fusiform Cortex (R) 28 -48 -20 37 3.2
Lower activation in Non-Responders vs. Responders
Superior Parietal Lobule (L) -44 -46 56 40 3.8
Frontal Gyrus (L) -30 20 54 8 3.5
Frontal Gyrus  (R) 50 30 12 45 3.2
Table 6.8 Local maxima of other areas showing differences in BOLD signal between non-responders vs. 
responders to the sight of high calorie food images.
Brain Region (Hemisphere)
Montreal Neurological 
Institute (MNI) Coordinates
Estimated 
Brodmann 
Area
Z-Score
FWE cluster corrected (voxel p < 0.001; cluster > 24 contiguous voxels – p < 0.05). 
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responders showed that non-responders showed greater baseline activation across key reward 
and motivation regions to the sight of high calorie foods than responders. In addition, non-
responders showed higher pleasantness ratings of cookies after mCPP than responders. 
 
mCPP attenuated BOLD activity to the sight of high calorie foods in the insula bilaterally. 
The insula is involved in the sensory processing of appetitive stimuli, and shows reduced 
activity when individuals report higher levels of fullness (Wang et al. 2008). Therefore, the 
reduced BOLD signal might represent a neural marker of mCPP induced enhancement of 
satiation. BOLD activity to the sight of high calorie foods was also reduced by mCPP in the 
anterior cingulate cortex, an area that has been reported to support goal directed behaviour 
(Holroyd and Yeung, 2012). Hence, this mCPP-induced effect may reflect reduced 
motivation to consume the cookies. mCPP unexpectedly decreased activity in the dorsolateral 
prefrontal cortex, which is implicated in a range of executive functions, including memory 
and cognitive control (Barbey et al. 2013). Hence, the attenuation may reflect an effect of 
mCPP on memory processes. However, as the dlPFC is involved in cognitive control, and 
previous work has related an increase in dlPFC BOLD signal to greater behavioural 
inhibition (Shackman et al. 2009), the reduction here might represent lowered control, due to 
a reduced demand for this process. mCPP also reduced the BOLD response in the 
hippocampus, which is a key area involved in reward and memory. For low calorie food 
pictures, attenuation of BOLD signals was limited to the OFC (bilaterally) which plays a role 
in evaluating the subjective pleasantness of food (Kringelbach et al, 2003). Hence, while 
attenuation of the BOLD response to low calorie images was limited, and primarily related to 
areas implicated in food liking, reduced BOLD responses to high calorie foods was more 
widespread, encompassing a number brain regions involved in motivation, sensory 
processing, inhibitory control and memory.  
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mCPP also increased BOLD activation to high calorie food images in the vmPFC and vlPFC. 
The ventral prefrontal cortex is often associated with reward, and activity in the vmPFC has 
specifically been associated with food reward and goal directed processes (Hare et al. 2009). 
mCPP increased activation to the sight of low calorie food images in the midbrain and 
amygdala, both of which are implicated in food reward (Small et al. 2001; Berridge, 1996; 
Arana et al. 2003). As there is evidence that satiation enhances reward processing in response 
to low calorie foods (Siep et al. 2009), it is possible that mCPP might cause low calorie foods 
to be evaluated as more rewarding versus placebo. However, the absence of enhanced 
pleasantness ratings of the pasta in the mCPP condition suggests this explanation is unlikely. 
 
mCPP at 30mg reduced the rate of pasta consumption by 26% and cookie consumption by 
39%, and increased the duration of pauses between mouthfuls of pasta and cookies by 49% 
and 109%, respectively. Hence, mCPP exerted a greater magnitude of effect on 
microstructural measures of cookie consumption than pasta consumption. mCPP did not 
significantly reduce the amount of pasta consumed, which is consistent with the results of 
Study 1. However, the drug significantly reduced the consumption of cookies.  
 
To assess the possibility that these effects of mCPP were secondary to other effects such as 
nausea, VAS ratings were analysed. mCPP increased ratings of nausea-like symptoms 
(nausea, light-headedness and faintness VAS ratings) and reduced mood and energy. 
However, analysis of nausea ratings indicated that these were not correlated with food intake, 
suggesting they were unlikely to account for the attenuated eating behaviour, which is 
consistent with previous findings (Walsh et al. 1994; Study 1). In addition, the differential 
effects of mCPP on pasta and cookie intake would also suggest the effects are not secondary 
to nausea as it would be expected that nausea would suppress intake of both foods. Hunger 
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ratings correlated with pasta intake, and there was a trend for pleasantness ratings to correlate 
with cookie intake. Thus the pasta consumption might have been more affected by metabolic 
factors, whereas cookie consumption may have been more influenced by non-homeostatic 
factors such as hedonic hunger. 
 
The preferential effect of mCPP on cookie eating is interesting and may relate to a specific 
effect of 5-HT2C agonists on high calorie/palatable foods. In rodents, 5-HT2C receptors 
mediate the anti-obesity effects of the drug d-fenfluramine (Vickers et al.1999; Clifton et al, 
2000). There is evidence that d-fenfluramine selectively reduces fat consumption in rats 
(Smith et al.1998) and may block a reward system triggered by a high fat diet (Fisler et al. 
1993). Similarly, pre-clinical studies with sibutramine, which exerts its effect on appetite at 
least partly via a 5-HT2C receptor agonist action (Higgs et al., 2011), also demonstrated a 
reduction in the consumption of high fat food in rats (Popik et al.2011). In humans, 
dexfenfluramine and sibutramine selectively decreases fat intake (Lafreniere et al. 1993; 
Rolls et al. 1998). Dexfenfluramine produces a similar effect in healthy men, which is 
abolished by treatment with ritanserin, a 5-HT2C receptor antagonist (Goodall et al. 1993). 
Hence, it possible that an agonist action at 5-HT2C receptors is associated with a decreased 
intake of high calorie foods such as those high in fat, though this is speculative and needs to 
be tested in future studies. It is also possible that these effects might involve actions at other 
serotonin receptors. 
 
Participants who were aware of the presence of the UEM did not behave differently to 
participants who were not aware of its presence indicating that awareness does not affect 
eating. This finding is consistent with the results of Study 2. Hence, in future studies, it might 
be preferable and logistically easier to make all participants aware of the UEM setup.  
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To investigate the relationship between brain activity and food consumption, BOLD 
responses were correlated with cookie consumption. Cookie consumption was positively 
correlated with BOLD signals in the OFC and vlPFC. Hence, greater mCPP induced 
suppression of activity in these areas to high calorie food images, resulted in greater 
reductions in cookie intake. vlPFC activity has previously been shown to positively correlate 
with the subjective pleasantness of food consumed (Kringelbach et al, 2003), and thus a 
reduction in vlPFC activity may be related to a mCPP-induced reduction of the hedonic 
response to these foods. There was also a trend for a positive correlation between 
hypothalamic BOLD response and cookie intake. This is particularly interesting as prior work 
has suggested that the hypothalamic response to sibutramine administration predicts intake of 
an ad-libitum snack, and subsequent weight change (Fletcher et al. 2010). Thus, these 
correlations might have utility as longer term indicators of drug induced weight-loss, and 
should be further explored in future studies.  
 
It is worth noting that in the present study the foods used varied in energy density and 
palatability. Based on the experimental design it is not possible to conclude whether the 
effects of mCPP were related to the palatability of the cookies, their relatively high energy 
density or both. Indeed, there are a number of other differences between pasta and cookies, 
including their sensory characteristics (salty, sweet, bitter, crunchy, creamy, etc) that may 
also be related to the preferential effect of mCPP that was observed. In addition, the cookies 
were served after a satiating meal, and it may be that the preferential effect of mCPP is 
dependent upon food having been consumed ad-libitum prior to their presentation. For 
instance, the effect of mCPP on cookie intake might have been observed for any food served 
after a meal, and this needs to be followed up in future work. 
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A secondary aim of Study 6 was to examine differences between drug responders and non-
responders. Examination of pleasantness ratings showed that after dosing with mCPP, non-
responders rated the cookies as more pleasant than responders, in the absence of differences 
in rated hunger. Analysis of the BOLD signal showed that at baseline (pre-drug), non-
responders showed greater BOLD activity than responders to high calorie foods across a 
range of reward and appetite regions. Taken together, the results suggest that non-responders 
exhibit greater reward responses to food images and to cookies, and this heightened reward 
response may explain their difference in response to mCPP. interestingly, Stice and 
colleagues (2011) reported that healthy individuals at risk of becoming obese, versus those 
not at risk, show enhanced caudate, putamen, insula, and OFC responses to rewarding 
stimuli. In addition, it has been reported that the OFC response to rewarding appetitive 
stimuli predicts subsequent food intake (Nolan-Poupart et al. 2013) and subsequent increases 
in BMI (Yokum et al. 2011). Hence, it is seems credible to suggest that the heightened 
reward response might be responsible for a blunting of the hypophagic effect of mCPP on 
cookie intake.   
 
This study provides the first evidence of a preferential effect of mCPP on BOLD responses to 
food images and intake of a palatable energy dense snack compared to a pasta meal. These 
data confirm that the experimental medicine model is capable of detecting distinct neural and 
preferential behavioural effects, which could help to elucidate the neural and behavioural 
mechanisms of novel drugs to treat obesity. The marked reduction in activity in reward-
related brain areas to high calorie foods could indicate that mCPP and other 5-HT2C receptor 
agonists may be able to suppress the intake of highly palatable energy dense foods, which 
would be particularly useful in treating obesity. In addition, investigating drug responders and 
non-responders has shown that individuals who fail to reduce their cookie intake after 
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treatment with mCPP show enhanced ratings of cookie pleasantness, and enhanced baseline 
BOLD signal responses in key reward and appetite areas. The clear differences between 
responders and non-responders suggests that it may be possible to identify patients who are 
likely to respond to serotonergic anti-obesity treatments.   
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CHAPTER 7: General Discussion 
 
7.1. Introduction 
The overall objective of this thesis was to develop an experimental medicine model to 
evaluate the potential efficacy and psychiatric safety of novel anti-obesity drugs. This 
resulted in three broad aims examining: (1) whether measures of eating behaviour provided 
by a UEM might have utility as indicators of whether a drug will have a positive impact on 
eating behaviour and help to elucidate a drug’s neural and behavioural mechanism of action; 
(2) the utility of using measures of emotional processing obtained from the ETB to detect 
negative psychiatric side-effects; (3) whether using fMRI BOLD signals would provide 
indications of drug mechanism and whether these measures might prove predictive of eating 
behaviour. The studies presented in this thesis addressed these questions and the findings 
from each study will be reviewed briefly to provide an overview of the results. The 
behavioural and neural markers that emerged and the strengths and limitations of the studies 
and the model will be discussed.  Finally, the broader significance of this work and possible 
future directions for research will be considered.  
 
7.2. Overview of findings  
Chapter 2 investigated whether acute effects of the 5-HT2C receptor agonist mCPP on eating 
behaviour and emotional processing could be detected using the UEM and ETB in healthy 
volunteers. It was possible to detect reductions in appetite for a pasta lunch in both men and 
women which was consistent with previous research (Cowen et al. 1995). However, standard 
UEM measures such as food intake and eating rate did not show any mCPP-induced 
alterations. Interestingly, use of the satiation quotient showed that for women, the satiating 
capacity of the food was enhanced early within the meal by both 15mg and 30mg mCPP. 
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There were no negative effects of mCPP on any ETB measures, or any other measures of 
mood and unexpectedly the ETB revealed an enhancement of memory by mCPP. Hence, this 
Chapter 2 showed that it is possible to detect acute drug effects on appetite and eating 
behaviour using the UEM and provided a novel finding on memory, illustrating potential for 
the ETB to detect drug effects on cognitive mechanisms relating to eating behaviour.  
 
A surprising finding reported in Chapter 2 was that a large number of individuals invalidated 
their test session by interacting with the UEM, e.g. by leaning on the balance or removing 
their plate from the balance. Chapter 3 aimed to address these issues by examining whether a 
covert approach was necessary to ensure reliable UEM readings, or whether participants 
could be made aware of the UEM set up to reduce disruption arising from non-awareness. 
Chapter 3 also investigated the feasibility of providing a cookie snack 20 minutes after a 
pasta lunch, to examine whether this could be used in future studies to examine responses to 
different types of food (highly palatable, energy dense, high calorie cookies versus pasta). 
 
The results from Chapter 3 showed that awareness of the UEM did not affect consumption of 
a pasta lunch, but significantly reduced cookie consumption. Appetite ratings were affected 
for both foods, whereby awareness of the UEM decreased ratings of fullness while 
consuming pasta, and increased ratings of hunger whilst consuming cookies. Overall, the 
results suggest that the effects of awareness are limited and that use of the UEM without a 
covert approach should be explored in future studies.  
Chapter 2 also provided evidence of a large degree of variability in eating behaviour between 
participants. One method to reduce such variance is to use a cross-over design, such that 
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participants act as their own controls. However, the ETB had not been used in cross-over 
designs and thus, there was a need to examine whether this was a valid approach. Similarly, it 
was not known whether differences in appetitive state (due to differences in hunger, 
consuming food, or drug induced changes in appetite) might affect ETB performance, and 
thereby confound study results. The use of a cross-over design and the potential influence of 
appetitive state were addressed in Chapter 4. Satiation had no significant effect on any ETB 
measures. Hence, it seems unlikely that differences in baseline hunger, the consumption of 
food, or the satiety enhancing effects of a drug would confound ETB test performance. Using 
a within-subject design with testing over four sessions, it was shown that two of the three 
memory tasks (ECAT + EMEM) were free from practice effects. However, during the three 
remaining ETB tasks (FDOT, FERT, EREC), there was evidence of practice effects occurring 
in the first two sessions, but not the latter two, suggesting that after two initial ‘training 
sessions’ to stabilise test performance, it might be possible to use the ETB in cross-over 
designs.  
 
The aim of Chapter 5 was to profile the brain changes associated with satiation, which could 
provide a benchmark for comparisons to satiation enhancing drugs. The results showed that 
satiation decreased BOLD activity across a range of reward areas and increased activity in an 
area associated with inhibitory control. Further, BOLD activity between prefrontal reward 
and inhibitory control centres (vmPFC and dlPFC) was correlated, providing novel 
information on the neural control of appetite and mechanisms governing satiation.  
 
Chapter 6 examined the effects of mCPP on both behavioural and neural responses using a 
cross-over design. This design was used to address the variance in eating behaviour observed 
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using an independent groups design noted in Chapter 2. Based on the results from Chapter 3, 
the effects of mCPP on consumption of both a pasta lunch and cookie snack was assessed in 
participants who were either aware or unaware of the UEM. Finally, differences between 
drug responders and non-responders were also investigated. mCPP significantly reduced the 
eating rate of pasta and cookies and increased the pauses between consumption of both foods. 
The effect sizes on eating and pauses were greater for cookies, and consumption of cookies 
was significantly reduced by mCPP whereas there was no effect of the drug on pasta intake. 
Hence, the model identified a preferential behavioural effect of mCPP on the consumption of 
a palatable high calorie food. Awareness of the UEM did not affect eating behaviour, 
suggesting that future studies might benefit from using the UEM in a non-covert design. 
mCPP reduced brain activity to the sight of the high calorie food images across a range of 
key appetitive and reward areas, but had a more limited effect on responses to low calorie 
food images. Hence, the fMRI results mirrored the behavioural results, with more marked 
effects on the response to high calorie foods images. The fMRI results from this Chapter 6 
also overlapped with some of the brain regions indicated in Chapter 5, suggesting potential 
satiation biomarkers which are reliable across studies. The change in BOLD signal in 
response to high calorie food images was also shown to be predictive of the amount of high 
calorie food consumed after mCPP. Thus, investigation of responders and non-responders to 
mCPP revealed that non-responders showed significantly greater BOLD activity to high 
calorie food images in reward and appetite regions at baseline than responders. In addition, 
non-responders showed enhanced rated pleasantness of the cookies. Together these data 
suggest the novel hypothesis that non-responders to serotonergic weight-loss drugs might 
have heightened reward responses at baseline which confers insensitivity to the effects of 
drugs which have 5-HT2C agonist actions (as well as acting at other receptors) such as mCPP. 
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Furthermore, it is possible that the model might have utility in stratified medicine, as 
indicator of which individuals are likely to respond to an anti-obesity drug. 
In summary, six experimental studies have investigated the potential of an experimental 
medicine model comprising the UEM, ETB and fMRI to assist with go/no go decisions for 
anti-obesity drugs undergoing early phase trials in healthy volunteers. The data suggest that 
the UEM can detect acute and preferential drug effects on eating behaviour. The ETB was 
able to detect a novel memory enhancing effect of mCPP. Finally, fMRI has been shown to 
have utility in identifying the neural circuitry underlying satiation and in examining 
differential responses to distinct types of food stimuli. These measures may also be useful in 
predicting behavioural responses, and in identifying whether individuals will respond to a 
given anti-obesity drug. The potential utility of these behavioural and neural markers will be 
examined in more depth in the following sections. 
 
7.3. Behavioural markers   
The behavioural markers of primary interest in this thesis were derived from the UEM and 
the ETB to measure eating behaviour and emotional processing respectively. The success of 
these measures across the studies presented in this thesis and their application in the 
experimental medicine model will be considered here. 
 
7.3.1. UEM Behavioural Markers  
The UEM generates several measures of eating behaviour comprising: (1) within-meal 
appetite ratings (hunger, fullness and desire to eat); (2) measures of meal microstructure 
(duration of eating, eating rate, number of mouthfuls and pauses between mouthfuls). In 
addition, using appetite ratings and consumption data it is possible to derive a satiation 
quotient (SQ).  
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In Chapter 2 mCPP at doses of 15mg and 30mg was shown to have no effect on within-meal 
appetite ratings. In contrast, in Chapter 3 it was shown that awareness of the UEM decreased 
rated fullness while consuming pasta and increased rated hunger while consuming cookies, in 
the absence of changes in rated pleasantness. This is an important finding, as it shows that 
within-meal appetite (hunger and fullness) ratings can be dissociated from within-meal 
pleasantness ratings. In Chapter 6, it was shown that mCPP did not significantly affect 
within-meal measures of appetite during the consumption of a pasta lunch which is consistent 
with the results reported in Chapter 2, but significantly reduced the rated pleasantness of a 
cookie snack. Hence, effects on pleasantness were observed in the absence of effects on 
appetite, a finding that is similar to previous work with naltrexone (Yeomans and Gray, 
1997). Although satiety and reward are tightly interlinked in the human brain (Berthoud, 
2011) and it is unlikely that they can be completely dissociated, it is possible that UEM 
measures could help to indicate whether a drug might have a greater effect on satiation 
(appetite) or reward (pleasantness). Hence, these measures might be particularly useful in 
profiling the neural and behavioural mechanisms of drug action.  
 
From this perspective, a simple interpretation of the UEM subjective rating results from 
Chapters 2 and 6 would suggest that mCPP does not affect appetite and has a selective effect 
on food pleasantness. This seems unlikely as sibutramine reduces within-meal hunger and 
increases within-meal fullness (Halford et al. 2010). However, sibutramine also blocks the 
reuptake of noradrenaline which could account for the disparity. It is worth noting that in 
both Chapters 2 and 6, mCPP suppression of appetite (via VAS ratings) was observed during 
the test days, so it seems likely that appetite would also be suppressed during the UEM 
sessions. Hence, it is possible that mCPP does affect within-meal appetite, but that we were 
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unable to demonstrate this due to insufficient statistical, power caused by the loss of UEM 
data.  
 
It is potentially significant that the reduction in pleasantness was preferential for consumption 
of the cookie snack. mCPP may have a greater effect on higher energy density foods, more 
palatable foods or foods higher in certain macronutrients and there is previous evidence that 
serotonin can selectively reduce fat intake (which is linked to energy and palatability) in both 
rodents and humans (for a review, see Blundell et al. 1995). Indeed, as noted in Chapter 6 
there is evidence that the preferential effect is likely due to a 5-HT2C agonist effect on fat 
intake. However, it is also possible that the effect was due to the consumption of cookies in 
the absence of hunger; i.e. mCPP might exert a greater effect on food consumed after 
metabolic needs have been met. Unfortunately, the study design does not enable the 
dissociation of these factors. It is also possible that the effects of mCPP are mediated by 
actions at other serotonin receptors. However, it would be useful to explore these issues in 
future studies.  
 
In Chapters 3 and 6, the experimental manipulations (awareness of the UEM and 30mg 
mCPP) decreased eating rate whereas no effect of mCPP was observed in Chapter 2. 
Interestingly, in Chapter 3, the reduced eating rate of cookies was accompanied by changes in 
within-meal appetite which were reflective of weakened satiety (i.e. increased hunger). 
Hence, although a decrease in eating rate might be associated with increased satiation 
(Halford et al. 2010) it has limitations when used in isolation as an indicator of enhanced 
satiation and ideally should be measured in conjunction with ratings of appetite.  
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Eating rate is derived from total amount eaten and duration of eating, and the rate can be 
altered by a change in either one or both of these variables. In Chapter 6, mCPP was observed 
to have no significant effect on the duration of eating cookies, but a significantly (30%) 
decreased in the amount of cookies consumed. It is possible that amount eaten and duration 
of eating reflect the behavioural mechanisms affected by the experimental manipulations. For 
instance, hunger or non-hedonic influences on intake might be more closely associated with 
the temporal component of a meal, while food pleasantness might be more closely linked to 
the amount of food consumed. In support of this interpretation, Yeomans (1996) presented 
data on the intake and eating rate of a bland versus palatable pasta. Using the data presented 
in the paper, it is possible to derive the impact of palatability on eating duration and amount 
consumed. Hence, the bland pasta was associated with a small increase in duration of eating 
(+2%), but a larger decrease in the amount of pasta consumed (- 11%), which supports the 
hypothesis that palatability might be more closely linked to amount eaten than meal duration. 
Further work investigating the effects of satiety and food pleasantness on these meal 
components in humans would help to clarify this hypothesis. 
 
In addition to eating rate, eating duration and amount eaten, average pause between 
mouthfuls was also investigated in Chapters 3 and 6. Average pause between mouthfuls was 
not affected in Chapter 3 by the awareness manipulation, but was significantly increased by 
mCPP while consuming pasta and cookies in Chapter 6, which might suggest that mCPP 
reduces motivation to consume both foods.  
 
The within-meal satiation quotient was also examined as a measure of the satiating power of 
a given amount of food. In Chapter 2, the satiation quotient for pasta was increased during the 
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first and second quartiles by 30mg mCPP and during the second quartile by 15mg mCPP. 
These data suggest that mCPP accelerates satiation within a meal. In Chapter 3, participants 
who were aware of the UEM had lower satiation quotient scores when consuming cookies, 
than participants who were non-aware of the UEM, suggesting they experienced the food as 
less filling. Finally in Chapter 6, there were no significant effects of mCPP on the satiation 
quotient. It is possible that the lack of effect on the satiation quotient in Chapter 6 was due to 
the difference in paradigm from Chapters. In Chapter 3, participants sat in a test room for 2 
hours between dosing and food consumption and periodically completed VAS. In Chapter 6, 
there was a longer interval of 2.5 hours between dosing and consuming food, as participants 
were required to walk to and from the scanner room (a 10 minute walk each way) on two 
occasions and look at food images in the scanner for approximately 1 hour in total (2 x 30 
minute sessions). Thus, the Chapter 6 conditions comprised 40 minutes of light exercise and 
60 minutes of exposure to food stimuli. Either of these factors may have stimulated appetite, 
and thereby, attenuated the effect of mCPP on appetite. 
 
It is relevant to consider whether these microstructural measures could be used to detect non-
specific drug effects on eating behaviour. For instance, in rats, the behavioural satiety 
sequence has been used to differentiate behaviourally specific satiety induced by mCPP from 
non-specific hypophagic effects (caused by locomotor stimulation and stereotypy) induced by 
the selective 5-HT1B receptor agonist RU-24969 and the 5-HT2A receptor agonist 1-(2,5-
dimethoxy-4-iodophenyl)-2-aminopropane (Kitchener and Dourish 1994).  Although it was 
not tested in the current model, it would be beneficial to study the effects of drugs that cause 
sedation, stimulant effects and/or nausea on eating microstructure to investigate whether 
characteristic patterns could be identified and subsequently used to detect drugs which 
attenuate food intake due to non-specific side effects. 
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Finally, it is important to ask whether the UEM adds anything beyond standard laboratory 
measures of food intake such as amount eaten. In Chapter 2, mCPP had no effect on amount 
eaten, but the satiation quotient identified an mCPP-induced acceleration of satiation. In the 
absence of quartile data for both food intake and VAS, this effect would not have been 
detectable. In Chapter 6, mCPP reduced the amount of cookies consumed but did not reduce 
pasta intake. In the absence of additional measures, this may have suggested that mCPP had 
no effect on pasta intake. However, eating rate was decreased and the duration of pauses 
between mouthfuls was increased, showing that mCPP affected how the pasta was consumed, 
but not the amount that was consumed. Hence, the ability to examine the structure of a meal, 
together with the additional measures that are produced by measurement of the temporal 
profile of an eating episode, provide rich insights beyond that of a single measure of amount 
eaten. There has been little exploration of the microstructure effects of other drugs that affect 
eating behaviour. However, it is possible that other drugs also have such within-meal effects, 
which might be used to distinguish between compounds with different mechanisms of action. 
For instance, subtle differences between drugs (e.g. on the eating rate or pauses between 
mouthfuls of cookies) should be detectable by the UEM. 
 
In summary, the UEM is a valuable component of the experimental medicine model, 
providing rich data regarding drug effects on eating behaviour that might otherwise be missed 
with cruder outcome measures. The data from the UEM has shed further light on mCPP-
induced reductions in food intake, highlighting early within-meal satiation enhancement 
(Chapter 2), effects on eating rate (Chapters 3 and 6) and preferential effects on highly 
palatable energy dense foods consumed in the absence of hunger (Chapter 6).  
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7.3.2. ETB Behavioural Markers  
In Chapter 2, the ETB did not detect any anxiogenic effects of mCPP and similarly the 
questionnaire measures of state and trait anxiety (STAI) also showed no increases in anxiety. 
While it might have been predicted that mCPP would produce an anxiogenic effect, this is 
typically observed after intravenous administration, rather than oral dosing (Kahn et al. 1990; 
Silverstone and Cowen, 1994; Cowen et al. 1995; Anderson et al. 2002b). Hence, it appears 
that the ETB measures accurately classified oral mCPP as having a safe psychiatric profile at 
the doses used in Chapter 2. It should be noted however that in Chapter 6, state anxiety was 
elevated during the mCPP test day and BFS measures of energy and mood were lower after 
mCPP. The reasons for the discrepancy with Chapter 2 are unclear.  It could be speculated 
that anticipation of being scanned caused mild apprehension for participants, which may have 
interacted with the drug to produce these effects.  
 
Although no negative psychiatric effects were detected in the current studies, there is 
previous evidence that the ETB can detect negative psychiatric effects (Horder et al 2009; 
2011). Seven days dosing with rimonabant induced a negative bias in memory recognition, 
which suggests a possible mechanism by which rimonabant induces depressogenic effects 
(Horder et al. 2011). Furthermore, in a single dose study, rimonabant increased incidental 
recall of negative information, which also suggests a negative bias (Horder et al. 2009). 
Hence, the ETB is capable of detecting these adverse effects on mood after single or repeated 
drug administration.  
 
The ETB might also be useful for assessing other non-specific effects. For instance, some 
drugs which affect appetite, such as amphetamine, have also been shown to increase alertness 
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and arousal (Smith and Beecher, 1960). As alertness and arousal are linked to cognitive 
performance it might be predicted that faster performance on the ETB could be indicative of 
a drug that increases alertness and arousal and has a general stimulatory effect. Conversely, 
drugs that have sedative effects and affect eating behaviour (e.g. naltrexone; Oncken et al. 
2001) might reduce performance on ETB cognitive measures. This is a particularly important 
issue, as even in the absence of a negative emotional response (e.g. not showing a 
depressogenic bias towards negative emotional stimuli), a sedative effect might indicate other 
symptoms associated with low mood (e.g. tiredness). In a similar approach to that suggested 
above in relation to the UEM, it would also be interesting to examine how nausea affects 
responses on the ETB, as it might affect either mood or cognition in a detectable manner.  
 
Investigation of practice effects showed that the ETB can be used in cross-over designs after 
two practice trials. In addition, the validation study investigating satiety effects showed that 
neither VAS mood measures nor the ETB task scores were affected by satiation. . Hence, 
ETB measures are unlikely to be confounded by food consumption which would be 
particularly advantageous when using drugs which produce large reductions in food intake 
compared to placebo. 
 
The ETB detected an mCPP-induced enhancement of memory in Chapter 2. This was a novel 
and unexpected finding and suggests that the ETB might have further utility in eating studies 
beyond providing an indication of psychiatric safety. For instance, it has been proposed that 
memory plays an important role in eating (Higgs 2002), and studies in baboons with the 
memory enhancing drug memantine have shown  that the drug enhances satiation (Foltin et 
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al. 2008). Hence, it is possible that the satiation enhancing effect of mCPP is at least partly 
due to enhancement of memory.  
 
In conclusion, the ETB provides a sensitive tool to investigate the psychiatric safety of 
potential anti-obesity drugs. It may also provide the ability to elucidate how a drug affects 
food intake, particularly by influencing cognitive processes. To this end, it would be 
particularly advantageous to test the memory enhancing drug memantine using the ETB and 
UEM and to examine whether any effects on memory are related to any subsequent 
enhancement of satiation and reductions in food intake.  
 
7.4. Neural markers 
In Chapter 5, satiation was observed to decreased neural activity to the sight and taste of 
appetitive stimuli in the vmPFC, OFC, NAcc (food reward), hypothalamus (energy balance 
circuitry) and insula (sensory processing), but increased activity in the dlPFC (inhibitory 
control). These results are important in extending our knowledge of the neural basis of 
satiation in healthy individuals. For instance, it was unclear from previous studies whether 
differences in brain activity after a prolonged fasting period (e.g. a 14 hour fast; Führer et al. 
2008) would also be present after a shorter period of fasting that would be commonplace 
between meals for most people. Führer and colleagues (2008) found that satiation (compared 
to 14 hour fasting) decreased BOLD signals in the amygdala and anterior cingulate cortex to 
the sight of food images (compared to non-food images), areas which were not significantly 
attenuated by satiation in the studies of this thesis.  
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A negative correlation between vmPFC and dlPFC activity was reported in Chapter 5, which 
raises interesting questions about how reward processes and inhibitory control might interact 
during satiation. There is evidence that the dlPFC modulates vmPFC activity in response to 
food stimuli (Hare et al. 2011), which suggests that cognitive (inhibitory) control modulates 
reward responses. If this is the case, then drugs which enhance inhibitory control might be of 
use in weight-loss or weight-loss maintenance. Moreover, this would suggest that the dlPFC, 
and possibly other neural markers of cognitive control such as the dorsal ACC (Mohanty et 
al, 2007), could be useful indicators of a drug which reduces food intake by this mechanism. 
Hence, these findings suggest both a novel target for obesity and a means by which to 
identify drugs with this neural mechanism. It is also interesting to note that the vmPFC-
dlPFC negative correlation was observed in satiated but not hungry individuals. It could be 
speculated that the interaction between these areas was triggered by a bottom-up process; i.e. 
that it was produced by the metabolic consequences of food consumption. Given that the 
correlation shows a rise in dlPFC (inhibitory control area) and a decrease in vmPFC (reward 
area) it is feasible that this interaction then forms the basis of a subsequent top-down 
influence to limit further food intake. If this were the case these prefrontal areas occupy a 
pivotal position, both being modulated by, and in turn modulating metabolic consequences. 
This would be consistent with evidence that there is a significant interaction between top-
down and bottom-up influences on eating behaviour (for review see Berthoud, 2011).  
 
Chapter 6 presented a study that investigated the effects of mCPP on BOLD responses to the 
sight of low and high calorie foods. mCPP at a dose of 30mg decreased activity to the sight of 
high calorie foods in the insula (bilaterally), anterior cingulate cortex (ACC), hippocampus 
and dlPFC, but increased activity in the ventromedial and ventrolateral PFC. Conversely, 
mCPP decreased activity to the sight of low calorie foods in the OFC (bilaterally) and 
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increased activity in the amygdala and midbrain. Overall, the fMRI results suggest that mCPP 
had a more wide-ranging effect on brain activity to high calorie, palatable foods, attenuating 
activity across multiple cortical regions involved in reward and appetite, than to low calorie, 
less palatable foods. This is consistent with the behavioural data, which showed a more 
pronounced effect of mCPP on the consumption of high calorie food (cookies) than low 
calorie food (pasta). The cause of these preferential effects is difficult to determine in the 
present study, and may be due to differences in a range of factors, e.g.: palatability, energy 
density, fat content, texture, meal type, etc. Regardless of the precise cause of the preferential 
effects, the different profiles of BOLD activity for low and high calorie foods confirms the 
utility of paradigms using different types of food, which may have advantages over the 
reward-aversion fMRI model used in Chapter 5 for investigating drug effects on specific food 
categories. Further work is clearly warranted to investigate the precise nature of these 
preferential effects of mCPP on eating in both lean and obese individuals. 
 
One of the advantages of Chapter 6 was the opportunity to correlate food intake with brain 
responses to relevant food images  (i.e. BOLD signals in response to high calorie food images 
correlated with amount of cookies consumed). Thus, the magnitude of mCPP induced 
attenuation of the BOLD signals in OFC and vlPFC to the sight of high calorie foods was 
correlated with the magnitude of the decrease in cookie intake caused by the drug. There was 
also a trend towards a correlation when considering the hypothalamus. Thus, while mCPP did 
not affect the mean hypothalamic response to food images, there is an association between 
the magnitude of the mCPP effect on hypothalamic response and on cookie intake. This is 
consistent with the work of Fletcher and colleagues (2010) showing that the magnitude of the 
effect of sibutramine on hypothalamic responses, correlated with ad-libitum eating and 
weight over time. Together with the correlations with the prefrontal reward areas, the data 
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suggest that energy balance circuitry in conjunction with food reward regions mediate the 
effect of 5-HT2C receptor activation on the amount of food consumed. Hence, the BOLD 
signal in these regions is predictive of food intake, and may provide a useful longer term 
indicator of weight change, though this remains to be investigated further. 
mCPP attenuated BOLD response in the hippocampus, an area which is implicated in reward. 
The ventral hippocampus is particularly noted for connectivity with the NAcc and VTA in 
humans (Kahn and Shohamy, 2013). Hence, it is likely that the hippocampus is part of the 
wider reward circuitry affected by mCPP. It is also interesting to note that the hippocampus is 
a key memory centre, and that mCPP was observed to enhance memory in the studies 
reported in Chapter 2. Unfortunately, measures of memory were not taken in Chapter 6; 
nevertheless, it is tempting to speculate that the hippocampal BOLD modulation might be 
related to the cognitive enhancing effect of mCPP.  
 
ACC attenuation in Chapter 6 is likely to represent a decrease in motivation and attention 
towards the food presented, while dlPFC attenuation might indicate a decrease in inhibitory 
control. The dlPFC and ACC are functionally connected to one another, and interact to exert 
cognitive control over behaviour (MacDonald et al. 2000; Cieslik et al. 2013). Hence, it is 
possible that mCPP attenuation of ACC attention and motivation to food stimuli reduced the 
need for dlPFC control, resulting in a decrease in dlPFC activity. However, this is speculative 
and requires investigation. 
 
Both natural satiation and mCPP attenuated activity in the insula and the OFC (see Chapter 5 
and 6). This raises the possibility that the effect of satiation in Chapter 5 was driven, at least 
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in part, by an agonist action of endogenous 5-HT at 5-HT2C receptors, as these brain regions 
express a high density of 5-HT2C receptors (Abramowski et al. 1995; Sharma et al. 1997). A 
caveat is that the use of different scanner tasks might be expected to yield different patterns 
of activation, regardless of any differences due to natural satiation and mCPP- induced 
satiation. Nevertheless, it is also possible that any disparity in results between these studies 
may reflect differences between how mCPP and natural satiation affect the brain. If this were 
the case, then natural satiation may primarily attenuate hypothalamus and NAcc activity, 
whereas mCPP may primarily attenuate activity in the dlPFC (inhibitory control), ACC 
(motivation) and hippocampus (memory).  
 
Both the work presented in Chapters 5 and 6, and the results of Fletcher and colleagues 
(2010) show that the NAcc response to food is attenuated by satiation with food, but not by 
sibutramine or mCPP, which suggests that 5-HT2C receptor stimulation does not directly 
affect this key reward structure. Perhaps more surprising is that mCPP did not affect 
hypothalamic activity (Analysis 1 in Chapter 6), as the hypothalamus is a 5-HT2C rich area in 
humans (Marazziti et al. 1999). Sibutramine has been shown to decrease hypothalamic 
activity (Fletcher et al. 2010) while intravenous dosing with mCPP has been shown to 
immediately increase the hypothalamic response (Anderson et al. 2002b; McKie et al. 2011). 
It is possible that the additional noradrenergic effects of sibutramine contribute to its effect on 
the hypothalamus, and that the increased response seen immediately after intravenous 
administration in the scanner, is not present 60 minutes after oral dosing. Also, as BOLD 
changes in the hypothalamus can be difficult to detect and the hypothalamus is a 
heterogeneous region, the lack of effect may also be due to technical limitations of our 
studies.   
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Satiation was shown to enhance dlPFC activity in Chapter 5 and mCPP was observed to 
enhance ventral PFC, amygdala and midbrain activity in Chapter 6. These areas are 
associated with motivation and liking (Small et al. 2001, Berridge, 1996). Previous work has 
noted that satiation can enhance reward processing in response to less energy dense foods 
(Siep et al.2009). However, as pleasantness ratings of the pasta were not enhanced by mCPP, 
it may be that these increased activations are not representative of reward enhancement.  
 
Collectively the results suggest that mCPP does not affect core reward and appetite areas in 
the same manner as natural satiation (NAcc and hypothalamus), but primarily exerts its 
influence more comprehensively across a range of areas implicated in reward (see Figure 
7.1).  
 
 
Figure 7.1 Model of natural satiation and mCPP-induced changes in BOLD signals to appetitive stimuli (based 
on the results described in Chapters 5 and 6).  
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The neural profile of mCPP points more strongly towards modulation of reward circuitry than 
energy balance circuitry (compared to natural satiation) and this is supported by effects on 
food pleasantness (but not hunger or fullness) within meal reported in Chapter 6. If the 
primary effect of mCPP is on the rewarding aspects of food, it is interesting to consider 
which processes may be directly affected. One possibility is that mCPP enhances alliesthesia. 
Alliesthesia refers to the phenomenon whereby eating food is more pleasant when an 
individual is hungry and less pleasant when they are satiated. Thus, food pleasantness is 
dependent upon the internal state (Cabanac, 1971). It is possible that mCPP enhances 
alliesthesia such that food becomes less pleasant at a faster rate during the meal, thereby 
accelerating satiation. The early effect of mCPP on the satiation quotient reported in Chapter 
2 lends support to this theory. In addition, cyproheptadine is an antagonist at 5-HT2A, 5-HT2B 
and 5-HT2C receptors, and increases food intake and significantly reduces alliesthesia in 
humans (Silverstone and Schuyler, 1975; Fantino et al. 1990). Hence, it seems plausible that 
decreased food intake induced by serotonergic agonists might be due to enhanced alliesthesia. 
However, to date, the only research which examined the effects of enhanced 5-HT function  
(by administration of dexfenfluramine) on alliesthesia reported no significant effects 
(Blundell and Hill, 1988). A study that examined the effects of mCPP or another 5-HT2C 
receptor agonist in an alliesthesia paradigm would provide an important test of this 
hypothesis. 
 
The final application of fMRI within this thesis was the exploration of drug responders and 
non-responders. During their pre-drug baseline scan, non-responders (compared to 
responders), showed increased BOLD responses across multiple brain areas involved in 
reward and motivation to the sight of high calorie foods. Hence, while mCPP and other 5-
HT2C agonists such as lorcaserin might not be particularly effective for treating obesity in 
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these individuals, perhaps drugs which are known to target other neurotransmitter reward 
mechanisms (e.g. naltrexone) would be more useful and this would be interesting to test in 
this model. Thus, the responder versus non-responder approach could be useful for stratified 
medicine as an investigative tool to identify the appropriate drug for individual subjects 
during clinical trials, and possibly in the future, as a diagnostic tool in the clinic to identify 
the drug to which a patient is most likely to respond. 
 
In conclusion, the data from this thesis suggest that experimental medicine models that 
incorporate fMRI measures may be useful in identifying drugs at an early stage of 
development that may be useful in treating obesity and in identifying individuals who might 
best benefit from particular drug treatments. Further work to assess the relationship between 
BOLD responses to food images and weight change over time would greatly enhance the 
potential utility of fMRI within an experimental medicine model. 
 
7.5. Strengths, limitations and future work 
To assess the strengths and limitations of the experimental medicine model that has been 
developed in this thesis, it is useful to consider objective criteria. In a recent review, Harmer 
and colleagues (2011) suggested that experimental medicine models should be able to meet 
five requirements. First, they must respond to conventional drug treatments. Second, similar 
effects should be observed in healthy volunteers and clinical populations, meaning the model 
must be translational. Third, the model should be sensitive to drugs operating via different 
pharmacological mechanisms and be able to discriminate between them. Fourth, they should 
not be sensitive to failed or ineffective drugs, to allow go / no go decisions to be made. 
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Finally, the model should be sensitive to bi-directional results (e.g. changes in either 
direction, such as in this case increased or decreased food intake). 
 
It was not possible to directly test the first criterion (that the model must respond to 
conventional drug treatments) within this thesis due to the lack of available licensed centrally 
acting anti-obesity drugs to test. However, the recent approval of lorcaserin, Qsymia and 
Contrave by the FDA could change this landscape. As mCPP has been used in many studies 
over a number years to assess appetite and food intake in rats and humans (Kitchener and 
Dourish 1994; Kennett et al. 1994; Hewitt et al. 2002; Walsh et al. 1994; Sargent et al. 1997), 
it could be argued that the studies with mCPP in this thesis has provides evidence to start to 
address the first criterion.  
 
In addition, previous work has shown that the UEM is capable of detecting the effects of 
sibutramine on eating behaviour (Barkeling et al. 2003; Halford et al. 2010); the ETB can 
detect negative psychiatric effects of rimonabant (Horder et al. 2009; Horder et al. 2011) and 
fMRI can be used to detect the effects of sibutramine (Fletcher et al. 2010) and rimonabant 
(Horder et al. 2010). Hence, there is reasonable evidence that the proposed model can fulfil 
the first criterion. 
 
The second criterion is that similar effects should be observed in healthy and clinical 
populations. However, the model was exclusively validated with healthy volunteers in the 
studies that comprise this thesis and hence future work is required with clinically obese 
patients to ensure that results are translational. This is particularly important as there are 
known differences between lean and obese participants in eating behaviour measured by the 
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UEM (Laessle et al. 2007), responses to food stimuli measured using fMRI (for review see 
Carnell et al. 2012); and in cognition and prevalence of depression which might be detectable 
with the ETB (Smith et al. 2011; Carey et al. 2014). In addition, it is not known whether 
using the UEM in a non-covert manner might affect the eating behaviour of obese 
individuals, to a greater extent than their lean counterparts. Hence, by incorporating acute 
testing of clinical groups alongside healthy controls in a future study, it would be possible to 
assess whether results are translational. 
 
The third criterion (the model should be sensitive to drugs operating via different 
pharmacological mechanisms) has not been directly addressed in this thesis. However, we 
have shown that the UEM, fMRI and ETB are sensitive to other experimental manipulations. 
Nevertheless, a key question is whether the model can differentiate between different drugs. 
Unlike mCPP, sibutramine has been shown to reduce the total amount of pasta consumed in 
UEM studies (Halford et al.2010; Barkeling et al. 2003). In addition, UEM work by Yeomans 
and Gray (1997) showed that naltrexone produces a differential response to mCPP, reducing 
total intake and rated pleasantness of pasta. Further, Horder and colleagues (2009; 2011) 
showed that rimonabant has a contrasting profile to mCPP in the ETB inducing a negative 
memory bias. Finally, there is fMRI evidence that sibutramine produces different effects to 
mCPP on BOLD responses (attenuating hypothalamic and amygdala responses). Hence, it 
has been independently shown that each component of the model responds to different drugs 
with different mechanisms to produce distinctive effects. However, it would still be 
instructive in future to compare different drugs within a single study. Although there were no 
centrally acting licensed drugs available for obesity in the UK while these thesis studies were 
being conducted, the recent approval of lorcaserin, Qsymia and Contrave may allow for such 
a study. 
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The fourth criterion is that the model should not be sensitive to failed or ineffective drugs. 
Although the withdrawn drug rimonabant was tested in an fMRI paradigm and the ETB and 
showed a profile that was consistent with the reason for its withdrawal from the market 
(Horder et al. 2009; 2010; 2011), the UEM has not been tested with ‘failed or ineffective 
drugs’ and this could usefully be investigated in future work.  
 
The final criterion is that the model should be bi-directionally sensitive. In the fMRI studies, 
increased and decreased BOLD activity in response to food stimuli was reported in Chapters 
5 and 6. The changes in UEM measures were largely uni-directional and so it would be useful 
to test a drug which enhances appetite and food intake. While the studies in this thesis did not 
show bi-directional results for all of the ETB measures, there are a wealth of studies that have 
reported such changes (Chapter 1 – Table 1.1). Hence, with the exception of the UEM, the 
model has been proven to be capable of detecting bi-directional results. 
 
Therefore, in relation to Harmer and colleagues original five criteria: (1) each element of the 
model has been shown to be responsive to an anti-obesity drug, and to mCPP within this 
thesis; (2) the model remains to be translated into obese populations in future work, and this 
should be done as a matter of priority; (3) each element of the model has been shown to be 
sensitive to drugs operating via different pharmacological mechanisms, and the testing within 
this thesis has contributed to this body of data; (4) further investigation of ‘ineffective’ agents 
is required; (5) the ETB and fMRI have demonstrated a capacity for detecting bi-directional 
results but further testing of appetite enhancing drug would help confirm this ability for the 
UEM. Thus, overall, the model is performing in line with the majority of these criteria. The 
most immediate priority for validation would be to replicate these studies in an obese 
population. 
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It is also worth noting that the model was validated with healthy women in the majority of 
studies in this thesis (4 out of 6). The focus on women was because men exhibited unusual 
eating behaviour (eating very large amounts of food) during the study reported in Chapter 2. 
It is unclear at present whether the results reported from the UEM studies in Chapter 3 would 
extend to male participants, although it appears unlikely that such effects would be gender 
specific. The majority of work examining awareness has focussed exclusively on female 
participants (Polivy et al. 1986; Roth et al. 2001; Robinson and Field, 2015). However, there 
is evidence that gender influences other social phenomenon such as conformity, whereby 
males are less likely to conform than females (Eagly et al. 1981). Hence, further examination 
is required to clarify whether gender interacts with awareness.  
 
It is possible that the UEM results reported in Chapter 6 might fail to translate to male 
participants, based on the disparity between male and female eating profiles observed in 
Chapter 2. Indeed, there is evidence that in rodents that mCPP has a greater hypophagic 
effect in females than males (Clifton et al. 1993). In humans, mCPP takes longer to reach 
peak plasma levels in females (Cowen et al. 1995) and dexfenfluramine (which releases 5-HT 
and inhibits reuptake by the 5-HT transporter) induces greater prolactin responses in females 
compared to males (McBride et al. 1990). Hence it is possible that females may be more 
sensitive to serotonergic manipulations, and that any effects in males may be smaller in 
magnitude. Thus, the UEM component of the model will need to be validated with men, 
particularly as safety data for compounds in the early stages of clinical development may 
only enable studies in males. Future studies may need to exclude men who eat excessive 
amounts of food or exhibit unusual eating patterns to enable the collection of robust data. 
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In the ETB studies, the absence of gender effects (Chapter 2) suggests that gender is unlikely 
to influence results. Similarly, in the natural satiation fMRI study (Chapter 5) the lack of 
gender effects suggests this is also a suitable endpoint for both males and females. However, 
recent data suggest that fMRI BOLD signals as a measure of brain reward can be influenced 
affected by the stage of the menstrual cycle (Dreher et al. 2007). Thus, it is recommended 
that this factor is controlled for in future experimental studies.  
 
It is also worth noting that while the effects of mCPP on appetite and food intake are likely to 
be mediated by agonist actions at 5-HT2C receptors, it is possible that agonist actions of the 
compound at other serotonin receptor subtypes could also contribute to these effects. To help 
clarify this situation in humans, it would be useful to examine the effects of a more selective 
5-HT2C receptor agonist such as lorcaserin on appetite and food intake in the UEM model. 
 
A final, more general, point concerns the use of fMRI. While the method has clear utility, it is 
worth noting there are some limitations to this technique. Firstly, the use of different 
paradigms and different analysis techniques has the potential to yield different results. Hence, 
it is important to standardise analysis procedures, and this has been the case within this thesis 
wherever possible (i.e. consistent use of FSL, pre-processing techniques, threshold values, 
local maxima exploration and FWE correction). A second point concerns the attribution of 
function to a neural correlate. As an example, in Chapter 5 we observed an increase in 
activity in an inhibitory control area (dlPFC). However, this does not imply that inhibitory 
control was measured in the study. Instead, based on previous published findings we were 
able to identify the dlPFC as an area involved in inhibitory control, and speculate that 
modulation of response in this area could represent a change in this function. The third point 
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concerns interpretation of the directionality of a result. To clarify, in the non-responder 
analysis we observed differential BOLD signal responses between mCPP responders and 
non-responders. It was concluded that non-responders showed greater reward-related activity 
compared to responders. However, it could also be concluded that the responders showed 
lower reward activity when compared to responders. We speculate, based on previous 
studies, that the former interpretation is a better fit with current theories of reward processes. 
In addition, it is important to note that an increase or decrease in BOLD signal does not 
necessarily imply an increase or decrease in functional activity either, only a change or 
difference from baseline. Hence, inferring directionality should be treated with caution and 
the limitations of the conclusions considered carefully.  
 
In terms of the future direction of the model presented in this thesis, several suggestions, and 
future studies have already been outlined above and a number of others are considered below. 
For instance, structural MRI data were collected in the studies described in Chapter 6 and 
hence, it will be possible to explore potential structural differences between drug responders 
and non-responders.  
 
An exciting future addition to the model would be to examine the role of genotypes in drug 
responding. For instance, polymorphisms in SLC6A2 and GRIN1 (associated with 
noradrenaline and NMDA, respectively) are associated with increased weight-loss in a sub-
group of patients treated with GW320659 (Spraggs et al. 2005). This suggests that 
genotyping could have utility in identifying drug responders versus non-responders, or even 
populations that show a maximal therapeutic response. There is evidence from 
pharmacogenetic studies that this work can be translated to serotonergic drugs, as 
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polymorphisms in the serotonin-transporter-linked polymorphic region (5-HTTLPR) are 
associated with differential responses to sibutramine (Vazquez Roque et al. 2007; Grudell et 
al. 2008). Similarly, polymorphisms of the HTR2C gene are associated with body weight 
(Bah et al. 2010). Hence, it seems plausible that a genetic exploration of the response to 
serotonergic drugs, in addition to other anti-obesity drugs, could significantly increase the 
ability of the model to detect drug responders versus non-responders.  
 
7.6. Concluding remarks and significance 
In conclusion, the work in this thesis has contributed to the development of an experimental 
medicine model for testing of anti-obesity drugs. The studies described provide evidence that 
the UEM can be used in non-covert within-subjects designs to detect preferential drug 
induced effects on eating behaviour and provide information on drug neural and behavioural 
mechanism. The ETB is also sensitive to single dose drug- induced effects, can be used in 
within-subjects designs, is robust to changes in appetite and satiety, and may also provide 
information on behavioural mechanism. Finally, fMRI represents a valuable tool to examine 
responses to a variety of appetitive stimuli and to understand the neural circuitry and 
behavioural mechanisms involved in drug response. It may also be particularly valuable for 
its predictive utility regarding individual responses to drugs.  
 
The results shed light on a number of interesting psychological and pharmacological issues. 
mCPP was shown to affect memory, which raises the interesting question of whether memory 
enhancement might facilitate satiation and ultimately weight-loss. mCPP was also shown to 
have a preferential effect on cookie intake, which might be particularly advantageous in 
combating the consumption of energy dense foods in treating obesity. Investigation of natural 
satiation has provided a comprehensive neural profile of the process that mediate eating 
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behaviour., The results identified the involvement of multiple brain regions, including energy 
balance and reward circuitry in the control of appetite in healthy human volunteers. 
 
This thesis has also raised broader issues such as the nature of drug response and non-
response. This issue has significance that extends beyond anti-obesity drugs and may apply to 
most if not all drugs used to treat psychiatric disorders. It seems likely that in the years ahead, 
medicine will become increasingly personalised and as such, research will need to take this 
into account and adjust to be able to detect the finer grains of drug response. It is hoped that 
this line of thinking, and the data in this thesis, will assist in the much needed re-calibration 
of anti-obesity medication towards a stratified approach.  
 
While there are limitations to the work presented in this thesis, implementation of suggestions 
for future work should enable the validation of a robust experimental medicine model with 
the capacity to successfully identify safe and promising anti-obesity drugs. The most pressing 
area is the validation of the model for clinical populations to ensure that results translate to 
obese patients. The model would also benefit from testing other drugs with different 
mechanisms, to investigate the model’s ability to differentiate between them and to further 
investigate whether they possess preferential effects which have not been detected to date. 
The incorporation of genotyping would further augment the ability of the model to 
investigate populations who will benefit most from a given drug, and might ultimately lead to 
the most swift and economically efficient method of identifying which drug a patient is likely 
to respond to. 
 
This thesis opened with a consideration of the urgent need for new treatments for obesity. 
That need is still pressing, and a robust neuropsychopharmacological approach can play a 
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pivotal role. This model presents a novel opportunity to enhance the development of anti-
obesity drugs and to contribute to stratified medicine, in a way that could greatly enhance the 
treatment of obesity. 
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